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Ovarian cancer is the fifth leading cause of death associated with cancer. Initially, the disease 
responds to surgical cytoreduction, followed by chemotherapy. The primary response rate for 
chemotherapy is about 80%. Unfortunately, most patients relapse and tumours eventually 
become frontline therapy refractory. At this point, the lack of widely successful treatments 
contributes to a low 5-year survival. New therapeutic agents or therapy approaches are therefore 
required. Statins exert anticancer modality by cause cancer cell death by preventing the 
synthesis of geranylgeraniol an intermediate of mevalonate pathway. Moreover, we found that 
exogenous geranylgeraniol can suppress the pro-apoptotic activity of pitavastatin in vitro. Thus, 
suggesting that strict dietary regimen should be maintained to achieve correct pitavastatin 
therapeutic efficacy. Likewise, supplementation of diet with geranylgeraniol observed to 
suppress the pitavastatin-induced regression of ovarian cancer xenografts in mice. Several 
human foods have already been shown to contain geranylgeraniol. We tested 30 organic solvent 
foods extracts to see their ability to suppress anticancer activity of pitavastatin in vitro. The 
foods included eight oils, several types of solid foods and eleven fruits and vegetables. The 
IC50s of growth inhibition of pitavastatin were (5.2 μM, 8.2 μM) for Ovcar-4 and Fuov1 ovarian 
cancer cell line respectively. Pitavastatin anticancer activity is blocked completely by adding 
of geranylgeraniol or solvent extracts from sunflower oil. Some food extracts from lettuce, corn 
oil, ground nut oil, grape seed oil black bean and oats partially blocked the effect of pitavastatin, 
whereas the other foods did not. This research identified several foods apparently lack 
geranylgeraniol and which patients could eat while enrolled in clinical trials of pitavastatin.  
Among the most effective and commonly used cancer treatment agents are natural and synthetic 
compounds that disrupt the dynamics of microtubules. However, there is still a lack of reliable 
markers that disrupt the dynamics of microtubules can decide the sensitivity of cancer cells to 
targeting agents of microtubules and play a role in tumour cell resistance to these agents. This 




apoptosis regulators, suggesting that altering the dynamics of microtubules may be one of the 
critical events in tumour origin and tumour progression. The objective of this study is to 
integrate microtubule-targeting therapies and relevance with highlight MAP7-tubulin-
pitavastatin interactions as a new avenue for isoprenoid-related activity to inhibit mevalonate 
production. We found highly express of MAP-7 in sensitive cells to pitavastatin (OVCAR-8 & 
OVSAHO) and the sensitivity is decreased after gene transfection of MAP-7 especially in 
OVSAHO cell line while no significant changes with KIF5-B on the sensitivity of cancer cells. 
Interestingly, we noticed a significant change in tubulin level after course time of treatment 
(24,48,72h) of ovarian cancer cell lines with single /double IC50 of pitavastatin.   Consequently, 
we tried the CNP role in rescuing of mevalonate pathway which show significant change as 
well, based on the available evidence, we suggest that the isoprenoid (GGOH & FARNSOL) 
has important role in microtubules changes at its carboxyl-terminals but does not binding 
directly, CNP make association between isoprenoid and Cytoskeleton of cancer cell. 
 Repurposing statins for use in oncology is an attractive strategy, while legitimate concerns 
about the drug's potential for myopathy. In addition, certain pharmacological agents inhibiting 
the ovarian cancer cell therefore we evaluated causes of ovarian cancer cell death 
synergistically. To identify additional drugs that could interact synergistically with pitavastatin, 
it was identified ivermectin that potentiated pitavastatin activity and/or had notable activity as 
a single agent. In several cell growth and viability assays, this study confirmed the synergistic 
interaction between ivermectin and pitavastatin. These data suggest that inhibiting drug 






Table of Contents 
Chapter 1:                                                                                                                                                             
Introduction .............................................................................................................................. 15 
1.1. Female Reproductive System .................................................................................... 16 
1.1.1. Anatomical structure of ovaries ......................................................................... 16 
1.1.2. Hormonal control of female’s gonads ............................................................... 17 
1.2. Etiology ..................................................................................................................... 18 
1.2.1. Risk factors and preventive factors .................................................................... 18 
1.2.1.1. Hormonal and reproductive risk factors ..................................................... 18 
1.2.1.2. Age at Menarche and menopause age ........................................................ 19 
1.2.1.3. Parity and infertility .................................................................................... 20 
1.2.1.4. Lactation ..................................................................................................... 21 
1.2.1.5. Benign gynecologic conditions and gynecologic surgery .......................... 21 
1.2.1.6. Oral contraceptives and other forms of contraception ............................... 22 
1.2.1.7. Hormone replacement therapy (HRT) ........................................................ 23 
1.2.1.8. Obesity ........................................................................................................ 24 
1.2.1.9. Diet and nutrition ........................................................................................ 25 
1.2.1.10. Exercise and physical activity ........................................................................ 26 
1.2.2. Other lifestyle and environmental factors .......................................................... 27 
1.2.2.1. Cigarette smoking ....................................................................................... 27 
1.2.2.2. Alcohol consumption .................................................................................. 28 
1.2.2.3. Asbestos and talcum powder ...................................................................... 28 
1.2.2.4. Drug use ...................................................................................................... 30 
1.3. Origin of ovarian cancer ............................................................................................ 31 
1.3.1. Type I Tumours ................................................................................................. 31 
1.3.1.1. Endometrioid and clear cell ovarian cancers .............................................. 31 
1.3.1.2. Mucinous ovarian cancer ............................................................................ 31 
1.3.2. Type II Tumours ................................................................................................ 32 
1.3.2.1. Serous ovarian cancer ................................................................................. 32 
1.4. Neoplasms of the ovary ............................................................................................. 33 
1.4.1. Class I: Epithelial Ovarian Tumours ................................................................. 34 
1.4.1.1. Benign epithelial Ovarian Tumours ........................................................... 35 
1.4.1.2. Borderline epithelial Ovarian Tumours ...................................................... 35 
1.4.1.3. Invasive carcinoma epithelial Ovarian Tumours ........................................... 35 
1.4.2. Class II Germ cell tumour .............................................................................. 35 




1.4.2.2. Malignant germ cell tumours ..................................................................... 36 
1.4.3. Class III: Stromal Ovarian Tumours .............................................................. 36 
1.4.3.1. Benign tumours of stroma cell .................................................................. 36 
1.4.3.2. Malignant tumours of stroma cell .............................................................. 36 
1.4.4. Other cancers that are similar to epithelial ovarian cancer ................................ 37 
1.4.4.1. Primary peritoneal carcinoma ..................................................................... 37 
1.4.4.2. Fallopian tube cancer .................................................................................. 37 
1.4.4.3. Ovarian germ cell tumours ......................................................................... 38 
1.4.4.4. Dysgerminoma ........................................................................................... 38 
1.4.4.5. Endodermal sinus tumour (yolk sac tumour) and choriocarcinoma ........... 38 
1.5. Theories for cancer of the ovaries ............................................................................. 38 
1.5.1. Theory 1:  The incessant theory of ovulation .................................................... 39 
1.5.2. Theory 2:  gonadotropin of pituitary theory ...................................................... 39 
1.5.3. Theory 3:  The theory of androgen / progesterone ............................................ 40 
1.5.4. Theory 4: The theory of inflammation .............................................................. 41 
1.5.5. Theory 5: The theory of tubal origin ................................................................. 41 
1.6. Epidemiology ............................................................................................................ 42 
1.6.1. Descriptive epidemiology .................................................................................. 42 
1.6.2. Genetic epidemiology ........................................................................................ 43 
1.7. Symptoms of ovarian cancer ..................................................................................... 44 
1.8. Diagnosis ................................................................................................................... 45 
1.9. Treatment .................................................................................................................. 45 
1.9.1. Surgery ............................................................................................................... 46 
1.9.2. Chemotherapy .................................................................................................... 46 
1.9.2.1. Platinum chemotherapy .................................................................................. 47 
1.9.2.2. Taxanes .......................................................................................................... 47 
1.10. Mechanisms of Chemotherapy Resistance ................................................................ 48 
1.10.1. Reduce intracellular Drug Accumulation....................................................... 49 
1.10.2. Drug Inactivation ........................................................................................... 49 
1.10.3. Apoptosis Deregulation .................................................................................. 49 
1.11. The Mevalonate Pathway .......................................................................................... 50 
1.11.1. Protein Prenylation and the Role in Cancer ................................................... 51 
1.12.1.1. Protein Prenylation ........................................................................................ 51 
1.12.1.2. Prenylated Proteins Involved in Cancer Development ............................... 52 
1.12.1.2.1. Ras GTPases ......................................................................................... 53 




1.12.1.2.3. Rab GTPases ........................................................................................ 54 
1.12.1.2.4. The Arf family ...................................................................................... 54 
1.12.1.2.5. Ran GTPase .......................................................................................... 55 
1.13. Molecular Mechanisms of Tumourigenesis and the Cytotoxic Activity of Statins .. 55 
1.13.1. The Cell Cycle and Cancer Progression ......................................................... 55 
1.13.2. Statins & apoptosis ......................................................................................... 56 
1.14. The Potential of Statins for Cancer Prevention or Treatment ................................... 58 
1.14.1. Statins and Cancer Risk Reduction ................................................................ 58 
1.14.1.1. Clinical Trials of statins for Cancer Treatment .......................................... 58 
1.14.1.2. Xenografts of Statins as anticancer activity ............................................... 60 
1.14.1.3. Preclinical study ......................................................................................... 61 
Chapter 2 Aims and objectives ................................................................................................ 66 
2. Aims and Objectives ................................................................................................. 67 
Chapter 3 .................................................................................................................................. 68 
3.1. Cell culture ........................................................................................................................ 69 
3.1.1. Ovarian cell lines ............................................................................................... 69 
3.1.2. Mediums and conditions for cell growth ........................................................... 69 
3.1.3. Reviving Cryopreserved Cells ........................................................................... 70 
3.1.4. Trypsinisation of Adherent Cells ....................................................................... 70 
3.2. Chemical agents ........................................................................................................ 71 
3.3. Extraction of Lipids from Foodstuffs ........................................................................ 71 
3.4 Cell Growth Assays (sulforhodamine B assay) ..................................................... 72 
3.5.  GC/MS experiments ........................................................................................................ 73 
3.6. Trypan blue assay .................................................................................................. 73 
3.7. Measurement of annexin V/PI labelling ................................................................ 73 
3.8. Caspase 3/7 activity assay ..................................................................................... 74 
3.9. Cytoplasmic and membrane protein fractionation ................................................ 75 
3.10. Western blot analysis ......................................................................................... 76 
3.10.1. Whole cell lysate ........................................................................................ 76 
3.10.2. Bicinchoninic acid protein assay ................................................................ 76 
3.10.3. Gel electrophoresis and immunodetection of proteins using SDS-page and 
western transfer ............................................................................................................. 77 
3.11. RNA extraction from culture cells ..................................................................... 79 
3.11.1. Synthesis of cDNA by reverse transcriptase .................................................. 80 
3.11.2. qRT-PCR ........................................................................................................ 80 




3.12.1. Experiment of small interfering ribonucleic acid (siRNA) transfections ...... 83 
3.13. Immunocytochemistry ............................................................................................... 84 
3.14. Analysis of drug combination ................................................................................... 85 
3.14.1. Combination index ......................................................................................... 86 
3.15. Bliss independence criterion ..................................................................................... 87 
3.16. Statistical Analysis to Determine IC50 Value ............................................................ 88 
4. Introduction ...................................................................................................................... 90 
4.1 MVA-derived metabolites in cancer ......................................................................... 90 
4.1.1 Cholesterol ......................................................................................................... 91 
4.1.2. Dolichol ..................................................................................................................... 91 
4.1.3. Coenzyme Q10 .................................................................................................. 92 
4.1.1 Farnesyl-diphosphate and gernaylgernayl-diphosphate ..................................... 93 
4.2 Results ........................................................................................................................... 95 
4.2.1 Inhibition of the growth of Ovcar-4 and Fuov-1 cells by Pitavastatin .................... 95 
4.2.2 Food extraction .................................................................................................. 96 
4.2.2.1 Solid foods ................................................................................................... 101 
4.2.2.2 Fruit & Salad ................................................................................................ 108 
4.3 Trypan blue experiment .......................................................................................... 116 
4.2.4. GC/MS experiments ................................................................................................ 117 
4.2.5. The effect of mevalonate pathway intermediate metabolites on pitavastatin 
anticancer activity .................................................................................................................. 120 
4.4 Discussion ................................................................................................................... 122 
5.  Introduction ....................................................................................................................... 128 
5.1. Microtubules and MAPs ...................................................................................... 131 
5.2.2. Pitavastatin growth inhibition activity in six cells line of ovarian cancer .............. 141 
5.2.3. Results of gene expression ............................................................................... 142 
5.2.3. Knock-downs of the pitavastatin-sensitive genes in Ovcar-8 and Ovsaho cell 
line 153 
5.2.4. Effect of genes knock-down on the sensitivity to pitavastatin in cell growth 
assays 157 
5.2.5. Expression of -tubulin in ovarian cancer cell treated with pitavastatin ........... 160 
5.2.6. Immunostaining of -tubulin expression in OVCAR-8 and OVSAHO ovarian 
cancer cell treated with pitavastatin ............................................................................... 162 
5.2.7. Expression of Actin in ovarian cancer cell after treatment with pitavastatin .. 165 
5.2.8. CNP expression and immunohistochemistry ................................................... 166 
5.2.3. Immunostaining of CNP expression in OVCAR-8 ovarian cancer cell treated 




5.3. Discussion ............................................................................................................... 173 
Chapter 6 ................................................................................................................................ 180 
6.  Introduction ....................................................................................................................... 181 
6.1.   Ivermectin .............................................................................................................. 185 
6.1.1. Ivermectin Uses in Veterinary and Human Medicine ..................................... 185 
6.1.2. Mechanism of action of Ivermectin ................................................................. 186 
6.2.1. Testing the activity of Ivermectin on the ovarian cancer cell lines ................. 189 
6.2.2. Confirmation of antiproliferative combination effect of pitavastatin with fixed 
doses of Ivermectin ......................................................................................................... 190 
6.2.3. Cell viability assay after combination treatment ..................................................... 194 
6.2.4. Caspase 3/7 activity assay ....................................................................................... 196 
6.2.5. Confirmation of the synergy between Ivermectin and Pitavastatin by flow 
cytometry ........................................................................................................................ 197 
6.3. Discussion ............................................................................................................... 199 
7. Conclusion ...................................................................................................................... 206 
8. References ............................................................................................................... 211 
 
Figures: -  
Figure (1-1) explain the whole organs of female genital system --------------------------------------------17  
Figure (1-2) The hormonal control of female reproductive system ------------------------------------------18 
Figure (1-3) Average ovarian cancer death rate per year and age -------------------------------------------20  
Figure (1-4) Shows the origin of ovarian cancer. Types of cancer of the ovaries according to cell origin -------34  
Figure (1-5) Classification of ovarian cancer based on cell origin ------------------------------------------------34 
Figure (1-6) The prevalence of ovarian cancer has wide variation in geography ---------------------------------43 
Figure (1-7) Cellular Chemotherapy resistance mechanisms ------------------------------------------------------48 
Figure (1-8) The mevalonate pathway ---------------------------------------------------------------------------51 
Figure (1-9) Ras-superfamily the subfamilies of Ras-superfamily are shown ----------------------------- 53  
Figure (1-10) The role of Cdc25s which involve a Cellular Interactions ----------------------------------- 56  
Figure (3-1) the method of isoprenoid extraction --------------------------------------------------------------72 
Figure (3-2): Annexin V staining mechanism ------------------------------------------------------------------74  
Figure (3-3) Caspase 3/7 cleavage of the luminogenic substrate containing the DEVD sequence -----75 
Figure (3-4) show the process of staining cells in slide chamber --------------------------------------------85 
Figures (4-1&4-2) Dose response curve of pitavastatin in ovarian cancer cell lines---------------------- 95  
Figure (4-3) The effect of sunflower extract on pitavastatin activity against the Ovcar-4 --------------- 97 
Figure (4-4) The effect of sunflower extract on pitavastatin activity against Fuov-1 -------------------- 97  
Figure (4-5) The effect of corn oil extract on pitavastatin activity against Ovcar-4---------------------- 98 




Figure (4-7) The effect of ground nut oil extract on pitavastatin activity on Ovcar-4--------------------- 99 
Figure (4-8) The effect of rape seed oil extract on pitavastatin activity on Ovcar-4---------------------- 99 
Figure (4-9) the effect of sesame oil extract on pitavastatin activity on Ovcar-4--------------------------100   
Figure (4-10) the effect of coconut oil extract on pitavastatin activity on Ovcar-4-----------------------100 
Figure (4-11) The effect of walnut oil extract on pitavastatin activity against ovcar-4 ------------------101 
Figure (4-12) the effect of bread oil extract on pitavastatin activity on Ovcar-4--------------------------102 
Figure (4-13) the effect of bread extract on pitavastatin activity on Fuov-1-------------------------------103 
Figure (4-14) The effect of oats extract on pitavastatin activity against ovcar-4--------------------------103 
Figure (4-15) the effect of cheese extract on pitavastatin activity on Ovcar-4-----------------------------104 
Figure (4-16) The effect of butter extract on pitavastatin activity on Ovcar-4-----------------------------104  
Figure (4-17) the effect of milk extract on pitavastatin activity on Ovcar-4-------------------------------105 
Figure (4-18) the effect of spaghetti extract on pitavastatin activity on Ovcar-4-------------------------105 
Figure (4-19) The effect of pasta sauce extract on pitavastatin activity on Ovcar-4----------------------106 
Figure (4-20) the effect of potato extract on pitavastatin activity on Ovcar-4-----------------------------106 
Figure (4-21) the effect of boiled bean extract on pitavastatin activity on Ovcar-4-----------------------107 
Figure (4-22) the effect of boiled egg extract on pitavastatin activity on Ovcar-4------------------------108 
Figure (4-23) The effect of pecan nuts extract on pitavastatin activity on Ovcar-4-----------------------108 
Figure (4-24) The effect of kiwi extract on pitavastatin activity on Ovcar-4------------------------------109 
Figure (4-25) the effect of lettuce extract on pitavastatin activity on Ovcar-4 ----------------------------110 
Figure (4-26) the effect of lettuce extract on pitavastatin activity on Fuov-1 -----------------------------110 
Figure (4-27) The effect of passion fruit extract on pitavastatin activity on Ovcar-4 --------------------111  
Figure (4-28) The effect of Pomegranate extract on pitavastatin activity on Ovcar-4--------------------111 
Figure (4-29) The effect of cherry extract on pitavastatin activity on Ovcar-4----------------------------112 
Figure (4-30) The effect of fig extract on pitavastatin activity on Ovcar-4 --------------------------------112  
Figure (4-31) The effect of fig extract on pitavastatin activity on Ovcar-4 --------------------------------113 
Figure (4-32) The effect of gooseberry extract on pitavastatin activity on Ovcar-4----------------------113 
Figure (4-33) The effect of pear extract on pitavastatin activity on Ovcar-4 ------------------------------114 
Figure (4-34) the effect of tomato extract on pitavastatin activity on Ovcar-4----------------------------114 
Figure (4-35) the effect of tomato extract on pitavastatin activity on Fuov-1----------------------------- 115 
Figure (4-36) The effect of strawberry jam extract on pitavastatin activity on Ovcar-4 -----------------115  
Figure (4-37) the effect of squash extract on pitavastatin activity on Ovcar-4 ----------------------------116 
Figure (4-38) The effect of sunflower extract and milk extract with/without pitavastatin---------------117 
Figure (4-39) shows the Standard geranylgeraniol of GC-MS chromatogram-----------------------------118  
Figure (4-40) shows the GC-MS chromatogram of sunflower oil ------------------------------------------118 
Figure (4-41) shows the GC-MS chromatogram of black bean ---------------------------------------------119  
Figure (4-42) Shows the GC-MS chromatogram of Egg extract oil ---------------------------------------119 
Figure (4-43) Shows the GC-MS chromatogram of lettuce extract-----------------------------------------120  




Figure (4-45) the effect of metabolites of mevalonate pathway on pitavastatin activity on Fuov-1----121 
Figure (5-1) MAPs and cancer cell resistance / sensitivity to the action of microtubule-targeting ----132 
Figure (5-2) Dose response curve of pitavastatin in ovarian cancer cell lines-----------------------------141 
Figure (5-3) Evaluation of the expression of 18 genes in ovarian cancer cells by western blotting ----143 
Figure (5-4) A explain the level of AXL protein expression-------------------------------------------------144  
Figure (5-5) A explain the level of Frizzled-2 protein expression -----------------------------------------144 
Figure (5-6) A explain the level of FGF-5 protein expression ---------------------------------------------145 
Figure (5-7) A explain the level of VIM protein expression -----------------------------------------------145 
Figure (5-8) A explain the level of RAB11-FIP4 protein expression -------------------------------------146 
Figure (5-9) A explain the level of GRHL2 protein expression--------------------------------------------146 
Figure (5-10) A explain the level of CYR61 protein expression ------------------------------------------147 
Figure (5-11) A explain the level of PTRF protein expression---------------------------------------------147 
Figure (5-12) A explain the level of BSPRY protein expression-------------------------------------------148 
Figure (5-13) A explain the level of MAP7D1 protein expression---------------------------------------- 148 
Figure (5-14) A explain the level of PRR-15L protein expression ----------------------------------------149 
Figure (5-15) A explain the level of HMGCS1 protein expression ---------------------------------------149 
Figure (5-16) A explain the level of RBM35A protein expression ----------------------------------------150 
Figure (5-17) A explain the level of MARVELD3 protein expression -----------------------------------150 
Figure (5-18) A explain the level of CCDC64B protein expression -------------------------------------- 151 
Figure (5-19) A explain the level of FXYD3 protein expression ------------------------------------------151 
Figure (5-20) A explain the level of MAP-7 protein expression ------------------------------------------ 152 
Figure (5-21): OVCAR-8 cells were transfected with each of the indicated siRNA to MAP7 --------153 
Figure (5-22): OVCAR-8 cells were transfected with each of the indicated siRNA to KIF5B--------153 
Figure (5-23) Figure (5-23): Knock-down of OVCAR-8 with MAP-7 and KIF5B ---------------------154 
Figure (5-24) Quantification of knock-down of MAP-7 in OVCAR-8------------------------------------154 
Figure (5-25) Quantification of knock-down of KIF5-B in OVCAR -------------------------------------155 
Figure (5-26) Knock-down of OVSAHO cells with MAP-7 and KIF5B ---------------------------------155 
Figure (5-27) Quantification of knock-down of MAP-7 in OVSAHO -----------------------------------156 
Figure (5-28) Quantification of knock-down of KIF5-B in OVSAHO -----------------------------------156 
Figure (5-29) OVCAR-8 cells were transfected with either 100 nM NT-1 or 100 nM of the siRNA-157 
Figure (5-30) OVCAR-8 cells were transfected with either 100 nM NT-1 or 100 nM of the siRNA-157 
Figure (5-31) OVSAHO cells were transfected with either 100 nM NT-1 or 100 nM of the siRNA-158 
Figure (5-32) OVSAHO cells were transfected with either 100 nM NT-1 or 100 nM of the siRNA-159 
Figure (5-33) The expression of tubulin protein was determined by western blotting ----------------- 160 
Figures (5-34) Tubulin expression in OVSAHO cells were measured by western blotting ------------160 
Figures (5-35) Tubulin expression in OVCAR-8 cells were measured by western blotting -----------161 
Figure (5-36) Measurement of tubulin by immunocytochemistry in Ovcar -8 cells---------------------162 




Figures (5-38) Measurement of tubulin by immunocytochemistry in OVSAHO -----------------------163 
Figure (5-39) Quantification the effect of pitavastatin on microtubules tubulin in OVSAHO --------164 
Figure (5-40) The expression of actin protein was determined by western blotting --------------------164 
Figure (5-41) Actin expression in Ovcar-8 were measured by western blotting ------------------------ 165 
Figure (5-42) Actin expression in Ovsaho were measured by western blotting -------------------------165 
Figure (5-43) (A) The expression of CNP protein was determined by western blotting -------------- 166 
Figure (5-44) (A) The expression of CNP protein was determined by western blotting--------------- 167 
Figure (5-45) (A) The expression of CNP protein was determined by western blotting ---------------168 
Figure (5-46) (A) The expression of CNP protein was determined by western blotting ---------------169 
Figure (5-47) CNP Immunostaining of Ovcar-8 -------------------------------------------------------------170 
Figure (5-48) quantitate the CNP expression in Ovcar-8 ---------------------------------------------------171 
Figure (6-1) shows the drug repurposing ---------------------------------------------------------------------182 
Figure (6-2) Mechanisms of antitumour for ivermectin ----------------------------------------------------187 
Figure (6-3) Effect of ivermectin on ovarian cancer cell lines ---------------------------------------------188 
Figures (6-4) Effect of Ivermectin combination with pitavastatin on ovarian cancer cell lines -------191 
Figure (6-5) Evaluation of the combination of pitavastatin and ivermectin in cell growth assays ----192 
Figure (6-6) Evaluation of the combination of pitavastatin and ivermectin in cell growth assays ----192 
Figure (6-7) Evaluation of the combination of pitavastatin and ivermectin in cell growth assays ----192 
Figure (6-8) The effect of ivermectin in combination with pitavastatin on cell toxicity ---------------193 
Figure (6-9) The effect of ivermectin in combination with pitavastatin on cell toxicity -------------- 194 
Figure (6-10) The effect of ivermectin in combination with pitavastatin on cell toxicity--------------194 
Figures (6-11): Relative caspase 3/7 activity in COV318 cells --------------------------------------------195 
Figure (6-12) The effect of ivermectin combinations on annexin V/propidium iodide -----------------197 
Figure (6-13) The effect of ivermectin combinations on annexin V/propidium iodide -----------------198 
Tables: - 
Tables (1-1) the frequency of ovarian cancer symptoms ---------------------------------------------------- 45  
Tables (3-1) representation of HGSOC and Description of cell lines used in this study. ----------------69 
Tables (3-2) The list of primary and secondary antibodies used in protein immunodetection assay ----79  
Tables (3-3) The list of Primer sequences (Forward and Reverse) ----------------------------------------- 82 
Tables (3-4) Thermal cycling profile for qRT-PCR----------------------------------------------------------- 82 
Table (3-5) The list of siRNA transfection Oligos------------------------------------------------------------ 84 
Tables (3-6): Symbols and definition of synergism ---------------------------------------------------------- 87 
Tables (4-1) the weight of oils extractions in 50 grams of foodstuff ---------------------------------------96 
Tables (4-2) the weight of   meals extractions in 50 grams of foodstuff---------------------------------- 102 
Tables (4-3) the weight of   Fruits and vegetables extractions in 50 grams of foodstuff----------------109 
Tables (5-1) The mechanism of highly expression genes which used in our experiments -------------135 
Tables (5-2) The mechanism of low expression genes which used in our experiments ----------------139 




Tables (6-1) Table (6-1) IC50s of Ivermectin as a single agent of inhibition for six cell lines---------188 




ATM  Ataxia-telangiectasia mutated  
ATR  Ataxia telangiectasia and RAD3-related  
BER  Base excision repair  
Cdks  Cyclin dependent kinases  
CRH  Corticotrophin-releasing hormone  
DRC  Dose response curve  
ECACC  European collection of authenticated cell cultures  
ERCC1  Excision repair cross-complementing group 1  
FDPS  Farnesyl diphosphate synthase  
FOH  Farnesol  
FTase  Farnesyl transferase  
GAPs  GTPase activating proteins  
GDIs  Guanine nucleotide dissociation inhibitors  
GDP  Guanosine diphosphate  
GEFs  Guanine nucleotide exchange factors  
GGOH  Geranylgeraniol  
GGPPS  Geranylgeranyl pyrophosphate synthase  
GGTII-β  Geranylgeranyl Transferase-II beta subunit  
GGTI-β  Geranylgeranyl Transferase-I beta subunit  
GR  Glucocorticoid receptor  
GTP  Guanosine-5-triphosphate  
HIDS  Hyperimmunoglobulinaemia D syndrome  
PPC Primary peritoneal carcinoma 
GnRH Gonadotropin-releasing hormone   
FSH Follicle-stimulating hormone 
LH     luteinizing hormone 
LMP    Borderline low-malignant potential 
HGSC High grade serous ovarian cancer 
PPC     Primary peritoneal carcinoma 
EOPPC Serous surface papillary carcinoma, extra-ovarian and primary 
peritoneal carcinoma 
FR   Folate receptor alpha 
PFS Progression-free survival 
LGSOC low-grade serous OC 
CDK cycline-dependent kinase 
MDSCs myeloid-derived suppressor cells 
IGF Insulin-like growth factor 
FAK Focal adhesion kinase 
TNF-α tumour necrosis factor-alpha 
PCOS Polycystic ovary syndrome 




IUD   Intrauterine device 
HRT Hormone replacement therapy 
ET Oestrogen therapy 
BMI    Body mass index 
SNPs Single nucleotide polymorphisms 
IARC International Cancer Research Agency 
GSTM 1 glutathinine S-tansfase M1 
GSTT1 GSS-transferase T1 
NSAIDS non-steroidal anti-inflammatory drugs 
OSE ovarian surface epithelium 
Erk    extracellular signal-regulated kinase 
HNPCC Hereditary non-polyposis colorectal cancer syndrome 
MOC mucinous ovarian carcinoma 
PET positron emission tomography 
CT computed tomography 
CTR1   copper transporter-1 
DSS Disease-specific survival 
ATCC American Tissue Culture 


















I would first like to thank my God for the guidance and good fortune throughout my graduate 
research and whole my life, then I would like to extend my great gratitude to my country, Iraq, 
for paying all my research fees and my life expenses.    
I would like to take this opportunity to express my gratitude to all those who have played an 
important role in completing my PhD. First of all, I would like to thank my supervisor Dr. Alan 
Richardson, for his support during my research career in the UK, I feel that his scientific 
curiosity, enthusiasm and energy inspired me. He gave me honest feedback to make me a better 
researcher, and I owe him a great debt to help me overcome my weaknesses. Without presence 
of my wife beside me along my study, I would not have been able to complete my research 
therefore, I am very appreciated for her support.  I would like to thank my Mom and Dad, for 
having confidence in me and for supporting me to pursue the education of my choice. I would 
also like to thank all my sisters and brothers for their encouragement 
I am fortunate to have wonderful colleagues at the Guy Hilton Research Center who have 
created a very friendly helpful with supportive in the lab and office environment and helped me 
to forget all the stress of study life and provided me with energy to get all the work done in the 
lab, I am thankful to Katy Cressy and John Misra for maintaining the laboratory research 
environment and training me on the experimental techniques required in my research projects, 
I would like also to thank Joshua Price for helping me with the project of cell staining. I would 
like also to thank Dr. Wen-Wu Li for helping me with the GC-MS of food extracts analysis.  
Finally, I owe heartfelt thanks to all Keele University staff members which resolved the 
difficulties and worked as a beehive to make scientific research a success, I particularly would 
























1. Introduction  
1.1. Female Reproductive System  
The female reproductive system consists of organs outside and inside the body. The uterus, 
ovaries, and fallopian tubes made up the internal organs used in the reproductive system of 
women. The ovaries develop, store and release needed eggs for reproduction. An ovulated egg 
passes across the fallopian tube and down the uterus. It may be fertilised by sperm during this 
period, implant into the uterus lining and grow into a foetus. [1]. 
 
1.1.1. Anatomical structure of ovaries 
The ovaries are paired organs situated close to the wall on each side of the minor pelvis. The 
uterus, fallopian tubes and the ovaries, which are almost completely covered with peritoneum, 
are suspended by the peritoneal ligaments in the lower space of pelvis that is also occupied by 
the ileum and sigmoid colon and fill the cavity of pelvis completely. The suspensory ligament 
of the ovaries, which is called mesovarium, consists of two layers of peritoneum, the 
posterosuperior layer of the broad ligament, in addition the second layer continuous coated 
epithelium of both the ovaries. The blood supply of the ovaries is provided through the ovarian 
arteries that originate as branches of the abdominal aorta. The ovaries have two surfaces, lateral 
and medial; two borders, anterior and posterior; and two poles, tubal and uterine.  Each ovary 
weighs from 2 to 5 grams and is about 4 cm in length, 1.5-3 cm in diameter, 2 cm wide, and 1 
cm thick. The main functions of the ovaries are the production of ova and steroid hormones, 






Figure (1-1): The major organs of the female genital system. The female reproductive system is made up of ovaries, 
fallopian tubes, uterus, cervix and vagina (vaginal canal)[3].  
 
1.1.2. Hormonal control of female’s gonads 
The reproductive system is governed by a complex neuroendocrine system. The hypothalamic 
area located in the forebrain controls reproduction by releasing Gonadotropin-releasing 
hormone (GnRH) from the anterior hypothalamic, preoptic and ventromedial hypothalamic 
areas as well as in the supra-optic nucleus, arcuate nucleus, medial eminence and medial basal 
hypothalamus. The collection of dispersed GnRH neurons is called the “GnRH pulse 
generator”, and is activated by endogenous stimuli including neurotransmitters, hormones and 
growth factors [4]. GnRH regulates gonadal activity by controlling the production and release 
of the pituitary gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH). Secretion of GnRH induces increased synthesis and secretion of FSH, stimulating 
gametogenesis, steroidogenesis and secondary sexual behaviour. In addition, 
hypothalamic/pituitary function is regulated by feedback mechanisms by gonadal steroid or 



















Figure (1-2): The hormonal control of female reproductive system. Gonadotropin releasing hormone (GnRH), 
follicle-stimulating hormone (FSH) and leutenizing hormone (LH) are the hormones regulating the female 
reproductive system[6].  
 
1.2. Etiology  
Ovarian cancer ranks fifth in cancer deaths among women and is associated with an overall 5-
year survival rate of less than 45%. Ovarian cancer is the principal cause of death from 
gynaecological cancer in the UK[7]. Several factors have been identified which can increase 
the probability of developing ovarian cancer. 
 
1.2.1.  Risk factors and preventive factors 
1.2.1.1. Hormonal and reproductive risk factors 
Epidemiological research has clearly shown that pathogenesis of ovarian cancer is associated 
with hormonal and reproductive variables. There have emerged two predominant hypotheses 




cycles rises is linked to surface epithelium repair and that this can act as driver of spontaneous 
mutation [8]. There is a correlation between the number of lifetime ovulations and a greater risk 
of ovarian cancer.  
 
The gonadotropin theory postulates that the ovarian surface epithelial cells are also activated 
by the bursts of pituitary gonadotropins that cause each ovulation and remain at high levels for 
years after menopause and induce cell transformation of the ovaries [9]. 
 
1.2.1.2. Age at Menarche and menopause age 
Early age at menarche and late age at menopause raises the risk of developing ovarian cancer 
potentially as a result of raising the number of ovulatory cycles (Fig. (1-6)). This is 
understandable when considering the incessant ovulation hypothesis.  
 
In comparison, according to the gonadotropin hypothesis, a late menopause age slows the 
production of postmenopausal gonadotropin hormones, potentially reducing the risk. Results 
from research that examined age at menstrual initiation are not terribly consistent [10]. One 
study of Chinese women revealed lower risk of ovarian cancer in women with menarche at a 
late age (after 18 years) [11]. In contrast, other research found a slightly higher risk in patient’s 
menarche at an earlier age [12]. Further study has failed to resolve the discrepancies in the 
literature[13], although a meta-analysis of a total of 27 observational studies were included in 
their study, consisting of 22 case-control and five cohort studies which reported a reciprocal 
association between risk and age at menarche (RR=0.85, 95% CI: 0.75–0.97) [14], [15]. In the 
European Cohort of Prospective Research on Cancer and Nutrition (EPIC), menopause age 
(>52 vs. ≤45 years) was correlated with enhanced risk (HR=1.57, 95 percent CI: 1.16–2.13). 
However, the risk was slightly reduced and marginally statistically significant after women 




0,98–2.00) [16]. The writers speculated that elderly females may mistake bleeding for 
menstration in the sub-clinical phase of ovarian cancer. Other[17] case-control studies and 
several cohort studies discovered no connection. 
Figure (1-3): Average ovarian cancer death rate per year and age-specific mortality rate per 100,000 female 
population, UK, 2015-2017 From (Cancer Research UK, 2017). 
 
1.2.1.3. Parity and infertility 
There has been extensive study of the connection between pregnancy and ovarian cancer risk. 
Pregnancy triggers an ovulation and suppresses pituitary gonadotropin secretion and is 
therefore compatible with both the incessant ovulation and gonadotropin hypotheses. In fact, 
the risk of parous women is 30%-60% smaller than that of nulliparous women [18]. And each 
extra full-term pregnancy reduces the danger by around 15% [19]. Similar outcomes have been 
observed in African American[20] and Asian communities [21]. The protective effect 
associated with parity is evident across major histotypes, although perhaps slightly weaker in 
the case of serous carcinomas, with approximately 20% lower risk in parous women compared 




Recent data also show that the risk of OC does not differ between the first and last birth 
periods[23]. Whether spontaneous or induced abortions affect the risk of ovarian cancer is 
uncertain. Approximately half of the published research discovered that an enhanced amount 
of incomplete pregnancies could mildly reduce risk [24], whereas others have been increased 
[25], while other not affected [26]. In several studies, induced abortions were correlated with 
lower risk [27], but again this was not found in other studies [26]. 
 
1.2.1.4. Lactation 
Lactation suppresses pituitary gonadotropin secretion and leads to anovulation, especially in 
the first months following delivery [28]. This is consistent with both the incessant ovulation 
and gonadotropin hypothesis as contributing to ovarian cancer. Indeed, most trials show a slight 
protective impact from breastfeeding, with odds ratios approximating 0.6–0.7 [29] although 
this has not been observed in other studies [26]. Few trials investigated a link to tumour subtype, 
with one study showing that lactation conferred the biggest decrease in decrease for 
endometrioid tumours [29], although another reported the biggest decrease in risk for mucinous 
cancers[22].  A recent meta-analysis shows a substantial protective impact for breastfeeding 
(summary RR=0.68, 95 percent CI: 0.61–0.76) that increased with the duration of  
breastfeeding (the RR was0.85, 0.73, and 0.64 for < 6 months, 6–12 months, and > 12 months 
of complete breastfeeding, respectively) [30]. Thus, particularly for long-term duration, 
lactation protects against epithelial ovarian cancer. 
 
1.2.1.5. Benign gynecologic conditions and gynecologic surgery 
Several gynecological conditions, including polycystic ovary syndrome (PCOS), 
endometriosis, and pelvic inflammatory disease (PID), were examined as risk variables for 
ovarian cancer. PCOS is a multi-factor disease that often results in obesity, hirsutism, menstrual 




due to unopposed endogenous estrogen and/or elevated androgens. Data from the Cancer and 
Steroid Hormone Study, a population-based case-control study [10], were used to investigate 
the connection between PCOS and ovarian cancer. The limited data was inadequate to create a 
consensus that PCOS is a risk factor for ovarian cancer [31].  
Endometriosis is one of the most common gynaecological disorders in women, affecting about 
10%–15% of reproductive years[32]. Endometriosis has been linked to ovarian cancer in the 
medical literature since 1925, despite being deemed a benign condition. Ovarian cancers with 
endometriosis and clear cell histologies[22], [32], show the strongest connections with 
endometriosis, consistent with molecular information supporting endometrial epithelium as the 
origin of these subtypes[33]. In addition, Pearce and colleagues [34], recognized an enhanced 
threat of low-grade serous ovarian cancer ovarian cancer (OR=2.11, 95 percent CI: 1.39–3.20) 
and clear cell cancer (OR=3.05, 95 percent CI: 2.43–3.84) among women with endometriosis 
and endometriosis (OR=2.04, 95 percent CI: 1.67–2.48). The writers suggested that 
endometriosis and endosalpingiosis procedures may result from a comparable underlying host 
susceptibility to both endometrium and fallopian tube implantation of exfoliated Müllerian 
epithelial neurons. The association of endometriosis and endometrioid with apparent ovarian 
cell carcinomas may constitute mutual risk factors[32], genetic susceptibility[35], and/or 
pathogenesis rather than a causal association[36].  
 
1.2.1.6. Oral contraceptives and other forms of contraception 
Over the previous several decades, epidemiological literature has continuously revealed that 
the use of oral contraceptives is inversely linked to ovarian cancer danger. With longer use, the 
protective effect increases[17], [37] with about 20 percent reduced danger per 5 years of use 
persisting decades after use reduced [38]. In addition, risk decrease does not seem to be specific 
to any particular oral contraceptive formulation or ovarian cancer histotype [38], although in 




contraceptive use amounts to the avoidance of around 30,000 instances of ovarian cancer each 
year and is estimated to have already avoided 200,000 instances of ovarian cancer and 100,000 
fatalities over the past 50 years [39]. Mostly owing to the low incidence of use, progestin-only 
contraceptives were less researched, but the available information indicate that they may also 
lower the risk of ovarian cancer [40]. 
Other than oral contraceptives, relatively few studies have examined techniques of 
contraception. In several studies [41], the use of an intrauterine device (IUD) was associated 
with decreased danger of ovarian cancer, although a separate study noted enhanced risk [42]. 
However, a small incidence of intrauterine device (IUD) use happened in that population prior 
to the latest IUD formulations. Any protective impact connected with IUD use may depend on 
the length of use, similar to oral contraceptives. In the Shanghai Women's Health Study cohort, 
Huang and colleagues, 2015 assessed IUD use and ovarian cancer risk and discovered long-
term use of at least 20 years of IUD was associated with a 38% decrease in danger. IUD use is 
the most prevalent contraceptive technique in China, with a prevalence rate of approximately 
50 percent among year-old females[43]. The writers suggest that the elevated prevalence of 
long-term use of IUD and the related powerful protective impact may contribute to China's low 
incidence of ovarian cancer[41]. Vasectomy was assessed in conjunction with ovarian cancer 
danger and results were inconclusive [42], although Reid and colleagues[11] indicated that 
vasectomy could result in a tiny risk decrease, possibly owing to decreased sperm exposure.  
Because contraceptive methods can be modified, further study is required to replicate these 
results. Additionally, a study is required to clarify how distinct kinds of contraception affect 
ovarian cancer risk, particularly by histotype. 
 
1.2.1.7. Hormone replacement therapy (HRT) 
The connection with HRT is less evident than oral contraceptive use. HRT decreases 




concentrations are still greater than premenopausal females[44]. Postmenopausal HRT, on the 
other hand, may improve ovarian cell proliferation induced by oestrogen and thus boost 
risk[45]. Initial studies on the subject have concentrated among postmenopausal females on 
restricted oestrogen therapy (ET). Several case-control studies[9], [17], cohort [46] and meta-
analysis [47] discovered no link with length of use, although a substantial or suggestive trend 
in enhanced danger was noted by two[11]. More recent studies show that the risk of OC in HRT 
users is increasing[34], [48]. For instance, in one study present and previous HRT users of five 
years or more had a considerably greater risk than patients who had never used HRT (RR=1.41, 
95 percent CI: 1.07–1.86 and RR=1.52, respectively, 95 percent CI: 1.01–2.27). However, there 
was no change in risk if HRT was used for less than five years (RR=1.01, 95% CI: 0.70–1.44 
and RR=0.88, 95% CI: 0.64–1.19, respectively)[49]. The writers found that the increased 
danger appeared to be mainly driven by length rather than usage status.  In comparison, a 
collective re-analysis of 52 epidemiological studies found increased the risk of OC in existing 
HRT users, even those with less than 5 years of use[39]. In addition, risk reduced over time 
after discontinuation of use, although a tiny excess of risk was still noted even 10 years after 
discontinuation of long-term HRT. Only recently has research with adequate statistical power 
examined the effect of the combined oestrogen and progestin use. It was assumed that progestin 
promotes apoptosis while oestrogen encourages ovarian epithelial cell proliferation [50].  
 
1.2.1.8. Obesity 
In postmenopausal females, aromatization of androgens in adipose tissue is the predominant 
source of circulating oestrogens [51]. The convincing role of obesity in hormone-related 
cancers pathogenesis, such as endometrial and post-menopausal breast cancers [52], has 
spurred research into the prospective connection with ovarian cancer [53]. Body mass index 
(BMI) is one metric of significant concern. A meta-analysis of 28 population surveys revealed 




females (30 kg / m2 BMI) compared to normal weight (18.5–24.9 kg / m2 BMI), RR=1.2 and 
1.3 pooled, respectively [54]. In a 2008 evaluation of premenopausal obese women, there were 
an increased risk of incidence in compared to normal weight females (RR=1.72; 95 percent CI: 
1.02–2.89); however, this enhanced risk was not evident among postmenopausal females 
(RR=1.07; 95 percent CI: 0.87–1.33) [55].  A more recent assessment by the Ovarian Cancer 
Association Consortium (OCAC) of 12 case-controlled studies also discovered that the positive 
association with BMI was greater among premenopausal females[56]. The EPIC cohort study, 
on the other hand, found the greatest risk connections for adiposity measurements (BMI and 
weight) among postmenopausal females[57]. In the NHS, a measure of fat distribution, higher 
hip circumference was a risk factor among post-menopausal females, but there was no link to 
waist-to-hip ratio, waist circumference, and BMI [57]. 
 
1.2.1.9. Diet and nutrition 
Despite countless epidemiological analytical research, it is mainly unresolved whether diet 
impacts ovarian cancer risk. The noteworthy exception is the intake of vegetables, for which 
there is proof that greater intakes are connected with reduced risk and also to some extent for 
the consumption of whole grain products and low fat milk[58]. The risk associated with specific 
fats and oils, fish and meats and certain dairy products are inconsistent and there can be no firm 
conclusions. Recently, the EPIC cohort study and the Netherlands Cohort Study conducted a 
nutrient-wide association assessment assessing 28 food groups and 29 nutrients from 430,476 
females, including 1,522 incident ovarian cancer instances, using nutritional questionnaires. 
Meta-analysis of the two cohort research discovered that females with high saturated fat 
consumption had increased hazards (HR=1.21, 95 percent CI: 1.04–1.41). There are no 
consistent studies of meat consumption[59], [60]. A major prospective study found that women 
had an increased risk of OC in the highest intake quartile of dietary nitrate (HR=1.31, 95 percent 




tea consumption [61]–[63]. While most vitamin D is manufactured from UV-B exposure in the 
skin[64], it is also partially derived from our diet or dietary supplements. Vitamin D is 
transformed in the liver to 25- hydroxyvitamine D (25(OH)D) and metabolized in the kidney 
to the active form. 1, 25-dihydroxyvitamin D (1, 25(OH)2D3) controls bone metabolism, 
immune reaction modulation, and cell proliferation and differentiation regulation [64], [65]. 
Experimental studies showed that 1, 25(OH)2D3 inhibits the proliferation of cells in ovarian 
cancer cell lines and induces apoptosis [66]. However, there is inconsistent epidemiological 
evidence that vitamin D affects the risk of ovarian cancer. A systemic evaluation found that 
there is no evidence that vitamin D reduces risk [67]. A comparable conclusion was reached by 
a meta-analysis of ten longitudinal studies[68] and other cohort studies[69]. However, a recent 
Mendelian randomization study of nearly 32,000 European women was conducted to address 
conflicting findings from observational studies and found single nucleotide polymorphisms 
(SNPs) associated with low circulating vitamin D levels were associated with increased risk of 
ovarian cancer (OR=1.27; 95% CI: 1.06–1.54)[70]. 
 
1.2.1.10. Exercise and physical activity 
The overall health advantages of exercise are well known and a particular impact on ovarian 
cancer could be anticipated, at least indirectly, by reducing adipose tissue (and thus oestrogen 
concentrations), lower ovulation frequency and decreased chronic inflammation [71]. To date, 
29 epidemiological studies have explored physical activity and risk of ovarian cancers, 
including fourteen prospective cohort studies [72]–[74] two historical cohort studies [75], ten 
population-based case-control studies [76]–[79], and three case-control studies based on 
hospital[80]. Results are not completely coherent, but a 2007 meta-analysis estimated an 
approximately 20 percent reduced risk compared to the least active (pooled relative risk=0.81, 
95 percent CI: 0.72–0.92) for the most active females [54]. Most lifelong physical activity 




[72]. Similarly, prolonged sedentary behaviour [73], elevated rates of complete sitting duration 
[73], [74], and chronic physical recreational inactivity were all associated with increased 
risk[78]. It does not seem that the advantage of physical activity varies by histological type 
[74], [78], but there is inadequate information to draw a convincing conclusion [77]. While 
further study may refine this situation, the promotion of periodic activity should be encouraged 
when considering the extra advantages of exercise on weight control, bone density, and heart 
disease. 
 
1.2.2. Other lifestyle and environmental factors 
1.2.2.1. Cigarette smoking 
Many early reports have concluded that smoking is not a risk factor[81]. Results from more 
recent research indicate that this is most probably because analyses for the effect on different 
histological subtypes were not performed. Indeed, smoking appears to boost the risk of 
mucinous ovarian cancer, but not other subtypes[22]. A meta-analysis of 51 epidemiological 
surveys in 2012 found that present smokers have a 50 percent rise in the danger of invasive 
mucinous ovarian cancer and a more than double rise in the danger of borderline mucinous 
ovarian cancer (RR=2,25, 95 percent CI: 1,64–3,08) compared to none smokers, however, there 
is no increased risk of serous (0.96, 95% CI: 0.87–1.06) or clear cell (0.80, 95% CI: 0.63–1.01) 
cancer and a lower risk of endometrioid cancer (0.82, 95% CI: 0.71–0.95) [82]. In another meta-
analysis, the risk of mucinous disease increased with the quantity smoked in a dose-response 
relationship, but returned to the risk observed those who had never smoked within 20–30 years 
of stopping smoking [83]. Histologically, mucinous ovarian tumours are similar to mucinous 
gastrointestinal cancers, some of which have also been associated with smoking (pancreatic 
gastric and colorectal cancers) [83]. These results collectively indicate that ovarian cancer 





1.2.2.2. Alcohol consumption 
Consumption of alcohol raises the circulating levels of androgens, oestrogens and other sex 
hormones in serum and urine and is associated with enhanced risk of breast cancer [84], [85]. 
Studies examining the effect of alcohol use on the risk of ovarian cancer studies are inconsistent 
with reports of no associations [86], [87], proof of enhanced risk[88], and of reduced risk[88]. 
Efforts have been made to address the observed inconsistency by quantifying the danger by the 
type of alcohol consumed (wine, beer or alcohol)[88], [89]. In a large population-based case-
controlled study, intake of beer (not liquor or wine) during early adulthood (20–30 years of age) 
was correlated with a mildly enhanced danger of invasive ovarian cancer, with the association 
being restricted to serous tumours (OR=1,52, 95 percent CI: 1,01–2,30), although outcomes for 
other histological subtypes were based on sparse information. Regular intake (1 or more 
beverages per day) was connected with this risk, and there was no proof of a dose response 
relationship [90]. Data from the Netherlands Cohort Study on Diet and Cancer discovered no 
risk connection with wine, beer or liquor consumption[91]. A pooled assessment of 10 cohort 
surveys involving more than 500,000 females instances also found no risk connection with 
overall alcohol consumption (pooled multivariate RR=1,12, 95 percent CI: 0,86–1,44 
comparing more than> 30g to 0 g alcohol per day) or alcohol consumption from wine, beer or 
spirits [92]. In a recent meta-analysis of 10 studies (3 cohort studies and 7 case-control surveys) 
with 135,871 females, including 65,578 wine drinkers [93], there was no connection (OR=1,13, 
95% CI: 0,92–1,38) between wine intake and ovarian cancer risk. Based on this information, it 
seems reasonable to conclude that alcohol consumption minimally influences the risk of ovarian 
cancer and is potentially restricted to specific histological subtypes.  
 
1.2.2.3. Asbestos and talcum powder 
 Asbestos fibres have been discovered in the ovaries of both human [94] and animal studies[95]. 




owing to tiny numbers of exposed female subjects and misclassification of illness (i.e., 
asbestos-related peritoneal mesothelioma is often misdiagnosed as ovarian cancer on death 
certificates). A systematic review and meta-analysis of fourteen cohorts and two case-control 
studies observed a statistically important 75% increased risk of ovarian cancer in asbestos-
exposed females (impact size = 1.75, 95% CI: 1.45–2.10) [96]. The association, however, was 
attenuated (impact size=1,29, 95 percent CI: 0,97–1,73) in a study when the cancer diagnosis 
was restricted to pathologically confirmed instances [97]. Despite the absence of consistency, 
the International Cancer Research Agency (IARC) has stated that human proof that exposure 
to asbestos causes ovarian cancer is 'adequate'. Talcum powder, similar to asbestos, is a silicate 
that has been widely researched with inconsistent outcomes in relation to cancer risk. While 
mechanistic, pathological, and animal studies do not provide evidence of carcinogenicity of talc 
on the ovarian epithelium [98], epidemiological studies have shown that talc use is associated 
with enhanced risk of ovarian cancer. A meta-analysis of 21 studies recorded an increase in the 
risk of genital exposure to talc of approximately 35 percent in 2006, and a previous meta-
analysis had similar findings [94], and a previous meta-analysis had comparable results [99]. 
Newer studies, however, have continued to report conflicting outcomes. In 2014, among a 
cohort of 61,576 post-menopausal females, the Women's Health Initiative recorded no 
connection. Cramer and colleagues conducted a case-control retrospective study that found 
increased risk among talc users similar to those previously reported (OR=1.3, 95 percent CI: 
1.16–1.52) [100], especially among serous and endometrioid cancers. The research also 
discovered that risk among premenopausal females and in postmenopausal females using 
hormonal therapy was highest, indicating that oestrogen plays a part in the connection. 
Furthermore, genetic trials indicate that females with certain variations in glutathione S-
tansfase M1 (GSTM 1) a n d / o r Glutathione-transferase T1 (GSTT1) may have a greater risk 
of ovarian cancer connected with talc use [101]. Based on the evidence available, genital talc 





1.2.2.4. Drug use 
Epidemiological proof that links Pelvic Inflammatory Disease PID and endometriosis to 
increased risk of ovarian cancer indicates that inflammation plays a major role in ovarian 
carcinogenesis. Furthermore, studies in animals and in vitro indicate that aspirin inhibits 
development ovarian cancer[103]. Several prospective studies [104][105] and case-control 
[106]–[108] found an inverse connection between aspirin or non-steroidal anti-inflammatory 
drugs (NSAIDS) and ovarian cancer incidence, although no association was recorded in other 
trials [109], [110]. Prizment and peers studied these drugs using information from the Iowa 
Women's Health Study's prospective cohort of about 20,000 women [111]. Compared to 
females who did not report aspirin use, the relative risks of ovarian cancer for those who used 
aspirin < 2, 2-5 times and 6 times a week were 0.83, 0.77 and 0.61, respectively (P=0.04), but 
there was no connection between NSAID use and risk. In contrast, frequent use of NSAIDS 
was protective (HR=0.81, 95% CI: 0.64–1.01) [112], but aspirin use was not (HR=1.11, 95% 
CI: 0.92–1.33). No dose-response relationship was noted with enhanced frequency or length of 
use and outcomes were not different when tumour histology stratification was performed [112]. 
A later pooled assessment of 12 case-control studies evaluating aspirin in the Ovarian Cancer 
Association Consortium OCAC [106] showed aspirin use was correlated with a decreased risk 
of ovarian cancer (OR=0.91, 95 percent CI: 0.84–0.99), particularly among daily users of low-
dose aspirin (OR=0.66, 95 percent CI: 0.53–0.83). Thus, the same aspirin regimen prescribed 
to safeguard against cardiovascular occurrences and other diseases (e.g. colorectal cancer) 
could decrease ovarian cancer danger by 20%-34%. An increasing body of proof promotes the 
role of metformin, the antidiabetic agent, in various cancer prevention and therapy [113]. A 
case-control study was conducted using the UK-based General Practice Research Database 
[112], including 1,611 incident ovarian cancer instances. Long-term use (about 30 




reduction trend (OR=0.61, 95% CI: 0.30–1.25), but the findings were not being statistically 
significant. Additional trials have shown reduced incidence and mortality among groups treated 
with metformin [113]. Due to the lack of robust studies, further exploration of the potential for 
the use of metformin as a chemopreventive agent are needed. 
 
1.3. Origin of ovarian cancer  
1.3.1. Type I Tumours  
One group of ovarian cancers are termed type I tumours. Generally, these tumours behave in 
an indolent fashion and are relatively stable genetically. They lack mutations in TP53 but 
exhibits a distinctive molecular genetic profile for each histologic type[114]. 
1.3.1.1. Endometrioid and clear cell ovarian cancers  
Endometriod tumours morphologically resemble cells that line the internal part of the uterus 
(endometrium) and may result from the aberrant overgrowth (hyperplasia) of endometrium 
outside the uterus. Endometrioid tumours are occasionally benign; it is unilateral and occurs in 
association with cysts[115]. Malignant endometrioid ovarian tumours are either cystic or 
predominantly solid. The prognosis of malignant ovarian endometrioid carcinomas is better 
than either mucinous or serous carcinomas. The inflammatory processes that occur during 
endometriosis may have important role in the malignant transformation and growth of the 
surface epithelium of ovaries. This may be triggered by tumour necrosis factor-alpha (TNF-α) 
and growth factors that promote cellular growth and proliferation such as insulin-like growth 
factor (IGF)[116].  
 
1.3.1.2. Mucinous ovarian cancer  
Mucinous tumours are epithelial ovarian tumours containing cells that are similar to the 





Borderline mucinous tumours resemble benign mucinous tumours but the difference is that the 
cyst chambers have papillae projecting into them and exhibit solid regions. These accounts for 
about 10– 14% of all ovarian mucinous tumours[117]. 
 
1.3.2. Type II Tumours  
Type II Tumours are considered highly aggressive tumours and are often detected at advanced 
stages because they rapidly metastasize to the adjacent tissues to form many small nodules on 
the peritoneal surface. Recent studies have provided cogent evidence that ovarian tumours 
originate in other pelvic organs and metastasize to the ovary secondarily. 
Type II tumours are characterized by inactivation of TP53[118]. TP53 functions as a tumour 
suppressor and thus has a critical role to prevent cancer. Missense mutations of TP53 in many 
tumours lead to single amino acid substitution in full-length p53[119]. The tumour progression 
may be driven by accumulation of the mutant p53 protein in cancer cells, resulting from its 
prolonged half-life [119].  
 
1.3.2.1. Serous ovarian cancer  
Serous ovarian cancer is an epithelial – stromal tumour and it is now thought to gradually 
developed from the cells that are lining the Fallopian tube. Benign serous tumours are formed 
with a single chamber with a flat internal lining and filled with straw-coloured watery fluid. Up 
to 20 % of benign serous tumour are bilateral, simultaneously occurring in both ovaries[120]. 
Benign serous tumours have more exuberant fine papillary projections in the lining side of cyst 
cavity. Borderline serous tumour accounts from 10% to 15% of all serous tumour. Malignant 
serous tumour usually contains multiple chambers or locations in the same cyst with solid 






Figure (1-4): Shows the origin of ovarian cancer. Types of cancer of the ovaries according to cell origin. Different 
cell types may develop into different types of cancer cells in the ovaries. BRCA1's abnormal presence is associated 
with more probability of ovarian cancer predisposition that arises from these cells in women. Adapted from [121]. 
 
1.4. Neoplasms of the ovary 
Ovarian cancer is a broad and wide term used for a vast range of neoplasms which apparently 
arise in the ovaries. Based on their putative tissue of origin, ovarian neoplasms are broadly 
classified for three groups: surface epithelial–stromal tumours, germ cell, sex cord–stromal cell. 
Histologically, each group contains many subtypes of ovarian tumour. Since the tumours of 
ovarian epithelium are the most prevalent and the most lethal this discussion will focus 




Figure (1-5): Classification of ovarian cancer based on cell origin, There are four main histological subtypes of 
ovarian cancer: serous (the most common), endometrioid, mucinous, and clear cell [122]. 
 
1.4.1. Class I: Epithelial Ovarian Tumours 
Epithelial ovarian tumours are derived from the epithelial cells on the surface of the ovary. It is 
the most common form of ovarian cancer, starting from the cells that cover the outer surface of 
the ovary. Most ovarian tumours are epithelial cell tumours, accounting for approximately 85-
90% of ovarian cancers [123]. Some studies have suggested that serous ovarian carcinoma 
actually originate in the Fallopian tube. This is reinforced by the observation that analysis of 
gene expression showed a high similarity between tubal carcinoma gene expression profiles 
and those of high grade serous ovarian cancer (HGSC). About 50-60% from women who 
reportedly have been tubal carcinomas reported in with pelvic HGSC [124]. The ovaries 





1.4.1.1. Benign epithelial Ovarian Tumours 
Benign epithelia ovarian tumours are a non-cancerous tumour, with no cytologic atypia in the 
surface epithelium of ovaries, occasionally treated by surgical removal of the tumour with 
preservation of the ovarian tissue[125]. 
 
1.4.1.2. Borderline epithelial Ovarian Tumours 
Borderline low-malignant potential (LMP) tumours are a borderline type of cancer that is 
growing slowly, and which is less life threatening than most ovarian cancer, although it may 
eventually invade other tissues. This kind is different from typical ovarian cancers. It does not 
grow into the stroma of ovary (the supporting tissue of the ovary). This kind of cancer occurs 
in younger women and can be effectively treated if it is correctly diagnosed [126]. 
 
1.4.1.3. Invasive carcinoma epithelial Ovarian Tumours 
Invasive carcinoma has typically invaded other organs by invading and metastasizing from the 
ovaries[127]. Invasive epithelial ovarian cancers tend to invade the lining and organs of the 
pelvis and abdomen, results in accumulation of fluid in the abdominal cavity (ascites). These 
tumour cells can be classified into different histological types according to their morphology. 
Serous ovarian cancer is the most common and characterized by chromosomal anomalies and 
high genomic instability that include intrachromosomal breaks and aneuploidy. This type of 
ovarian cancer is almost invariably associated with mutations in tumour suppressor gene TP53 
[127], [128]. 
 
1.4.2. Class II Germ cell tumour  
These tumours start from the cells that produce the eggs (ova) and accounts for approximately 





1.4.2.1. Benign germ cell tumours 
Benign germ cell tumours often occur as non-cancerous matures cystic teratomas. 
Chemotherapy treatment is not necessary because these tumours can usually be successfully 
treated by surgical removal with preservation of the uninvolved ovarian tissue[129].  
 
1.4.2.2. Malignant germ cell tumours 
Ovarian germ cell tumours are relatively rare, accounting for less than 10% of total ovarian 
cancers, about 2% to 3% of germ cell tumours are malignant [130], [131]. Such tumours start 
from the primitive germ cell and then slowly separate to resemble embryonic developmental 
tissues (ectoderm, mesoderm, endoderm) and extraembryonic tissues (yolk sac and 
trophoblast). Tumours of germ cells originating in the ovary have homologous equivalents in 
the testis [132].  
 
1.4.3. Class III: Stromal Ovarian Tumours 
Sex cord stromal ovarian tumours are the least common type of ovarian tumous, accounting for 
approximately 5-10% of ovarian tumours. They originate from the structural tissue that hold 
the ovaries together, cells that produce the female reproductive hormones oestrogen and 
progesterone. Most of these tumours are benign and never spread beyond the ovary[133].  
 
1.4.3.1. Benign tumours of stroma cell 
Benign tumours can be treated by removing the ovary partially or completely[134]. 
 
1.4.3.2. Malignant tumours of stroma cell  
Stromal tumours arise from cells in the connective tissue of the ovaries and those containing 




which means that the cells grow slowly and appear almost healthy. These cancers have a 
survival rate of 95% when diagnosed at stage I[135], [136]. 
 
1.4.4.  Other cancers that are similar to epithelial ovarian cancer 
1.4.4.1. Primary peritoneal carcinoma 
Primary peritoneal carcinoma (PPC) is a rare form of cancer. At surgery, this form of cancer 
looks the same as epithelial ovarian cancer due to spread through the abdominal cavity[137]. 
Under the microscope, its histology suggests that it develops from the cells of the peritoneum 
lining of the pelvis and abdomen; these lining cells closely resemble the epithelial ovarian cells. 
As a result, this type of cancer may be referred to by different names including serous surface 
papillary carcinoma, extra-ovarian and primary peritoneal carcinoma (EOPPC)[138]. 
Primary peritoneal carcinoma occurs when women still have their ovaries, while it is more of a 
concern for women have had removed their ovaries to prevent ovarian cancer. The symptoms 
are similar to those of ovarian cancer, including increase in the blood level of the tumour marker 
CA-125 as well as changing in bowel habits, bloating, abdominal pain, vomiting and 
indigestion. In addition, patients with PPC usually receive the same treatment as those with 
ovarian cancer, including surgery to remove as much as possible of the cancer then followed 
by chemotherapy similar to that given for ovarian cancer [139]. 
 
1.4.4.2. Fallopian tube cancer 
This type of cancer is also rare and similar to epithelial ovarian cancer. It begins in the fallopian 
canal that carries an ovum from the ovary to the uterus. Fallopian tube cancer has similar 
symptoms of the PPC and ovarian cancer. Its treatment is similar to that for ovarian cancer, 





1.4.4.3. Ovarian germ cell tumours 
Ovarian germ cell tumours are principally diagnosed in young women but sometimes occur in 
infants and older women. Germ cell tumours account for 15-20% of all ovarian neoplasms and 
this type of cancer could be the life threating. There are many subtypes of this tumour, the most 
important one being teratomas, and more than one subtype can occur at the same time [141]. 
Teratomas may be a cancerous form called immature, which occurs usually in young women 
and girls younger than 18 years, and a benign form called mature, which is the most common 
type of germ cell tumour and usually affects women of reproductive age[142]. 
 
1.4.4.4. Dysgerminoma 
This type of ovarian germ cell cancer is relatively rare. It usually affects women less than 20 
years old, it is considered malignant, but it does not spread very quickly. The disease is limited 
to the ovaries in more than 75% of patients. Additionally, more than 75% of patients who are 
affected by this type of tumour are treated by surgical removal, without any further 
treatment[143]. 
 
1.4.4.5. Endodermal sinus tumour (yolk sac tumour) and choriocarcinoma 
This type of tumour typically affects girls and young women. It grows and spreads quickly but 
in most cases, it is very sensitive to chemotherapy[11], [144]. 
 
1.5. Theories for cancer of the ovaries 
The clear link between the history of ovulation in patients and the risk of developing ovarian 
cancer in clinical aspects of ovarian cancer pathogenesis theories has prompted many 





1.5.1. Theory 1:  The incessant theory of ovulation 
Fathallah proposed this first theory to explain the aetiology of ovarian cancer in 1971. This 
speculates that repeated damage to the ovarian surface epithelium (OSE) during ovulation 
accompanied by cell proliferation results in successive accumulation of DNA mutations, 
resulting in cancer of the ovaries. Based on this hypothesis, serial rounds of programmed cell 
death and OSE repair at the ovulation site cause genetic instability, rendering this cell layer 
more vulnerable to neoplasm growth [145], [146].  Murdoch and colleagues presented evidence 
to support this hypothesis where the OSE cells in the ovulation site experience oxidative DNA 
damage, p53 expression and apoptosis. A genetically altered progenitor cell with defective 
DNA that is not committed to death can result in a transformed phenotype that is then 
propagated after ovulatory wound healing. Then, with each ovulation cycle, there is an 
increased likelihood of generating genetically modified and carcinogenic cells in the OSE and 
this increases the risk of development of ovarian tumours[147]. 
 
1.5.2. Theory 2:  gonadotropin of pituitary theory  
Gonadotropins, FSH and LH, are important hormones for ovarian cell control and indicated a 
potential role in ovarian carcinoma pathogenesis. Specific gonadotropin receptors have been 
identified for ovarian cancer. The role of endocrine factors in regulating normal ovarian growth 
can also provide appropriate conditions for malignant transformation. In addition, the presence 
of high levels of FSH and LH in ovarian cancer fluids  indicates that these hormones play a role 
in ovarian cancer development and progression [148], [149]. Gonadotropins activate mitogenic  
pathways, including the extracellular signal-regulated kinase (Erk) pathway, promoting ovarian 
cancer cell proliferation and invasion [150]. Gonadotropins stimulate proteolytic enzymes and 
cytokines during ovulation to produce an inflammatory process that causes the release of the 
ovum to rupture the OSE surface. The oestrogen-producing follicle is transformed to a 




the OSE, which then provides feedback inhibition which lowers gonadotropin levels [151]. 
There is total depletion of the germ cells in the ovary during menopause, followed by loss of 
the follicular structure which protects the germ cells, resulting in the absence of corpus luteal 
input, resulting in high levels of serum gonadotropin and proinflammatory cytokines. High 
levels of gonadotropin in postmenopausal women may therefore promote an inflammatory 
environment that may not contribute to ovulation but may lead to a high risk of developing 
ovarian cancer by inducing morphological changes in OSE and promoting the transformation 
of genetically damaged cells into ovarian cancer [151]. Apoptosis failure in granulosa and theca 
cells after the ovulatory period can promote carcinogenesis because these cells retain the ability 
to produce steroid hormones [152]. Epidemiological evidence supports this theory and has 
shown that in women with multiple pregnancies, breast feeding, and those who use oral 
contraceptives, the risk of developing ovarian cancer has decreased as a result of suppressing 
pituitary gonadotropin secretion in these circumstances[150] . 
 
1.5.3. Theory 3:  The theory of androgen / progesterone 
The theory of hormonal enhancement, also known as the theory of androgen / progesterone, 
indicates that androgens (elevated after menopause) can induce ovarian cancer generation. On 
the other hand, progestins, protect against disease growth through increasing ovarian 
testosterone levels, progesterone contraception may reduce the risk of ovarian cancer [153]. In 
addition, androgen receptors can drive the proliferation of cells in the ovarian surface 
epithelium. The follicles are supposed to produce androgen and create a rich androgen 
environment around the epithelial cells. It has been shown that documented hyperandrogenic 
disorders such as acne, hirsutism and polycystic ovarian syndrome are associated with increased 





1.5.4. Theory 4: The theory of inflammation 
The inflammatory theory suggests that inflammation may work in conjunction with steroid 
hormones and ovulation to increase the possibility of ovarian epithelium carcinoma as a cause 
of ovarian cancer growth [155]. According to this theory, repair damaged DNA is impaired, 
particularly in those patients with defective BRCA1 and BRCA2 function, resulting in a high 
risk of carcinogenesis. Furthermore, inflammatory stimulation as a result of exposure to 
endometriosis, talc or asbestos, or as a result of ovulation itself, may work to support ovarian 
cancer development[156]. Inhibition of inflammation induced a decrease in cancer incidence 
in a study using anti-inflammatory drugs, where a statistically significant inverse correlation 
between the use of anti-inflammatory drugs and the risk of cancer was reported [157]. Several 
mechanisms have been anticipated to explain the beneficial effects of anti-inflammatory drugs 
in reducing the risk of this disease, including apoptosis induction, cyclo-oxygenase activation 
of prostaglandin synthesis, or cellular immune response enhancement [157]. Inflammation 
biomarkers can be used as a way of tracking ovarian cancer progression. These biomarkers can 
also help prevent and treat cancer by developing a new anti-inflammatory medication that can 
also be used as an adjuvant to radiation therapy or chemotherapy, activating NF-kB and 
mediating resistance on its own [158]. 
 
1.5.5. Theory 5: The theory of tubal origin 
This is the new theory which indicates that the vast majority of ovarian cancers occur in the 
fallopian tube, both in women at high risk and in the general population, and that there is no 
obstacle to peritoneal spread [159].  Most of the ovarian cancers found in women with BRCA 
mutations in the fallopian tube in their early stages [160]. Pre-invasive changes in the fimbriated 
tube end are usually associated with early HGSOC[161]. In addition, disabling PTEN, a crucial 
negative regulator of the PI3K pathway, and Dicer, an important gene for microRNA synthesis, 




and then rapidly metastasized to the abdominal cavity, leading to ascites and death[162]. 
Research is currently underway to investigate the molecular and genetic basis essential to the 
production of ovarian cancer from fallopian tube[163]. 
 
1.6. Epidemiology 
1.6.1. Descriptive epidemiology 
Ovarian cancer incidence shows broad geographic variation [164]. In advanced areas of the 
globe, including North America and Central and Eastern Europe, the largest age-adjusted 
incidence rates are found, with levels usually exceeding 8 per 100,000. Percentages are 
intermediate in South America (5.8 per 100,000) and lowest in Asia and Africa (3 per 100,000). 
Migration from low rates  countries to high rates countries leads to increased risk underlining 
the value of non-genetic risk factors [165].  Race differences in incidence and mortality within 
the United States mimic the observed international variation with the highest rates among 
whites, intermediate for Hispanics, and the lowest among Blacks and Asians, in big nations 
such as China, variation also mimics global variation with greater incidence and mortality in 
developed, urban, versus less advanced, rural areas[166]. Ovarian cancer incidence and 
mortality have gradually decreased in most developed countries, including North America and 
Europe, since the 1990s [167]. In contrast, the rates of incidence and mortality have increased 
in historically less developed countries with latest economic growth and lifestyle modifications. 
In China, the rise is only evident among rural females, rather than in more advanced, urban 





Figure (1-6): The prevalence of ovarian cancer has wide variation in geography[11]. 
 
1.6.2. Genetic epidemiology 
A family history of the disease is one of the most important risk variables for ovarian cancer 
[170]. First-degree probands relatives have a 3- to 7-fold increased risk, especially when 
multiple relatives are affected and at an early age [171], [172]. Rare elevated penetrating 
mutations in the genes BRCA1 and BRCA2 significantly boost lifetime risk [173] and account 
for the majority of inherited instances and 10%-15% of all instances [174], [175]. Data from 
the Breast Cancer Linkage Consortium indicate that the risk of ovarian cancer in BRCA1 
mutation carriers over the age of 70 years is as high as 44% and in BRCA2 mutation carriers it 
is close to 27%[176]. Hereditary non-polyposis colorectal cancer syndrome (HNPCC) can 
account for at least 2% of instances and confer a lifetime risk of up to 20% [173]. Women with 
mutations in DNA repair genes like BRIP1, RAD51C, and RAD51D have estimated lifetime 
hazards of 5.8%, 5.2%, and 12%, respectively, [177], [178]. Deleterious mutations in BRCA1/2 
and other double-strand DNA break genes are more closely correlated with susceptibility to 
HGS ovarian cancer, although they happen in other tumour subtypes [178]. Ovarian cancer 
associated with HNPCC typically occurs as endometrioid or clear cell tumours rather than the 




comparative ovarian cancer family danger [180]. Genome-wide association studies [181] found 
22 vulnerability alleles with weak to mild impacts in European populations for invasive ovarian 
cancer. Eighteen of these risk loci are associated with all and/or serous ovarian cancer, five are 
connected with mucinous ovarian carcinoma danger, one with ovarian cancer, and one with 
complete cytoreduction ovarian cancer, exemplifying histotype genetic heterogeneity[182]. 
Furthermore, a large-scale pooled assessment of ovarian, breast, and prostate cancer genome-
wide association research recognized five novel loci [183].  
 
1.7. Symptoms of ovarian cancer  
Most patients who have ovarian cancer have symptoms prior to diagnosis. There is no symptom 
specific to ovarian cancer. Most women diagnosed with ovarian cancer do experience pelvic or 
abdominal pain, bloating, difficulty eating, and quickly feeling full after eating with increase 
abdominal size. The symptoms  of ovarian cancer may be different for each woman. The 
symptoms may be caused by noncancerous conditions due to the ovaries being situated near the 
intestines and bladder. As a result, the gastrointestinal symptoms are common but sometimes 
women ignore these symptoms. Diagnosis is complicated by the fact that these symptoms also 
occur in  irritable bowel syndrome, gastritis, stress and depression and has several months may 
elapse before the patients are correctly diagnosed with ovarian cancer[184], [185].  
Table (1-1): the frequency of ovarian cancer symptoms [185]. 
No. Symptoms Frequency (%) 
1 Increased abdominal size 61 
2 Bloating 57 
3 Fatigue 47 
4 Abdominal pain 36 
5 Indigestion 31 
6 Urinary frequency 27 
7 Pelvic pain 26 
8 Constipation 25 
9 Back pain 23 
10 Pain with intercourse 17 
11 Unable to eat normally 16 
12 Palpable mass 14 




14 Weight loss 11 
15 Nausea 9 
16 None 5 
17 Bleeding with intercourse 3 
18 Deep venous thrombosis 1 
19 Diarrhoea 1 
 
1.8. Diagnosis 
The accurate diagnosis of ovarian cancer is complicated by non-cancerous and gastrointestinal 
cancers tumours which have similar symptoms to ovarian cancer. Physical examination is 
performed to look for signs of ovarian cancer and signs of fluid accumulation inside the 
abdomen. Further examinations will be done if ovarian cancer is suspected [186]. Of these, 
ultrasound imaging is preferred to detect whether the ovaries and abdominal cavity possess 
abnormal masses. Additionally, the ultrasound is able to detect whether the masses are solid or 
cyst filled with fluid [187].  Other imaging modalities may be conducted such as positron 
emission tomography (PET), computed tomography (CT) and magnetic resonance imaging 
(MRI), these imaging may be used to detect the type and stage of tumour [188]. CA-125, a 
biomarker of ovarian cancer, may also be measured in blood samples. Laparoscopy, and biopsy 
are used to detect precisely the type and stage of cancer so the treatment plan can be devised 
that is most appropriate to the patient’s ovarian cancer [189], [190]. 
 
1.9. Treatment  
Currently, several options are available for treatment of ovarian cancer. These often involve 
surgical removal of the tumour followed by chemotherapy which is used as adjuvant to reduce 
the residual number of surviving cancer cells. Radiation therapy is used rarely due to the 
adverse effects of it on the adjacent abdominal organs [191]. The chemotherapy regimen has 
advanced over the last 50 years. In the late 1970’s, the use of platinum-based therapy in 
combination with other chemotherapeutic agents became popular[192]. Currently it is 





1.9.1. Surgery  
The main treatment of ovarian cancer is surgery and it can be used for all types and stages of 
ovarian cancer. There is clinical evidence that debulking large masses of tumour is beneficial 
to the patient, even if all gross tumour cannot be removed. The main aim of surgery to remove 
all of the palpable tumour and in advanced stage diseases this may be accompanied by removal 
of the ovaries with Fallopian tubes, omentum, womb or a fatty layer that covers the abdominal 
organs. Surgery alone may be necessary only in patients diagnosed with early disease, 
chemotherapy is generally used in late-stage disease after debulking surgery [193], [194].  
 
1.9.2. Chemotherapy  
Chemotherapy is used after surgery to treat the remaining of cancer or delay relapse. The 
guidelines of chemotherapy in the UK are that must be started no more than 8 weeks after 
surgery [195]. Several factors govern the prescribing of chemotherapy, including the extent of 
surgical treatment that is required, the stage of disease and side effects of chemotherapy [196]. 
The adverse outcomes associated with chemotherapy outweigh the beneficial effects patients 
in early stage disease, so chemotherapy is not advised to be used with stage I disease [196]. 
Ovarian cancer typically is treated with a combination of two or more chemotherapeutics that 
are given intravenously or directly into the abdominal cavity. The chemotherapy used depends 
on the type and stage of ovarian cancer. Malignant germ cell tumours require removal of the 
whole ovary by surgery and intensive multi-agent adjuvant chemotherapy. The chemotherapy 
of malignant germ cell tumours is completely different from the chemotherapy administered 
after surgical treatment of surface epithelial tumours, these tumours consist of embryonic 
mature cells and embryonic cells carcinoma,  and metastasize frequently[197]. 
 The current typical chemotherapy for ovarian cancer is a combination of carboplatin with 




chemotherapy [198]. Initially, most patients respond to chemotherapy treatment, but patients 
may relapse with tumours resistant to the chemotherapy. This leads to a poor prognosis in the 
majority of these cases [199]. In advanced cases of ovarian cancer, the platinum-based 
chemotherapy is considered as essential treatment and has a better prognosis.   
 
1.9.2.1. Platinum chemotherapy  
Cisplatin and carboplatin are platinum-based drugs which cause inter- or intrastrand linking in 
DNA, there are also newer platinum-based drugs including satraplatin, oxaliplatin and 
picoplatin. These compounds lose chloride ions after entry into the cell, and then subsequently 
react with DNA. This process causes DNA damage, cells cycle arrest and apoptosis. Platinum-
based drugs are used for treating the cancer of ovaries, lung, breast, testicular, head, colorectal, 
neck, and bladder cancers. Cisplatin received approval for use in 1978 for testicular and ovarian 
cancer, while carboplatin (second generation platinum drug) was approved for the treatment of 
ovarian cancer in 1989. Carboplatin has fewer toxic side effects than cisplatin which causes 
nephrotoxicity, nausea, vomiting, bone marrow suppression, anemia and neutropenia. In 
addition, carboplatin and cisplatin have similar activity but carboplatin is more stable than 
cisplatin [200]. The third-generation platinum-based drug (oxaliplatin) received approval use 
from the FDA for treatment of colorectal cancer but is not widely used to treat ovarian 
cancer[201].  
 
1.9.2.2. Taxanes  
Taxanes are an important family of chemotherapeutic drugs identified in the early 1990s and 
which are derived from the bark of the yew tree.  They are used for treatment different types of 
cancers [202]. Taxanes cause cycle arrest and apoptosis by inhibiting cell division in G2/M 
phase by stabilising microtubules in a polymerised state. They inhibit mitosis by interfering 




[203]. Paclitaxel and docetaxel are widely used taxanes that are very active chemotherapeutic 
agents for earlier stages of cancer with an established beneficial effect. In addition, they are 
also used to treat other types of cancers including breast, head, oesophagus, lung and bladder 
[204]. Additionally, taxanes decrease cell migration and angiogenesis of tumour and stimulate 
the immune system also by increase the effect of tumour necrosis factor against cancers [205]. 
Patients who receive taxanes may suffer adverse effect such as erythema and desquamation, 
which primarily appeared on the hands and nail pigmentation due to induced cutaneous toxicity 
and skin reactions [206]. Unfortunately, these side effects may be exacerbated by impaired 
metabolism and excretion that results in increased level of drugs in the serum [207].  
 
1.10. Mechanisms of Chemotherapy Resistance  
Chemotherapy resistance prevents effective therapy and can eventually lead to death of the 
patient; thus, it is important to understand drug resistance mechanisms [208]. There are several 









Figure (1-7): Cellular Chemotherapy resistance mechanisms. Cells may develop resistance to chemotherapy 
through various pathways, such as increasing the activity of efflux pumps (such as ATP-dependent transporters) 
to reduce drug influx, resulting in drug removal, triggering detoxifying proteins (such as cytochrome P-450), 
repairing their damaged DNA, disrupting and preventing apoptotic signalling processes as well as changing cell 





1.10.1. Reduce intracellular Drug Accumulation 
One of the most important mechanisms that contributes to the resistance of cancer cells to 
chemotherapy is to reduce the accumulation of anticancer drugs inside the cells [210]. This may 
be due to decreased uptake of drug into cancer cells and/or increased efflux of drugs.  The 
copper transporter-1 (CTR1) regulates the entry of cisplatin and carboplatin, and 
downregulation of the transporter competitively inhibits the transport resulting in decrease 
entry of the drugs into ovarian cancer cells[208]. 
 
1.10.2. Drug Inactivation  
In vivo drug activation requires complex mechanisms in which drugs interact with different 
proteins, which can modify, partially degrade or confuse the drug with other molecules or 
proteins, ultimately leading to its activation. To achieve therapeutic effectiveness, most 
anticancer drugs must undergo metabolic activation. Nevertheless, cancer cells can also resist 
these treatments by reducing the activation of the drug. Furthermore, cancer cells can develop 
resistance through decreased drug activation due to many of anticancer drugs require metabolic 
activation. Resistance may also result from detoxification of platinum-based compounds via 
conjugation to glutathione S-transferase. This leads to inactivation of chemotherapeutic 
drugs[210].  
 
1.10.3. Apoptosis Deregulation  
Inhibition of cell death by apoptosis in ovarian cancer cells can also result in chemotherapeutic 
drugs resistance. Inhibition of cell death may be caused by expression of the Bcl-2 family of 





1.11. The Mevalonate Pathway  
The Mevalonate Pathway is considered as the most important and fundamental metabolic 
network for cholesterol synthesis in the cell[212]. It produces some essential constituents of the 
cells, including cholesterol, geranylgeranyl pyrophosphate and farnesyl pyrophosphate which 
tightly regulates proliferations and growth of cells. Therefore, blocking this pathway interfers 
with protein prenylation [213]. 
Statins inhibit HMG-CoA-reductase enzyme, the rate limiting step in lipid synthesis pathway . 
There are several commercially available statins. Type 1 derivatives of statins include 
lovastatin, simvastatin, and pravastatin. Full synthetic analogue (type 2 statins) include 
fluvastatin, cerivastatin, atorvastatin, rosuvastatin and pitavastatin. These synthetic products 
show better pharmacodynamics activities due to the size and polarity of the groups attached to 
the HMG-mimetic moiety and result in improved binding to HMGCR.  
These drugs are currently widely used to reduce plasma cholesterol. Unfortunately, statin-
induced myopathy is one of the most common adverse effects associated with statins and in 





Figure(1-8): The mevalonate pathway, Prenylated proteins play critical roles in cytoskeletal, cell growth and 
apoptotic regulation [215]. 
 
1.11.1. Protein Prenylation and the Role in Cancer  
1.12.1.1. Protein Prenylation  
The pathway for the biosynthesis of mevalonate, isoprenoid and cholesterol plays a crucial role 
in human health and disease. The importance of this pathway is highlighted by the discovery 
that two major isopreneids, farnesyl and geranylgeranyl pyrophosphate, are needed to alter a 
variety of proteins via a process called protein prenylation[216]. Farnesyl diphosphate and 
geranylgeranyl diphosphate are used to post-translationally prenylate several families of 
proteins[217], [218]. These proteins have a motif which identifies them for prenylation. A 
carboxy-terminal CAAX motif is recognised by the prenylation enzymes farnesyltransferase 
(FT) or geranylgeranyltransferase-I (GGT-1). CAAX represents cysteine (C), two aliphatic 




transfers either a 15-carbon farnesyl or 20-carbon geranylgeranyl to the cysteine residue.  The 
protein is either a substrate of FT or GGT1 depending on the terminal X amino acid. FT 
catalyses the interaction with CAAX motifs in which X is methionine, serine, glutamine or 
cysteine, while GGT1 interact preferably with CAAX motifs in which X is leucine or 
isoleucine. A subsequent step taken place in the endoplasmic reticulum where the three terminal 
amino acids (AAX) of the prenylated protein are removed by enzyme Ras-convertase-1 
protease resulting in a C-terminus prenylcysteine [220]. However, Rab family proteins possess 
a CC or CXC sequence instead of CAAX structure. These motifs are the binding site for Rab 
escort protein and through which they present the protein to geranylgeranyltransferase-II (Rab 
geranylgeranyltransferase, GGT2) [221]. The enzyme transfers two geranylgeranyl groups to 
the cysteine residues at CC and CXC motifs of the Rab protein and this phenomenon has been 
called a “dualistic prenylation”.  
 Prenylation of small GTPases is essential for their localisation to the cell membranes[222]. 
However, the small GTPases are further regulated by the binding of GTP and its hydrolysis to 
GDP. The cycling of the prenylated proteins between activated and deactivated states is 
regulated by guanine nucleotide exchange factors (GEFs) and GTPase proteins, resulting in 
downstream signal propagation. The transport and/or dissociation from cell membrane 
compartments is regulated by binding of guanine nucleotide dissociation inhibitors (GDI) to 
the prenylated inactive proteins[223]. Upon arrival at their final destination, the prenylated 
proteins are detached from the GDIs resulting in liberation of the protein to the membrane in a 
reaction catalysed by is catalysed by GDI displacement factors (GDFs)[223]. Many prenylated 
proteins are part of cancer pathogenesis involved in cancer cell replication, apoptosis, 
dissemination and blood vessel formation [224]. 
 
1.12.1.2. Prenylated Proteins Involved in Cancer Development  





Figure (1-9): Ras-superfamily the subfamilies of Ras-superfamily are shown  
 
1.12.1.2.1. Ras GTPases  
GTPases are a large group of proteins including Ras subfamily including, Harvey rat sarcoma 
viral oncogene homolog (H-Ras), K-Ras and N-Ras, all of which are confirmed to be mutated 
in human cancers [225]. Both K-Ras and N-Ras are farnesylated and geranylgeranylated while 
H-Ras is farnesylated, and this is essential for localisation to the cell membrane and interactions 
with downstream signalling molecules (e.g. Raf-1) [226]. It has been reported that ovarian 
cancer shows overexpression of both K-Ras and N-Ras [227]. Activation of oncogenic Ras 
pathway activates subsequent signalling pathways (e.g. Raf/Mek/Erk and PI3K pathways) 
resulting in the overgrowth, replication and survival of cancer cells[225].  
 
1.12.1.2.2. Rho GTPases  
The Ras superfamily includes Rho family of GTPases. This subfamily comprises around 20 
GTP-binding proteins such as RhoA, RhoB, RhoC, Rac1 and Cdc42. Some of these proteins 
are solely geranylgeranylated, for example, RhoA, RhoC, Rac1 and Cdc42 [228], [229], while 
RhoB is either geranylgeranylated or farnesylated [229]. Rho GTPases have been shown to 




promote cell cycle progression and Ras-dependent alteration. Rho GTPases have also been 
demonstrated to control processes during angiogenesis and cell dissemination, including the 
formation of membrane profusions [231]. 
 
1.12.1.2.3.  Rab GTPases  
The Rab subfamily has more than 60 members [232]. Rab GTPase's primary role is to regulate 
the trafficking of vesicles between organelles regulating protein secretion, endocytosis, 
recycling and degradation [232], [233] In some tumour types, Rab GTPases have been shown 
to contribute to tumour-stromal cell communication and advancement of the cell cycle [234]. 
Rab proteins were also involved in the development and metastasis of cancer[232]. Rab25 was 
discovered to encourage migration and cancer cell  invasion, and its over-expression is also 
associated with poor survival of ovarian cancer patients[235]. Finally, a number of this family's 
proteins also participate in drug resistance. Rab4a and Rab6, for instance, are under-expressed 
in multidrug resistant cells, whereas their overexpression is linked with enhanced sensitivity of 
cancer cells to cytotoxic medications due to enhanced intracellular accumulation. By 
comparison, Rab8 overexpression increases their resistance to cisplatin in delicate cancer cells 
[234]. 
 
1.12.1.2.4.  The Arf family  
The Arf family consists of about 27 proteins and there are three Arf protein classes, Class I 
(Arfs1–3), Class II (Arfs 4–5), and Class III (Arf6). They were involved in many cellular 
procedures, including vesicle membrane transport, morphology, metabolism, actin 
cytoskeleton, endocytosis, and exocytosis[236]. Despite being part of the Ras superfamily, Arfs 
are not prenylated, but instead are located on the membrane by adding a myristate fatty acid 
moetiy [223]. The Arf family plays a key role in the development of cancer and could be a 




has been demonstrated as a function in migration, invasion and proliferation[237]. Some Arf 
protein expression in breast cancer cell lines has been discovered to be upregulated [238]. 
Finally, Arf has lately been revealed to be negatively correlated with miR-221-3p, whose 
greater expression is connected with improved general survival in patients [239]. 
 
1.12.1.2.5.  Ran GTPase  
Nucleocytoplasmic transport is the major cellular function of Ran GTPase. The Ran protein 
consists of the assembly of mitotic spindles, the nucleation and dynamics of microtubules and 
the post-mitotic atomic assembly [240]. Numerous studies have shown that Ran GTPase is 
involved in cancer cell development, tumour transformation, apoptosis resistance, tumour 
aggression and increased metastasis in several cancer types [241]. Ran is overexpressed cancer 
tissue relative to ordinary tissue and its expression is linked with tumour development. In cancer 
cells, acute Ran silencing induces mitochondrial dysfunction and leads to cell death. Thus, this 
evidence suggests that the Ran pathway may be a useful target for cancer therapy [242]. 
 
1.13. Molecular Mechanisms of Tumourigenesis and the Cytotoxic Activity of Statins  
1.13.1. The Cell Cycle and Cancer Progression  
In normal cells proliferation, many hundreds of genes normally control the cell division process. 
Many of these genes are oncogenes or tumour suppressors. Cyclin dependent kinases (CDK) 
and cyclins form complexes which regulate the cell cycle intracellular machinery. The growth-
dependent cyclin-dependent kinase2 (CDK2) activity promotes DNA replication during the G1 
phase and initiates the G1-to-S step transition [243].  Hypophosphorylated Rb proteins exerts 
an inhibitory activity on G1 phase of the cell cycle through binding to transcription factors 
including E2F and downregulating the expression of genes whose synthesis is required for cell 
cycle propagation. Moreover, proteins like p15, p16, p17, p19, p21 and p27 are CDK inhibitors 




(M) [244]. This controlsthe transcription of the genes regulating G1–S transition including the 
gene encoding cyclin E. Cyclin E forms an complex with CDK2 proteins[245]. Cyclin 
D/CDK4/6 phosphorylate Rb, releasing E2F and allowing the cell enters S-phase. The cell then 
enters a second gap phase (G2) which functions to prevent the cell from undergoing mitosis 
with DNA damage. During this stage, the cyclin B activates CDK1, and further activated by 
the phosphatase Cdc25, thereby allowing G2 phase transition to mitosis (M). However, upon 
DNA damage or stalled replication, the phosphatase Cdc25 is hyperphosphorylated which 
results in the ubiquitination of Cdc25 and inhibition of cell cycle [246]. Aberrations in 
oncogenes (e.g. cyclins or CDKs) or tumour suppressor genes (e.g. Rb1 or CDKIs) have been 
associated with tumourigenesis. In high grade serous ovarian cancer, the genes encoding p16 
and Rb are inactivated in 32% and 10% of cases respectively. Furthermore, genes encoding 
cyclin D1, cyclin D2 and cyclin E1 are l amplified in 4-20% of high grade serous ovarian cancer 
cases, likely participating in the induction of some ovarian cancers [243]. 
 
Figure (1-10): The role of Cdc25s which involve a Cellular Interactions [247]. 
 
1.13.2. Statins & apoptosis 
In several and different kinds of cancers including breast [248]–[251], lung [252]–[254], 




thyroid [263], [264], glioma [265], [266] lymphoma [259], [267], myeloma [268], 
osteosarcoma [269], head and neck squamous cell [270], and medulloblastoma [271] statins 
have been shown to induce apoptosis, mainly via the mitochondrial pathway; such pro-
apoptotic effects have been induced on the mevalonate pathway via the degradation of 
geranylgeranyl diphosphate [252], [262]–[267], [269]. A variety of studies have shown that 
statins inhibit geranylgeranylation of RhoA, Rac1 and Cdc42, and subsequent translocation to 
the plasma membrane [264], [272].  
Several preclinical studies have shown that incubation of cells with statins leads not only cell-
cycle arrest but also cause cell death, via apoptosis, especially when prolonged exposure of 
cells to statins. Statins arrest cancer cells in G1 or S phase [273]. The arrested cancer cells in 
the S phase have shown increased phosphorylation and increased activation of Chk1 kinase. 
Chk1 kinase promotes the activation of p53 which in turn is responsible for the transcription of 
proteins that arrest the cell cycle. Cdc25 phosphate activity and level were also observed to 
decrease after exposure to statins, along with reduced CDK2 cycline A, caspase cleavage 9, 
downregulation of Bcl-2 and subsequent apoptosis [274]. Another study showed obvious 
increase in the activation of caspase-8 [275] implicating the extrinsic pathway in the anti-cancer 
activity of statins. Reducing cholesterol-rich membrane rafts that can lead to Fas (CD95) 
induction, the development of Fas-FADD complexes, and the activation of extrinsic apoptosis 
and activation of caspase-8, the exclusion of Fas from lipid rafts in some cell types leads to 
spontaneous, ligand-independent activation of this death receptor [276]. Furthermore, there is 
a proteolytic activation after treatment cholangiocarcinoma cell lines with statin that caused 
activation of executioner caspase 7 and their finding shows that simvastatin induces death of 
cholangiocarcinoma cells by disrupting Rac1/lipid raft colocalization and Rac1 depression 
[277]. Treatment of lymphoma cells with fluvastatin caused chromatin condensation and DNA 




that statins can cause apoptosis in cancer cells possibly as a result of the inhibition of the 
synthesis of cholesterol or inhibition of small GTPase prenylation. 
 
1.14. The Potential of Statins for Cancer Prevention or Treatment  
1.14.1. Statins and Cancer Risk Reduction  
1.14.1.1. Clinical Trials of statins for Cancer Treatment 
A limited number of phase I / II clinical trials have been performed to date investigating the use 
of statins in treating a variety of different cancers. This research evaluated statins both as single 
agents as well as in combination with chemotherapy. In addition, a small number of studies 
evaluated statins for up to 7 days at the maximum tolerated dose. Multiple clinical trials of 
statins evaluated their toxicity profile in combination with several chemotherapeutic regimens 
Simvastatin (40 mg / day) plus irinotecan,5-fluorouracil, and leucovorin (FOLFIRI) led to a 
21.8-month median survival in colorectal metastatic patients, with no further adverse effects 
from simvastatin supplement [279]. This was accompanied by a phase I study in patients with 
acute myeloid leukaemia where pravastatin (40-1680 mg / day) did not increase neutropenia or 
thrombocytopenia in combination with idarubicin and cytarabine, and the overall toxicity 
profile was unchanged compared to cancer treatment with chemotherapy alone[280]. Stage I / 
II clinical trials incorporating cyclosporine A, pravastatin, etoposide and mitoxantrone in an 
effort to circumvent drug resistance in acute myeloid leukaemia were aborted early due to 
undesirable toxicity[281]. This highlights the value of performing a small phase I trial and 
carefully evaluating the risk-benefit ratio while considering new drug combinations. For non-
small lung cancer (NSCLC), Han and colleagues’ studies showed that adding a normal dose of 
simvastatin (40 mg / day) to chemotherapy (irinotecan and cisplatin or gefitinib) did not 
significantly increase progression period or the one-year rate of survival[282], [283]. 
Nonetheless, in a subgroup of non-adenocarcinoma patients with wild-type epidermal growth 




compared to those receiving gefitinib as a single drug (3.6 months versus 1.7 months, P= 0.027). 
Nevertheless, the previous findings were confirmed by a study published in the journal in 
advanced patients with pancreatic cancer, where simvastatin (40mg / day) in combination with 
gefitinib had no additional clinical significance compared with gemcitabine alone [284]. 
Normal doses of pravastatin (20-40 mg / day) in hepatocellular cancer patients greatly increased 
PFS in transarterial chemoembolization (TACE) patients (18 months versus 9 months, P= 0.006 
[285]; 20.9 months versus 12 months, P=0.003[286]). In comparison, pravastatin (40-80mg / 
day) alone did not boost the median OS relative to TACE-treated patients [287]. In addition, 
there has been no change in outcome in advanced patients with stomach cancer treated with 
pravastatin 40 mg / day in combination with epirubicin, cisplatin, and capecitabine[288]. For 
patients with squamous cell carcinoma of the head and neck or cervix, high-dose lovastatin has 
been tested. During this Phase I trial, patients tolerated doses of up to 7.5 mg / kg / day and had 
stabilisation of disease approximately one quarter [289]. These findings were contrary to a 
previous study in which high lovastatin doses of 35 mg / kg / day were administered for 7 
consecutive days (repeated every 28 days) to patients with advanced gastric cancer and no 
respond was observed [290]. In addition, simvastatin (15 mg / kg / day) in patients with 
myeloma in combination with vincristine, adriamycin, and dexamethasone was discontinued 
due to poor response, because only one patient had a partial response [291], whereas the high 
dose was quite well tolerated for 7 days [292]. Nonetheless, a study in patients with relapsed 
and refractory multiple myeloma found that thalidomide, dexamethasone, and lovastatin (0.5 
mg / kg / day) substantially enhanced PFS compared with patients receiving just thalidomide 
and dexamethasone (33 months versus 16 months, P= 0.048), with comparable side effect 
profiles of both arms [293]. It has been shown that high-dose fluvastatin (80 mg / day) decreases 
tumour proliferation and induces apoptosis in high-grade breast cancer in stage 0/1[294]. In 
addition, fluvastatin (8 mg / kg / day) substantially improved survival between days 1-14 in 




children with brain stem tumours [295]. However, there was no significant PFS change in 
standard doses of fluvastatin (40 mg / day) or atorvastatin (20 mg / day) in combination with 
zoledronate relative to the findings of previous studies in patients with renal-cell carcinoma and 
bone metastasis [296]. Overall, clinical studies testing statins at normal doses used to treat high 
cholesterol showed minimal beneficial effects, and only two studies in patients with 
hepatocellular cancer indicated a survival advantage. This may represent the transporter liver-
selective uptake of pravastatin like OATP1B1, thus potentially raising the concentration of 
pravastatin in contact with the tumour [297]. Despite this weak positive story, the majority of 
the current clinical trials test statins for cancer care at doses which give rise to low drug 
concentrations in plasma [298]. Trials using higher doses of statins have shown some promising 
outcomes, and some clinical trials are currently testing lower doses of statins in combination 
with standard chemotherapy agents for leukaemia, glioma and lung cancer treatment [298]. 
 
1.14.1.2. Xenografts of Statins as anticancer activity  
Human ovarian cancer xenografts are commonly used to assess the activity of preclinical drugs. 
Xenograft studies with ovarian cancer cell lines have been used to evaluate drug cytotoxic 
activity and model biomarker responses. These studies make us of immunodeficient mice 
although this eliminates any activity of a healthy immune system on tumour growth or the 
interaction between tumour cells [299]. In addition, there may be significant variations in drug 
pharmacokinetics in mice xenografts compared to human pharmacokinetics which must be 
taken into account when conducting a research on xenograft[1]. 
 
 A wealth of evidence has shown how important the MP is for health and disease. In some 
animal models the inactivation of the MP seems fatal. Mice with HMGCR deficiency stop 




retardation and neural tube defects[300]. Furthermore, gunmetal mice, a GGT-II deficient 
mouse, usually mature but show a defect in platelet function and prolonged bleeding time [301]. 
Statin have shown anti-tumour effects uses cell lines origination from thyroid cancer [302]. Rat 
lymphoma [303], rat fibrosarcoma [303], mouse mammary tumour [304], murine colon tumour 
[305] and mouse melanoma [306]. Statins have also increased the antitumour effect of the 
tumour necrosis factor by inhibiting angiogenesis caused by tumour in a murine tumour 
model[307].  Previous studies in our laboratory have shown that pitavastatin causes regression 
of ovarian cancer xenografts in mice [308]. In vitro studies have shown that cerivastatin, 
pitavastatin, and fluvastatin are the most potent anti-proliferative, autophagous inducing agents 
in human cancer cells including primary glioblastoma cell lines of stem cells[309]. The 
combination of vorinostat and fluvastatin induced robust apoptosis and effectively inhibited 
both in vitro and in vivo development of renal cancer[310]. 
 
1.14.1.3. Preclinical study  
Preclinical in vitro studies in various cell lines have demonstrated statins' ability to inhibit cell 
growth. Statins exhibit antiproliferative, pro-apoptotic and anti-invasive activity in various cell 
lines of cancer [311]. Numerous in vitro studies have shown that statins have important tumour-
suppressive effects on various leukaemia and solid tumour cells[312]. Experimental studies 
have drawn the following conclusions. First of all, various statins have clear anti-proliferative 
and proapoptotic effects on different lineages of cancer cells. Secondly, the anti-neoplasty 
results only display lipophilic statins. Fluvastatin, simvastatin, and lovastatin is cytotoxic to 
adenocarcinoma breast cells [313]; Atorvastatin, simvastatin, lovastatin and cerivastatin were 
cytotoxic to cancer cells in myeloma [272], and simvastatin and lovastatin to cancer cells in 
ovaries [314]; Third, the statins vary in their ability for anti-neoplastics. Four cell lines of acute 
myeloid leukaemia were analysed using specific statins. Cell lines were most sensitive to 




sensitive [315]. Finally, cytotoxicity of statin can depend on the type of target tumour. 
Dimitroulakos et al. identified a subset of tumours (young monomyelocytic leukaemia, 
medulloblastoma, rhabdomyosarcoma, choriocarcinoma, and cervical, head and neck 
squamous cell carcinomas) that are prone to lovastatin-induced apoptosis and display HMG-
CoA reductase as a possible therapeutic target for these cancers [316]. Statin antimyeloma 
activity in humans was first recorded in refractory multiple myeloma (MM) with simvastatin 
administration [317]. A preoperative research in primary invasive breast cancer patients 
explored atorvastatin-induced effects on tumour proliferation and expression of HMGCR while 
evaluating HMGCR as a predictive marker for statin response, the findings of this study indicate 
that HMGCR is inhibited  by statins in in vivo breast cancer cells and that statins in HMGCR-
positive tumours may have an antiproliferative effect[318]. 
 
1.14.1.4. Retrospective studies 
Meta-analyses evaluating the likelihood of cancer-related death in patients using statins to 
control plasma cholesterol have also suggested an anti-cancer effect of statins. However, mixed 
results have been obtained. For example, there was not a significant correlation between statin 
therapy and breast[319], lung [320], colorectal, melanoma or non-melanoma [321] bladder 
[322], renal[323], and pancreatic cancers[324] in several studies. In contrast another 4 meta-
analysis studies in Asian and Western population reported a reduction in the risk of liver cancer 
in patients treated with statins (RR: 0.58 – 0.64) [322], regardless of the type of statin 
(hydrophobic versus hydrophilic) or duration of the therapy[325]. Furthermore, statin therapy 
was associated with a reduction in the risk of gastric cancer [326] and haematological 
malignancies (RR: 0.74 – 0.81) [327] while it has no effect on the risk of prostate cancer [328].  
Meta-analyses have reported that statin treatment reduced the risk of advanced prostate cancer 






Regarding the activity of statins against ovarian cancer, Elmore and colleagues reported that 
patients with end stage or invasive epithelial ovarian cancer that used statins showed significant 
improvement in PFS and OS in comparison to non-statin users [331]. Additionally, a case-
control study showed that statins significantly reduce the risk of ovarian cancer and mortality 
[332]. In another study, despite a non-significant improvement in PFS or disease-specific 
survival (DSS) in statin-based patients with ovarian cancer using statins in comparison to non-
statin user, patients with non-serous papillary subtypes showed improvement in both PFS and 
DSS [333]. Collectively, a recent meta-analysis combining different studies reported that statin 
therapy induces acceptable protection against ovarian cancer (RR: 0.79), and prolonged therapy 
(>5 years) induced reduction in the risk of ovarian cancer (RR: 0.48) [334]. However, a meta-
analysis of patients using statins to reduced plasma cholesterol showed discrepant results 
regarding cancer risk association with statin therapy. Some of these studies reported that 
generally there is no correlation between statin use and cancer risk [214]. 
 
1.14.2. Foods deregulate a mevalonate cancer pathway 
MP de-regulation was first confirmed in mouse hepatomas about 50 years ago [335]. Some 
studies indicate that HMG-CoA reductase plays a major role in human cancer. Most cancers 
displayed either increased expression and HMGCR activity or lack of feedback regulation of 
HMG-CoA reductase activity [336]. Synthesis of cholesterol that rely on the availability of MP 
precursors like Acetyl-Co-A [337]. For development, cancer cells need synthesis of de novo 
lipids. Increased lipid synthesis was found to be involved in the pathogenesis of cancer 
including ovarian neoplasms [338] . Evaluation of the MP in cancer by Fumagalli et al. (1964) 
[339] confirmed that large amounts of cholesterol are synthesised by human glioblastoma cells. 




tumours in xenograft-bearing mice [340]. Furthermore, mevalonate induces the growth of 
human cancer cell-tumours in vivo and induces proliferation in vitro [340].  
 
There are many dietary components known to inhibit HMG-CoA reductase activity and the 
synthesis of mevalonate. In comparison to statins, these compounds frequently have no 
recorded adverse effects. Evidence that inhibition of mevalonate synthesis by such components 
can mediate protective effects on experimental breast cancer has been obtained using 
cholesterol, plant isoprenoids, genistein, and long-chain n-3 polyunsaturated fatty acids 
(PUFAs)[341].  
 
Importantly, however, diet may alter the activity of statins as anti-cancer agents. Mevalonate is 
a precursor to cholesterol farnesol and geranylgeraniol isoprenoids[342]. If statins exert their 
anti-cancer activity by blocking the synthesis of these, the presence of these compounds in food 
may bypass the anti-cancer activity of statins in patients. In support of this, solvent extracts 
from human and mouse food have also been able to block pitavastatin-induced apoptosis in 
vitro and dietary geranylgeraniol blocks the growth of ovarian xenografts in mice, This suggests 
that a patient’s diet could influence the result of clinical trials[308] Specifically, a diet 
containing geranylgeraniol may restrict pitavastatin's anti-tumour activity and consequently 
diet should be controlled in clinical trials of statins as anti-cancer agents. Although the complete 
human food supplement Ensure does not contain geranylgeraniol it may be monotonous for 
patients to consume only this during a clinical trial. This makes it important to understand which 
foods contain geranylgeraniol, or any other isoprenoid that interferes with the anti-cancer 
activity of statins. Geranylgeraniol diterpenes (GGOH), has been identified in rice, sunflower 
oil, linseed oil, Cedrela to on a wood oil, sucupira branca fruit oil, and annatto seed oil[343]. 
However, the abundance of geranylgeraniol in other foods is unknown. The identification of 




statins in cancer because it would provide patients the opportunity to eat a more varied diet 








































Chapter 2 Aims and objectives 
 
 





2. Aims and Objectives 
Three different aims were set for this project. Firstly, to support clinical trials of pitavastatin in 
ovarian cancer patients by evaluating which foods patients do not interfere with the activity of 
pitavastatin. Secondly, identify genes whose expression correlates with sensitivity of cancer 
cells to pitavastatin to help further understand the mechanism of action of statins as anti-cancer 
agents. Finally, to identify additional drugs that are synergistic with pitavastatin’s anticancer 
activity in the expectation that this would allow lower doses of pitavastatin to be used and 
consequently minimize the likelihood of adverse drug reactions.  
The following targets were set to accomplish this. 
1- Prepare extracts from a range of human foods and evaluate whether these inhibit the 
cytotoxic activity of statins in cell growth assays using ovarian cancer cell lines.  
2- Make use of publically available database reporting gene expression profiles and drug 
sensitivity data to identify candidate genes whose expression correlates with activity of statins 
in cancer cells. Test the expression of these candidate genes in ovarian cancer cell lines and 
compare with the sensitivity of these cells pitavastatin. Use this information to develop and test 
hypotheses around the mechanism of action of pitavastatin in cancer. 
3- Conduct drug repurposing studies to evaluate whether the anti-parasitic agent 
ivermectin is synergistic with pitavastatin in cell growth assays and then confirm these results 





















Chapter 3  
 
 
















3. Materials and Methods 
3.1. Cell culture  
3.1.1. Ovarian cell lines  
The ovarian cancer cell lines used in these studies which were initially selected from the “NCI-
60” panel of cells. Subsequent information [344] identified cells lines that are more 
representative of high grade serous ovarian cancer (HGSOC) and these were then used instead 
(Table 3-1). 
 
Table (3-1): Description of the cell lines used in this study. 
Cell line  Description  
 
COV-362  





This cell line was developed by a woman with high-grade ovarian serous 
adenocarcinoma resistant to cisplatin1 [346]. 
 
COV-318  
This cell line was developed by a female with ovarian epithelial-serous carcinoma 
peritoneal ascites1[345] . 
 
OVSAHO  





This cell line was derived from a high-grade ovarian serous adenocarcinoma from 
carboplatin-resistant ovarian carcinoma1 [348].  
 
FUOV-1 
This cell line was obtained  after hysterectomy from a woman's tumour tissue with 
high-grade serous ovarian cancer1[346], [348]. 
 
3.1.2.  Mediums and conditions for cell growth 
Human ovarian cell lines (Ovcar4, Ovsaho and Ovcar-8) were grown in Roswell Park Memorial 
Institute (RPMI 1640; Lonza) medium supplemented with 10 % fetal bovine serum (FBS; 
Lonza), 2 mM glutamine (Lonza) and 50 μg/mL penicillin/streptomycin (Lonza). Fuov-1, 
Cov318 and Cov362 were grown in DMEM medium supplemented with 10 % fetal bovine 




Cells were incubated in a NAPCO water-jacketed incubator (Precision Scientific) at 37°C and 
in a humidified 5% CO2 atmosphere. 
 
3.1.3.  Reviving Cryopreserved Cells  
Frozen cells in liquid nitrogen were rapidly thawed in a Grant JB Series water bath (Grant 
Instruments) at 37°C and then added to 2 mL pre-warmed growth medium in a 15 mL 
polypropylene tube. Cells were then centrifuged at 150 g for 3 minutes at room temperature 
and the pellet was re-suspended in 8 mL growth medium. The resulting cell suspension was 
transferred into a T25 tissue culture flask and incubated for 24 hours at 37°C before checking 
the viability under a phase-contrast light microscope. Subsequently, the growth medium was 
replaced to remove residual DMSO and dead cells. The adherent cells were grown to an 
appropriate density for experimentation or sub-culture. 
 
3.1.4.  Trypsinisation of Adherent Cells  
All cells more than 80% confluent as determined by using an Olympus CKX41 light 
microscope were sub-cultured. The cells were washed with phosphate buffered saline (PBS; 
Lonza, 3 mL for 25 flasks and 6 mL for T75 flask) and subsequently exposed to trypsin (Lonza) 
(1700 U/L) EDTA (0.002 g/L) diluted in PBS, incubated at 37°C and gently agitated to 
encourage detachment. The trypsin was neutralized by the addition of 1 mL growth medium. 
Cells were transferred into a 15 mL polypropylene sterile tube, centrifuged at 150 g for 3 
minutes in a Thermo Scientific Heraeus Megafuge 8 centrifuge at room temperature. The 
supernatant was aspirated carefully and the pellet was re-suspended in fresh cell culture 
medium. At least 100 cells were counted by using a Neubauer haemocytometer to determine 
the appropriate number of cells for experiments (see below) or for routine passage 25% of the 





3.2. Chemical agents 
Pitavastatin (Adooq) & Ivermectin (Sigma-Aldrich), geranylgeranyl (Sigma-Aldrich), 
mevalonate (Enzo Life Sciences), isopentenol (Sigma-Aldrich), Farnesol (Sigma-Aldrich) 
dolichol (Avanti) and Coezyme Q10 were dissolved in DMSO (20 mM). siRNAs (Dharmacon) 
were dissolved (20 μM) in siRNA buffer (Dharmacon). 
 
3.3. Extraction of Lipids from Foodstuffs  
Thirty foodstuffs were obtained for the purposes of extracting isoprenoids. These comprised 
oils, food and fruits and were obtained in the United Kingdom from commercial suppliers. 
These included kiwi, pears, pomegranate, lettuce, cherry, tomato, squash, potato, passion fruits, 
gooseberry fruit, butter and milk (Aldi), strawberry jam, cheese, spaghetti, oat, beans, nuts, 
eggs, dolmio (spaghetti sauce), black bean, oats and bread (Tesco), cheddar, corn oil, pure Ripe 
seed oil, Sunflower oil, ground nut oil, grape seed oil and sesame oil(Sainsbury’s),  
Extracts were prepared by the method reported by[349] , with some modification of the “gold 
standard” methods by Folch [350], Bligh, and Dyer [351].  Each solid foodstuff (50 g) was 
homogenized in a food electric blender and then transfer to a mortar and homogenised manually 
with a pestle in 60 mL methanol. 30 mL of chloroform/methanol (50%/50%) were added and 
the extract homogenized briefly again.  The mixture of extracts and solvents were filtered 
through fluted filter paper. Oils (50 g) were directly mixed with methanol and chloroform 
methanol without homogenization. Both types of mixture extracts (oils & foods) were 
transferred to a separating funnel and the upper layer collected and evaporated by using an 
RE100 rotary evaporator (Fisher Scientific) to dryness in a round bottom flask. The dried 
residues were dissolved in 25 mL 99% ethanol and 25 mL 5M potassium hydroxide were added 
and the solution incubated at 56°C for 1 hour in a water bath. After cooling and neutralisation 
with 25 mL 5 M hydrochloric acid (Sigma-Aldrich) and addition of 30 mL water, the resulting 




collected in a pre-weighed round bottom flask and evaporated using an RE100 rotary evaporator 
to dryness. Residual solvent was removed under vacuum in a freeze dryer overnight and the 
weight of the extract determined. The residue was dissolved in 1ml DMSO and stored at -20°C 















Figure (3-1): the method of isoprenoid extraction[350]–[352].       
 
3.4 Cell Growth Assays (sulforhodamine B assay) 
Cells were collected by trypsinization and suspended in the culture medium (62,500 cells / mL, 
with the exception of OVCAR-8 cells which were suspended at a concentration of 25,000 cells 
/ mL). 80 μL of the suspension was seeded into each well of a 96 well plate and incubated for 
24 hours at 37 oC in 5% CO2. The following day, cells are treated with pitavastatin and/or 
geranylgeraniol at the indicated concentrations in 20 μL of growth media alone or in 
combination with 20 μL food extracts. Each experimental condition was measured in triplicate 
wells. The cells were incubated for 72 hours, the growth medium removed and the cells in each 
well were fixed in 100 μL cold 10% trichloroacetic acid (TCA, Sigma-Aldrich) for 30 minutes 
on ice. The TCA was removed and the cells washed in water, before being left to dry. They 
were then stained with 0.4% sulforhodamine B (SRB, Sigma-Aldrich) in 1% acetic acid 
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1 % acetic acid and the plates dried. Lastly, the dye was solubilised in 100 μL 10 mM Tris (pH 
10, Sigma-Aldrich) and the absorbance at 570 nm (A570) was determined using a BioTek 
Synergy 2 multi-mode microplate reader. 
 
3.5.  GC/MS experiments 
One—two mg of bioactive extract fractions were dissolved in 200 μl ethylacetate and sonicated 
for 5 minutes at 40 °C. Subsequently, 1-2 μl of the solution was injected into the gas 
chromatography mass spectrometer (GC-MS), an Agilent 7890 coupled with Agilent MS type 
5975 C MSD (Agilent Technologies, USA). The gas chromatography started for two minutes 
with an initial oven temperature of 60 °C and increased to 300 °C at a rate of 10 °C / min, 
followed by 4 minutes at 300 °C to produce a total run of 30 minutes at a steady helium pressure 
(10 psi). Mass spectral data were acquired in scanning mode within the 40-1000 m/z range. 
 
3.6. Trypan blue assay  
 To estimate the cell viability 100,000 cells / well were seeded in 12 well plates and incubated 
overnight and the cells exposed to the drug for 24-72 hours as indicated. To assess viability, the 
supernatant was removed from the cells and the cells collected by trypsinization. The detached 
cells were added to their corresponding supernatants, centrifuged at 150 g for 3 minutes and the 
pellet re-suspended in 0.5 mL of medium. The cells were mixed with an equal volume of 0.4 
% (v/v) trypan blue (Sigma-Aldrich) and viable and non-viable cells counted by light 
microscopy by using Neubauer haemocytometer. The viability percentage was determined on 
the basis of the following formula. 
Viability = 100 x number of viable cells / (number of dead cells + number of live cells). 
3.7.  Measurement of annexin V/PI labelling  
Cells were plated and exposed to drugs accordingas described in section 3.5. Cells were stained 




washed with 1 mL of 1X annexin V (Miltenyi Biotec) binding buffer and the cells collected by 
centrifugation (300 g, 10 minutes). The supernatant was aspirated and the cells were re-
suspended in 100 μL of 1X binding buffer.  10 μL of Annexin V were added and the suspension 
gently mixed and stored in the dark at room temperature for 15 minutes. After incubation the 
cells were washed with 1 mL of 1 × annexin V binding buffer again and collected by 
centrifugation (300 g, 10 minutes).  The supernatant was removed and the cells re-suspended 
in 500 μL of 1X of binding buffer. To detect dead cells, 5 μL PI solution was added immediately 
before flow cytometry analysis. 
 
Figure (3-2): Annexin V staining mechanism. 
 
3.8. Caspase 3/7 activity assay  
Caspase activity was measured using the Caspase-Glo assay (Promega; Madison, USA). Cells 
were collected by trypsinization as described above and resuspended (62,500 cells / mL) and 
80 µL seeded per well in 96 well plates and incubated at 37 oC overnight. The next day, 20 µL 




incubated for 72 hours at 37 oC.  To test caspase 3/7 activity assay, Caspase 3/7 reagent was 
prepared in compliance with the manufacturer's instructions and then stored at -80 oC. 25 μL of 
Caspase-Glo 3/7 reagent was added directly to each well. The plate was covered with foil to 
shield it from light and gently agitated on a rocker for 30 minutes at room temperature. 
Subsequently, 100 μL of each well was transferred to a white 96 well plate. The luminescence 
was being measured using a BioTek Synergy 2 multi-mode microplate reader.  
 
 
Figure (3-3): Caspase 3/7 cleavage of the luminogenic substrate containing the DEVD sequence. 
 
3.9. Cytoplasmic and membrane protein fractionation  
Ovcar-8 and Ovsaho were seeded in 6 well plates (2×105 cells in 2 mL) medium and incubated 
overnight. The next day, 20 μL of medium containing geranylgeraniol and farnesol with or 
without pitavastatin were added to the indicated final concentration. Both cytoplasm and 
membrane proteins were separated using a Mem-PER™ Plus Membrane Protein Extraction kit 
(Thermofisher) according to the manufacturer’s instructions. After harvesting the cells by 
trypsinization, cells were washed twice with 2 mL of ice cold washing buffer, then re-suspended 




mixing. The cytoplasmic fraction (the supernatant) was collected after centrifugation at 16, 000 
x g for 15 minutes at 4 °C. The membrane fraction was obtained by re-suspending the pellets 
in 0.5 mL of solubilisation buffer and incubating for a further 10 minutes at 4 °C with constant 
shaking. The supernatant was centrifuged at 16000 x g for 15 minutes at 4 °C and the 
supernatant collected to yield the membrane fraction. Both cytoplasmic and membrane fraction 
were stored at -80°C. 
 
3.10. Western blot analysis 
3.10.1. Whole cell lysate  
Ovarian cancer cell lines, Fuov1, Cov318, Ovsaho, Ovcar-4, Cov-362 and Ovcar8, were seeded 
in T75 flasks. The cells were incubated until the cells reach 80% of confluence. After 
trypsinization, the cells were washed with ice-cold PBS and lysed in a modified 
Radioimmunoprecipitation assay (RIPA) buffer (20 mM Hepes (CalbioChem) pH 7.0 , 150 mM 
sodium chloride (NaCl, Sigma-Aldrich), 2 mM ethylene-diamino-tetraacetic acid (EDTA, 
Sigma-Aldrich), 0.5% sodium deoxycholate (Sigma-Aldrich), 1% NP40 (Sigma-Aldrich)) 120 
μM leupeptin (Sigma-Aldrich), 10 μM pepstatin (Sigma-Aldrich) and 1 mM 
phenylmethanesulfonyl fluoride (PMSF, Sigma-Aldrich).The lysate was centrifuged at 14,000 
RPM for 15 minutes at 4°C, then the supernatant collected into a new tube and stored at -80°C. 
 
3.10.2.  Bicinchoninic acid protein assay  
To determine total protein concentration, protein standards were used for calibration in each 
assay were prepared using Bovine serum albumin (BSA, Sigma-Aldrich) at eight different 
concentrations varying from 0.1 to 2 mg/mL The bicinchoninic acid protein assay reagent was 
prepared by adding Copper (II) sulphate solution (4%) (Sigma-Aldrich) to BCA solution at a 
ratio of 1:50. 10 μL of the standard or the sample was mixed with 100 μL BCA reagent per 




570 nm. The concentration of protein was determined from a calibration curve using linear 
regression analysis of the results obtained with the standards. 
 
3.10.3. Gel electrophoresis and immunodetection of proteins using SDS-page and western 
transfer  
10-20 µg of protein was mixed with 5 μL of NuPAGE sample buffer (Invitrogen) containing 5 
% (v/v) β-mercaptoethanol (Sigma-Aldrich) and denatured by heating for 15 minutes at 80°C. 
Proteins were separated using 4-20% Tris-Glycine/SDS gels (Serva) using Tris-Glycine/SDS 
electrophoresis buffer (Serva) and Blue Plus® II Protein Markers (14 to 120 kDa) (BIO Corp) 
were included on each gel. Electrophoresis was performed at 240 V, for 40 minutes. Next, the 
proteins were transferred to PVDF Hybond membrane (Hybond-ECL, GE Healthcare) using 
ice-cold transfer buffer (200 mM glycine ,25 mM Tris, 0.075 % (w/v) SDS (Sigma- Aldrich) 
and 10 % (v/v) methanol (Sigma-Aldrich)) at 70 V, 250 mA for 1 hour and fifteen minutes. 
Subsequently, the PVDF membrane was blocked by incubation in skimmed milk blocking 
solution (5% (w/v) skimmed milk powder in Tris-Buffered Saline with Tween (TBST)) for 1 
hour with shaking at room temperature. The membrane was washed with Tris-Buffered Saline 
with 0.1% Tween (TBST) three times then incubated with primary antibody overnight with 
continuous shaking at 4 °C. The antibodies used are described in Table 3-2. The following 
morning, the membrane was washed five times (5 minutes each) in TBST buffer and the 
membrane was incubated with the secondary antibody for two hours. Then, the membrane was 
again washed with TBST buffer three times for five minutes each and the proteins visualized 
by using a chemiluminescent substrate (UptiLight HRP US chemiluminescent substrate 
(Interchim)) and imaged using a FluorChem M Imager. Each experiment was repeated at least 
three times, and the total signal of protein bands was quantified with AlphaView SA software 
(Protein Simple) after subtracting the product of the area of the region of interest and the mean 




Table (3-2): The list of primary and secondary antibodies used in protein 
immunodetection assay  
Antibody  Dilution  Product code  Supplier  
Anti-Frizzled-2 1:500-1:2000  St Johns Laboratory  
Anti-FGF  1:500-1:2000 STJ96555 St Johns Laboratory 
Anti-Axl  1:500-1:2000 STJ97643 St Johns Laboratory 
Anti-VIM 1:500-1:2000 STJ96243 St Johns Laboratory 
Anti-Rab11-FIP4 1:500-1:2000 STJ95310 St Johns Laboratory 
Anti-GRHL2 1:500-1:2000 STJ112192 St Johns Laboratory 
Anti-CFL2 1:500-1:2000 STJ110316 St Johns Laboratory 
Anti-CYR61 1:500-1:2000 STJ23329 St Johns Laboratory 
Anti-HMGCS1 1:1000-1:2000 STJ24047 St Johns Laboratory 
Anti-PTRF 1:1000-1:2000 STJ27803 St Johns Laboratory 
Anti-BSPRY 1:500-1:1000 ab92920 abcam 
Anti-MAP7D1 1 µg/ml ab98274 abcam 
Anti-PRR15L 1:100-1:500 ab171614 abcam 
Anti-RBM35A 1:1000 ab106585 abcam 
Anti-MARVELD3 0.25 µg/ml Ab118916 abcam 
Anti-CCDC64B 1 µg/ml ab177564 abcam 
Anti-FXYD3 1:1000 ab205534 abcam 
MAP7 Antibody  1:500-1:3000  PA5-31782 ThermoFisher  
Anti-KIF5B 1:1000-1:10000 Ab167429 abcam 
Anti-Tubulin antibody 
[YL1/2] - Loading 
Control 




Goat anti-Mouse IgG 
(H+L) Highly Cross-
Adsorbed Secondary 
Antibody, Alexa Fluor 
Plus 488 
1:1000 # A32723 ThermoFisher, 
Invitrogen 
Goat Anti-Rat IgG H&L 
(Alexa Fluor® 488) 
preadsorbed (ab150165) 
1:1000 ab150165 abcam 
Actin Polyclonal 
Antibody 
1:1000  PA5-11570 ThermoFisher 
Anti-CNPase antibody 
[11-5B] 
1:1000 ab6319 abcam 
GAPDH Polyclonal 
Antibody 
1:1000 TAB1001 ThermoFisher 
Anti-mouse IgG, HRP-
linked Antibody 
1:1000 7076S Cell signalling 
 
Goat anti-Mouse IgG 





3.11. RNA extraction from culture cells  
Ovarian cancer cell lines Fuov1, Cov318, Ovsaho, Ovcar-4, Cov-362 and Ovcar8 were seeded 
in T75 flasks. Cells were harvested using an RNeasy mini kit (Qiagen) following the 
manufacturer instruction. Lysates were centrifuged for 3 min at 16000 x g. The supernatant was 
transferred to a new 1.5 mL tube and mixed with 350 μL of 70% ethanol by pipetting up and 
down several times. Next, 700 μL of each sample was transferred to mini spin column placed 




centrifugation process was repeated to wash with 700 μL of RW1 buffer and subsequently twice 
more with 500 μL RPE buffer. The column was dried by centrifugation for 2 minutes. Lastly, 
the spin column was placed in new 1.5 mL tube and 50 μL of RNase free water added, incubated 
for 2 minutes and then centrifuged for 1 minute at 8000 x g in order to elute the RNA. The 
purity and concentration of the extracted RNA were measured using a Nano-Drop2000 
spectrophotometer (Thermo fisher scientific). The extracted RNA stored at -80 °C. 
 
3.11.1. Synthesis of cDNA by reverse transcriptase  
SuperScript™ III Reverse Transcriptase was used to generate the complementary DNA strand 
(cDNA). The reaction mixtures were maintained on ice during the procedure. A mixture of 11.5 
μL of RNA extracted from cells and 1.5 μL (0.5 μg) of Oligo (dT) 20mer (50 μM) were mixed 
and denatured at 65ºC for 5 minutes in thermal cycler (MJ Research PTC-200 Thermal Cycler, 
USA) and stored on ice. The reaction mixture for each sample was prepared by mixing 4 μL of 
5X reverse transcriptase RT reaction buffer, 1 μL of dNTP mix (10 mM), 1 μL of reverse 
transcriptase and 1 μL of DTT (0.1 M). The reaction mixture (7 μL) was added to the previously 
prepared RNA mixture. The tubes were briefly centrifuged and transferred to thermal cycler 
again and incubated for 5 minutes at 65 ºC, 30 minutes at 50 ºC, 5 minutes at 85 ºC and lastly 
cooled to 4 ºC. The concentration and purity of the cDNA was measured using Nanodrop2000 
spectrophotometer. The ratio of the absorbance measured at 260/280nm were used to assess the 
purity of DNA. The reaction product was diluted 5 times by adding 80 μL of water and the 
sample were stored in -80. 
 
3.11.2.  qRT-PCR  
A master mix was prepared by adding 6.25 μL of Sybr green (Absolute SYBR Green ROX mix 
Thermo Scientific), 0.125 μL of forward and reverse primer (10 mM) (Table 3-4) and 1.125 μL 




collected by brief centrifugation. 7.5 μL reaction mixture were added to each wells of 8-tube 
optical strips, then 5 μL of DNA sample or water were added to each tube in duplicate. The 
optical strips were briefly vortexed and centrifuged to collect the reaction mixture at the bottom 
of the wells. A Strata gene Mx3005P thermal cycler (Agilent Technologies) was used to 
conduct the analysis (Table3-4). To confirm that only one amplicon was detected the 
dissociation curves were analysed for each sample. In addition, the efficiency of genes was 
confirmed by measuring the CT value of four 4-fold serial dilutions of the samples using qRT-
PCR. The standard curve produced from the measured CT data and the log of the dilution factors 
were analysed by liner regression using the following equation to measure the efficiency.                   
                     Efficiency = (10-1/slope)-1  
A comparative cycle threshold (CT) method was used to analyses the data, which compares the 
CT value of target gene to the CT value of the reference gene.  
ΔCT= CT (target gene) – CT (reference gene)  
ΔΔCT=2(-ΔCT) Ratio (Fold changes) =ΔΔCT of treated sample ΔΔCT of control sample 
Table (3-3): The list of Primer sequences (Forward and Reverse) 
Primer 
Name  
Forward (5’ → 3’)  Reverse (5’ → 3’)  
BSPRY TCAAAGAGCAGTGAGCATGG TCTCGCAAAGACTCCTCACC 
CCDC64B GCAGGGGGAAAACCAGAT ACCCTTCTCCACCTCCTCAC 
MARVELD3 TACTTGTGCACTGGGAGAGC GCACCATCAAAGCCACTGTA 




RBM35A GCCCTCCGACAGTTTAACCA TTTGCCTGA CATGAAGCTGC 
VIM#209 TGACATTGAGATTGCCACCT TCCAGATTAGTTTCCCTCAGGT 








AXL GAGGCTCATCGGTGTCTGTT GAGCCGGGAATAGAGGAGGA 
CFL2-202 TCTGGGCTCCTGAAAGTGC CCAAGTGTCGAACGGTCCTT 
CYR61-201 GAAGGGGATCTGCAGAGCTC GCGCCATCAATACATGTGCA 
FXYD3-207 TAAGAGGCCCGAGTTTCACC GGGTCACCTTCTGCATGTCA 




MAP-7 AATAAACCAGACCCTCCGCC GCTGTTTCTCCCGTTCCTCA 
MAP7D1 GACATAAGACAATCGCAGCC GAGAGAGTGGGCGTCATCAG 
PTRF GGCAGATCAAGAAGCTGGAGGT CAGCGATTTGCTGATGCTCAGTT 
 
Table (3-4): Thermal cycling profile for qRT-PCR 
 First segment  Second segment  Third segment  
 Denaturation of 
DNA strands at 
95◦C for 15 
minutes  
 
Denaturation of the DNA 
at 95◦C for 30 second  
Primer annealing at 60◦C 
for 1minute  
DNA strand elongation at 
72◦C for 30 second  
For dissociation curve at 
95◦C for 1 minutes, 55◦C 
for 30 second and 95◦C 
for 30 second  
 





3.12. Small Interfering RNAs (siRNA) gene Transfections  
3.12.1. Experiment of small interfering ribonucleic acid (siRNA) transfections  
Suspensions of OVCAR-8 or OVSAHO cells in antibiotic-free growth media were seeded in 
96 well plates (5000 cells per well for OVSAHO and 2000 cells per well for OVCAR-8) and 
incubated overnight in 5 per cent CO2 at 37 ºC. The next day, 1 percent of Dharmafect-1 was 
prepared in the minimum critical media (Opti-MEM, Invitrogen) of a serum-free modified eagle 
and incubated at room temperature for 5 minutes before mixing with the same amount of siRNA 
prepared in serum-free Opti-MEM and incubated at room temperature for 20 minutes to 
facilitate complex formation between the siRNA and the liposomes. Consequently, the growth 
medium of the original seeding cells has been replaced by 80 μl of fresh and pre-warmed 
antibiotic-free medium and 20 μl of the siRNA / DharmaFECT 1 mixture has been applied to 
the 96 well plate.  In all transfection experiments a non-targeting siRNA (NT-1siRNA) and on-
targeting siRNA, which is designed not to target known genes, has been included as regulation 
(off-target gene silencing). The cells were incubated overnight after the transfection mixture 
was added, the growth medium was replaced by 100 μL of fresh antibiotic-free growth media 
and cells were incubated for an additional 48 hours, then the cells were either exposed to a 
range of different pitavastatin concentrations or left untreated. Finally, the number of cells was 
evaluated by staining with SRB to be calculated sensitivity of cells to pitavastatin. Similarly, 
western blotting was used to test proteins by following the same method as in whole cell lysate 
and immunoblotting. 






































































3.13. Immunocytochemistry  
25,000 Ovcar-8, Ovcar-4 or Ovsaho cells were seeded in 400 μL of growth medium per slide 
chamber of an 8-well Chamber Slide with removable wells (Thermofisher) and incubated 




in cell growth assay for three different periods (24, 48 and 72 hours). The medium was removed 
and the cells washed with PBS and fixed in 10% neutrally buffered formalin for 5-10 minutes. 
The cells were washed with PBS twice and permabilized using 0.01% Triton-X 100 for 15 
minutes. After washing twice in PBS, cells were treated with 1% BSA in PBS for 1 hour at 
room temperature, before incubating the cells with diluted primary antibody at room 
temperature (or overnight 4 oC) for two hours. The cells were washed twice with PBS for 5 
minutes and exposed to the secondary antibody (Goat anti-Mouse IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor Plus 488 from (Thermofisher) (2μg/ml (1/1000) 
in 0.1% BSA, 0.1% Tween-20 in PBS) for two hours protected from light. After washing with 
PBS three times cells were stained with DAPI (counterstain) for cell nuclei and F-actin 
(ActinRed™ 555 ReadyProbes™ Reagent) for cytoskeletal staining were performed and 
covered from light as well. Finally, the samples were placed in mounting medium then stored 
at 4 oC protected from light before viewing by confocal microscopy. 
 
Figure (3-4): show the process of staining cells in slide chamber.   
 
3.14. Analysis of drug combination  
There are several quantitative methods for measurement the effects of combinations drug[353]. 
Drug combinations are wide strategy used for immune disease indication, cancer treatment and 
infection. The Bliss independence criterion is an effect-based strategy to calculate the expected 




combination can by assuming that a drug used at a fraction of its IC50 will have the same effect 
as another drug used at the same fraction of its IC50 and hence the effect of the combination 
can be calculated and the change in concentration needed to have a certain effect when the 
drugs are used in combination expressed by a combination index [354].  
 
3.14.1. Combination index  
To evaluate the efficacy of the drug combinations, a combination index (CI) was measured 
using the equation Chou and Talalay, which offers a quantitative measure of the synergistic, 
additive or antagonistic effects between two drugs. Synergy is demonstrated when a CI value 
is less than one (CI<1) between two drugs CI values, however, are equal to or greater than 1 
and display additive and antagonistic effect respectively. The CI value for two compounds is 
described by the following equation. 
 
(D)1, represents the concentration of drug 1 and (D)2 the concentration of drug 2 which when 
tested in combination inhibit cell growth by X%; (Dx)1 represents the concentration of drug 1 
which inhibits cell growth by X% when used on its own; (Dx)2 represents the concentration of 
drug 2 which inhibits cell growth by X% when used on its own.  The combination index was 
quoted at 50% of cells   affected (fraction affected, fa = 0.5) and compared for deviation from 
unity using a paired t-test. If the IC equals 1 is an additive interaction, whereas the IC value of 










Table (3-6): Symbols and definition of synergism, additive and antagonism calculated by 
the combination index system in drug combination studies [355]. 
 
 
3.15.  Bliss independence criterion 
The Bliss independence criterion was used for trypan blue and Annexin V / PI assays to assess 
the expected effect of drug combinations. This has been used instead of the combination index 
in studies where the full dose response relationship curves have not been determined, and so 
fractional effects could not be calculated. This approach still allows quantification of synergy 
between two drugs. The criterion allows the expected effect of a combination of drugs to be 
estimated if the two drugs work additively. This can be compared with a drug combination's 
observed effect to determine if there is synergy or antagonism between drugs[356] . 
The Bliss independence principle is expressed in the following formula: 
                   E (x,y) = E (x) + E (y) – E (x) x E (y) 
Where E (x, y) is the combination's predicted effect and where E(x) and E(y) are the individual 
drugs' effect. Paired t-tests were used to compare the expected effect determined by the Bliss 





3.16. Statistical Analysis to Determine IC50 Value  
The data obtained from cell growth assays was analysed by using Graph Pad Prism software 
version 8. Non-linear regression was used to fit a four-parameter (Hill-equation) sigmoidal 
dose-response curve, and then subsequently, the concentration of drug which caused 50% 
inhibition of cell growth (IC50) was determined.   Statistical analyses were conducted by 




































The Influence of Food extracts on Pitavastatin Anticancer Activity of 















4. Introduction  
Ovarian cancer is a generic term used for all tumours of primary malignancy presenting in the 
ovaries [357]. It is considered the fifth leading cause of cancer death in women with more than 
4000 deaths annually in UK [358]. The 5-year survival rate for patients diagnosed with 
advanced (stage II or greater) ovarian cancer is less than 46 percent [359]. Initially ovarian 
cancer responds to chemotherapy but most of ovarian cancer patients relapse, often the tumours 
develop drug resistance alternative effective cancer therapies are urgently required [360], [361]. 
The poorer prognoses and the low survival rates command attention and force researchers to 
focus on ovarian cancers to find alternative methods of treatment [360], [362].  
 
Cancer cells utilise the mevalonate pathway to synthesize isoprenoids for the post-translational 
modification of proteins, some of which play important roles in tumour initiation, growth, and 
metastasis. Protein prenylation can be an essential step in protein recruitment to the cell 
membrane, protein-protein interaction and localisation [363]. In particular, farnesyl and 
geranyl-geranyl pyrophosphate are essential for post-translational modification of small 
GTPases, many of which are oncogenes. Consequently, statins have showed pro-apoptotic, 
anti-proliferative and anti-invasive effects of cancer cells in preclinical studies [274], [364], 
[365]. In addition to their pro-apoptotic effects, statins also induce cell cycle arrest at G1/S 
phase through up-regulation of the inhibitors of cell-cycle p21WAF1/CIP1 and/or p27KIP1, and also 
by reducing the expression of the CDK2, CDK4, Cyclin D1 and Cyclin E [366], [367]. 
Therefore, the mevalonate pathway appears a reasonable target to treat malignant disease.  
  
4.1  MVA-derived metabolites in cancer 
The mevalonate pathway is responsible for the synthesis of several metabolites, in addition to 




anticancer effect by blocking the production of mevalonate, it is possible that this is also due to 
the reduced supply of other mevalonate pathway products. [231], [368].  
 
4.1.1 Cholesterol  
Cholesterol is essential for the biosynthesis of cell membranes. As such, it is essential for rapid 
synthesis of cell membranes in cancer cells which are highly proliferative. In addition, 
cholesterol is an important precursor for steroid hormones, bile salts and vitamin D. Cholesterol 
and sterols have a direct effect on the mevalonate pathway by feedback inhibition [369]. Many 
epidemiological and experimental data indicate that ovarian cancer shares several pathways 
controlled by oestrogen analogous to other hormonal cancers. Local synthesis of oestrogen 
from circulating steroid hormone precursors by steroid-forming and steroid-inactivating 
enzymes could therefore be essential for the development of ovarian cancer in women after 
menopause. In addition, these enzymes and receptors have been identified in ovarian cancer 
cells and their expression has been shown to be linked to clinical outcome [370]. 
 
Cholesterol is generated primarily through the liver and transported through low-density 
lipoproteins to other tissues[231]. However, HMGCR activity is regulated not only by 
cholesterol concentration but by other intracellular factors (MP sterol and non-sterol products) 
and extracellular factors (insulin, tri-iodothyronin, glucagon and cortisol) (insulin, tri-
iodothyronin, glucagon and cortisol)[369], [371].  
 
4.1.2.  Dolichol  
Another candidate by which statins may exert an anti-cancer effect is by blocking the 
production of dolichol by the mevalonate pathway. Dolichols are polyisoprenoids with long 
chains that are unsaturated in all eukaryotic cells and consists of 18-20 isopentenyl units. 




protein in the endoplasmic reticulum[372]. This molecule can contribute to tumourigenesis, 
proliferation and metastasis due to the frequent alteration of protein N-glycosylation in cancer. 
Dolichol can contribute to tumourigenesis, proliferation and metastasis due to the frequent 
alteration of protein N-glycosylation in cancer. In some cases of cancer, the complex branching 
of N-glycans has a tumour-suppressive property. Consequently, N-linked glycosylation may 
prevent intracellular protein aggregation in the ER and may also be necessary for proper folding 
and cleavage of the precursor proteins. The N-linked oligosaccharides may also be required to 
guide proteins through various compartments of the Golgi network in which they are further 
processed before subsequent translocation to the cell surface [373]. Therefore, deficiencies in 
N-linked glycosylation at certain glycosylation sites can lead to incorrect protein folding, 
suppressed efficiency and reduced intracellular glycoprotein transport or impaired protein 
function[374]. 
 
4.1.3. Coenzyme Q10 
Inhibition of the mevalonate pathway also restricts the biosynthesis of coenzyme Q10 (also 
known as CoQ10 or ubiquinone (2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone)). 
In humans, the major role of this molecule is in electron transfer during oxidative 
phosphorylation in mitochondria [375]. It transfers electrons in its quinone group from complex 
I or complex II to complex III and participates in oxidative phosphorylation and ATP 
production. In addition, Ql0 is considered a potent antioxidant and scavenger of free radicals, 
as well as being considered to be a membrane stabilizer and preserves cellular integrity[375], 
[376], considering its role in ATP production, it is plausible that reduced levels of CoQ10 could 
contribute to the cytotoxic activity of statins. 
 
Statin-induced myopathy encompasses a wide range of statin-associated muscle symptoms 




showed a reduction in coenzyme Q10  after statin treatment, which could be associated with 
myopathy induced by statins [377]–[379]. Several studies have shown that Co-enzyme Q10 
supplementation reduced statin-associated muscle symptoms, indicating that Co-enzyme Q10 
supplementation may be a complementary solution to statin-induced myopathy treatment 
[380]–[384].  
 
4.1.1 Farnesyl-diphosphate and gernaylgernayl-diphosphate 
Farnesyl-diphosphate and geranylgeranyl-diphosphate, discussed above, are considered to be 
two keys products of the mevalonate pathway because they play important roles in protein 
prenylation, and consequently in differentiation and tumourigenesis. MP intermediate products 
(GGPP and FPP) are involved in post-translational modification, proliferation and 
differentiation of several important proteins involved in cell signals. This includes the GTPases 
Ras superfamily, a large protein family with over 150 members. In about 20 percent of human 
tumours, Ras itself is mutated. Mutated Ras can be stabilised in a constitutively active 
conformation and new therapies that inhibit Ras activity are being created [385]. 
Studies with cultured cancer cells have shown that supplementation of cell growth media with 
granylgeraniol can suppress apoptosis and inhibition of cell growth caused by statins[386]. 
Pitavastatin was found to be able to cause the regression of ovarian cancer xenografts in mice 
if the animals received a diet of “Ensure”. Ensure is a human complete liquid food used by 
many cancer patients and that lacks geranylgeraniol. However, when the Ensure was 
supplemented with geranylgeraniol, pitavastatin was no longer able to inhibit the growth of the 
xenografts in the mice. Importantly, geranylgeraniol is present in some human foods[387]. 
These observations raise the concern that the supply of one or more of these mevalonate 
pathway products in food, and in particular geranylgeraniol, may interfere with statins’ 
anticancer activity.  It is possible that patients’ diet may contain sufficient quantities of 




Therefore, clinical trials of statins in cancer may require patients to eat a diet limiting their 
exposure to geranylgeraniol. Consequently, it is important to identify foods that lack 
geranylgeraniol, or other metabolites that interfere with the anti-cancer activity of statins.  
Without this information, clinical trials of pitavastatin in cancer may fail. 
 
Previous studies have reported the presence of geranylgeranyl diphosphate and or 
geranylgeraniol in foodstuffs including extract of sunflower oil, olive oil [387], Kinuhikari 
polished rice [349], and virgin olive oil [388].  Previous studies in our laboratory[308] have 
shown that solvent extracts of human and mouse food were able to block the anticancer activity 
of pitavastatin by inhibiting pitavastatin-induced apoptosis. Consequently, the main objective 
of the research described in this chapter was to test a selection of foods commonly eaten in the 





4.2  Results  
4.2.1 Inhibition of the growth of Ovcar-4 and Fuov-1 cells by Pitavastatin 
Cells were exposed to the indicated concentration of pitavastatin for 72 h and the relative 
number of surviving cells measured by staining with SRB. Pitavastatin inhibited the growth of 
Ovcar-4 (IC50 = 5.2 ± 1.20 μM) and Fuov1 (IC50 = 8.3 ± 0.9 μM) cells (Figure (4-1) & (4-2)). 
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Figures (4-1&4-2): Dose response curve of pitavastatin in ovarian cancer cell lines (Ovcar-4 and Fuov-1 cells). 
The activity of pitavastatin was evaluated in cell growth assays and assessed by staining with SRB. The results are 
expressed as a fraction of the cells measured in samples treated with solvent alone (mean ± SD; n = 3) “C” on the 
x-axis indicates a measured absorbance in the absence of the drug. The cells were exposed to the indicated 





4.2.2 Food extraction 
To determine which foods could potentially interfere with the cytotoxic activity of pitavastatin, 
solvent extracts were made from a range of foods and their ability to inhibit the cytotoxic 
activity of pitavastatin was measured.  
4.2.2.1. Edible Oils  
Extracts were also prepared from several edible oils. Organic solvent extracts were prepared 
from a range of oil (Fig (3-1)). Between 110 and 600 mg were extracted from 50 g of each oil 
(table (4-1)). The effect of food extracts on the growth-inhibitory activity of pitavastatin (10 
M) was assessed using six two-fold serial dilutions of each extract.  Geranylgeraniol 5 μM in 
combination with pitavastatin in cell growth assays was used as a positive control. The extract 
from sunflower oil (fig 4-3 & 4-4) completely rescued the cells from the cytotoxic effect of 
pitavastatin while corn oil, ground nut oil and grape seed oil partially blocked the activity of 
pitavastatin (fig 4-5 & 4-6).  
Table (4-1): the weight of oils extractions in 50 grams of foodstuff. 
No Extracts Weigh of extract obtained from 50 g of oil 
1 Sunflower oil  510 mg 
2 Corn oil  370 mg  
3 Grape seed oil  580 mg  
4 Ground nut oil  347 mg  
5 Rape seed oil 394 mg 
6 Sesame oil 160 mg 
7 Coconut oil  110 mg 






Figure (4-3): The effect of sunflower extract on pitavastatin activity against the Ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extract 
concentrations are expressed as a percentage of the final concentration (v/v).  After 72 hours, the number of 
surviving cells was assessed by staining with SRB. The results (mean ± S.D., n=3) are expressed as a fraction of 
the absorbance measured in cells treated with solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) 
and the results were significantly different from this where indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; 
One Way Anova). 
 
 
Figure (4-4): The effect of sunflower extract on pitavastatin activity against Fuov-1 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 






Figure (4-5): The effect of corn oil extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-6): The effect of grape seed oil extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 






Figure (4-7): The effect of ground nut oil on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-8): The effect of rape seed oil extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 






Figure (4-9): The effect of sesame oil extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-10): The effect of coconut oil extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 





Figure (4-11): The effect of walnut oil extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
4.2.2.1  Solid foods 
Extracts were also prepared from several solid foods many of which are primarily considered 
to be primarily carbohydrates (table 4.2). In general, a smaller mass of solid was recovered in 
the extract from the solid foods than from the oils. The extract from Dolmio (pasta sauce), oats, 
boiled egg, pecan nuts and boiled black beans partially reversed the effect of pitavastatin in cell 
growth assays while other food extracts (bread, tomato, squash, spaghetti, strawberry jam, 









Table (4-2): the weight of   meals extractions in 50 grams of foodstuff 
No Extracts Weigh of extract obtained from 50 g of solid food 
1 Bread  140 mg 
2 Cheese  60 mg 
3 Butter 180 mg 
4 Milk 50 mg 
5 Spaghetti  30 mg 
6 Pasta  sauce 30 mg  
7 Boiled potato  30 mg 
8 Boiled black bean 70 mg 
9 Boiled egg 120 mg 
10 Oats 60 mg 
11 Pecan nuts 110 mg 
 
 
Figure (4-12): The effect of bread extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 





Figure (4-13): The effect of bread extract on pitavastatin activity against fuov1 ovarian cancer cell line. Cells were 
exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as a 
final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The results 
(mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent alone. GG 
denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where indicated (*, P< 
0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-14): The effect of oats extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells were 
exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as a 
final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The results 
(mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent alone. GG 
denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where indicated (*, P< 






Figure (4-15): The effect of cheese extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-16): The effect of butter extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 





Figure (4-17): The effect of milk extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-18): The effect of spaghetti extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 





Figure (4-19): The effect of pasta sauce extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-20): The effect of boiled potato extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 






Figure (4-21): The effect of boiled black bean extract on pitavastatin activity against ovcar-4 ovarian cancer cell 
line. Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
 
Figure (4-22): The effect of boiled egg extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 





Figure (4-23): The effect of pecan nuts extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
4.2.2.2  Fruit & Salad 
Extracts were also prepared from various fruits and salads. Again, relatively smaller amounts 
of solid were recovered compared to the oil extracts. These organic solvent extracts were also 
tested for their ability to suppress pitavastatin inhibitory activity in cell growth assays. The 
extracts from lettuce partially reversed the effect of pitavastatin while others (kiwi, pears, fig, 
passion fruit, pomegranate, gooseberry, tomato, squash, strawberry jam and cherry) showed no 










Table (4-3): the weight of   Fruits and vegetables extractions in 50 grams of foodstuff 
No Extraction Weigh of extract obtained from 50 g of solid food) 
1 Kiwi 10 mg 
2 Lettuce  550 mg 
3 Passion fruit  40 mg  
4 Pomegranate  10 mg 
5 Cherry 30 mg 
6 Fig  40 mg 
7 Gooseberry  10 mg 
8 Pears  30 mg 
9 Tomato  130 mg 
10 Strawberry jam  80 mg 
11 Squash  20 mg 
 
 
Figure (4-24): The effect of Kiwi extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 





Figure (4-25): The effect of lettuce extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-26): The effect of lettuce extract on pitavastatin activity against fuov1 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 





Figure (4-27): The effect of passion fruit extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-28): The effect of pomegranate extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 






Figure (4-29): The effect of cherry extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-30): The effect of fig extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells were 
exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as a 
final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The results 
(mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent alone. GG 
denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where indicated (*, P< 





Figure (4-31): The effect of fig extract on pitavastatin activity against fuov1 ovarian cancer cell line. Cells were 
exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as a 
final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The results 
(mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent alone. GG 
denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where indicated (*, P< 
0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-32): The effect of gooseberry extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 





Figure (4-33): The effect of pear extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells were 
exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as a 
final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The results 
(mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent alone. GG 
denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where indicated (*, P< 
0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-34): The effect of tomato extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 






Figure (4-35): The effect of tomato extract on pitavastatin activity against fuov1 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
Figure (4-36): The effect of strawberry jam extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. 
Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are 
expressed as a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with 
SRB. The results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with 
solvent alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 





Figure (4-37): The effect of squash extract on pitavastatin activity against ovcar-4 ovarian cancer cell line. Cells 
were exposed to pitavastatin (10 M) and/or the indicated concentration of food extract. Extracts are expressed as 
a final concentration (v/v).  After 72 hours, the number of surviving cells assessed by staining with SRB. The 
results (mean ± S.D., n =3) are expressed as a fraction of the absorbance measured in cells treated with solvent 
alone. GG denotes cells exposed to geranylgeraniol (5 M) and were significantly different from this where 
indicated (*, P< 0.05 and **P ≤ 0.01, ***P ≤ 0.001; One Way Anova). 
 
4.3 Trypan blue experiment  
The ability of various food extracts to suppress the cytotoxic activity of pitavastatin was further 
evaluated by trypan blue staining of cells exposed to pitavastatin and the extracts to confirm 
the previous results (figure 4-35). The results were generally consistent with the results obtained 
in cell growth assays. The sunflower extract again significantly interfered with the activity of 
pitavastatin and increased the number of viable cells, although the extract had no measurable 
effect on its own.  At the other hand, the extract from milk, which had limited effect in cell 
growth assays, proved unable to suppress the pitavastatin cytotoxic effect. In contrast, there are 



































































Figure (4-38): The effect of pitavastatin with/without geranylgeraniol and sunflower extract and milk extract 
with/without pitavastatin and the dead cells were measured by trypan blue staining after 72 of exposure ovcar4 to 
pitavastatin (10 M) with/ without GGOH(5 M)  and sunflower or milk extract. The results (mean ± SD; n = 3) 
were compared to the effect expected for an additive interaction then calculated using mean and SD, Results were 
significantly different where shown (*, P < 0.05; **, P < 0.01; ***paired t-test). 
 
4.2.4. GC/MS experiments 
To confirm the presence of geranygeraniol in the food samples, some of the extracts were 
analysed by GC/MS. Geranylgeraniol was used to as a standard. Analysis of GC / MS data was 
performed by integrating each resolved chromatogram peak and normalising the area for the 
chromatogram total area. Peaks were tested for their mass distribution, and the geranylgeraniol 
library was used to classify such peaks. Sunflower oil and boiled black bean extract (figures (4-
40, 4-41)) clearly contained geranylgeraniol. In contrast, free geranylgeraniol was not detected 
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Figure (4-39): Shows the Standard geranylgeraniol of GC-MS chromatogram (A), and the electron ionization mass 
spectrum of geranylgeraniol at Rt 8.82 min (B) 
 
Figure (4-40): Shows the GC-MS chromatogram of sunflower oil, 20 mg/ml in hexane, 1 uL injected (A), and the 
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Figure (4-41): Shows the GC-MS chromatogram of boiled black bean extract, 20 mg/ml in hexane, 1 uL injected 
(A), and the electron ionization mass spectrum of a geranylgeraniol derivative at Rt 13.88 min (B). 
 
 
Figure (4-42): Shows the GC-MS chromatogram of egg extract oil, 20 mg/ml in hexane, 1 uL injected (no 
geranylgeraniol derivatives found). 
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Figure (4-43): Shows the GC-MS chromatogram of lettuce extract, 20 mg/ml in hexane, 1 uL injected (no 
geranylgeraniol derivatives found). 
 
4.2.5. The effect of mevalonate pathway intermediate metabolites on pitavastatin 
anticancer activity 
Although it has previously been shown that geranylgeraniol can suppress the cytotoxic activity 
of pitavastatin, it was possible that other mevalonate pathway metabolites might also be able to 
do this. Consequently, several different metabolites of the mevalonate pathway were evaluated 
in combination with pitavastatin in cell growth assays using OVCAR-4 cells. Mevalonate & 
Geranylgeraniol showed nearly complete suppression of the cytotoxic activity of pitavastatin. 
In contrast, supplementation of cell culture medium with either coenzyme Q10 (5M), Dolichol 
(5M) or Cholesterol (5M) did not have significant effects on the cytotoxic activity of 
pitavastatin (fig. (4-44)). To confirm these results, the experiments were also repeated using 
FUOV1 cells (fig (4-45)) and similar results were obtained. 
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Figure (4-44): The effect of metabolites of the mevalonate pathway on pitavastatin’s activity against Ovcar-4 
ovarian cancer cells. Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of metabolites 
(coenzyme Q10 (5M), Dolichol (5M) or Cholesterol (5M)). After 72 hours, the number of surviving cells 
assessed by staining with SRB. GG denotes geranylgeraniol (5 M) The results (mean ± S.D., n =3) are expressed 
as a fraction of the absorbance measured in cells untreated and were significantly different where indicated  by an  


















































































































































M e ta b o l i t e s  o f  m e v a lo n a te  p a th w a y /F U O V 1
 
Figure (4-45): The effect of metabolites of the mevalonate pathway on pitavastatin’s activity against fuov1 ovarian 
cancer cells. Cells were exposed to pitavastatin (10 M) and/or the indicated concentration of 
metabolites(coenzyme Q10(5M), Dolichol(5M) or Cholesterol(5M)). After 72 hours, the number of surviving 
cells assessed by staining with SRB. GG denotes geranylgeraniol (5 M) The results (mean ± S.D., n =3) are 
expressed as a fraction of the absorbance measured in cells untreated and were significantly different where 







4.4 Discussion  
This study set out to evaluate if human foods could potentially impair the efficacy of 
pitavastatin as a drug to treat cancer. Unfortunately, statins have failed so far to show activity 
in prospective clinical trials as a cancer treatment. One plausible factor that contributes to this 
failure is that patients consume foods which contain geranylgeraniol and this bypasses the 
inhibitory effect of statins on the mevalonate pathway. Exposing cancer cells to pitavastatin in 
the presence of extracts collected from a variety of commonly consumed foods demonstrated 
that certain foods appear to contain a substance which inhibited the cytotoxic activity of 
pitavastatin against cultured ovarian cancer cells.  
 
Some foods appear better able to inhibit the activity of pitavastatin than others do. The extract 
from sunflower showed almost a complete reversal of the inhibitory effects of pitavastatin in 
both cell lines evaluated (OVCAR-4 & FUOV-1, (figures 4-3 and 4-4)), while some extracts, 
such as corn oil, groundnut oil, coconut oil, grape seed oil, lettuce, Dolmio (pasta sauce tomato), 
oats, boiled black bean, pecan nuts and boiled egg, only partially reversed the effects (see 
figures 4-5 to 4-23). These results were supported by GC-MS analysis which revealed the 
presence of geranylgeraniol in sunflower and boiled black bean extracts (fig. (4-40,4-41)). In 
contrast geranylgeraniol was not detected in the extract from milk, and milk extracts were also 
inactive in the bioassay. The boiled egg and lettuce extracts (figures (4-42, 4-43)) partly 
suppressed the cytotoxic activity of pitavastatin but geranylgeraniol was not detected by 
GCMS. There are several potential explanations for this minor discrepancy. Possibly only small 
amounts of geranylgeraniol were present in the extract, and not detected by GCMS. 
Alternatively, different sources and types of lettuce may have been tested (unfortunately 
different extracts were tested). Alternatively, there may be compounds other than 




mevalonate which is also able to block the cytotoxic effects of statins. In general, the oils seem 
to be a relatively rich source of geranylgeraniol and this is supported by a limited number of 
published analyses. Green foods may also contain geranylgeraniol than others. The results 
presented here provide identify some foods which patients could consume while receiving 
pitavastatin as cancer treatment as part of a clinical trial. However, there may be further 
complications because patients may prefer specific type food according to the traditional foods 
in the country or due to family habits. This could play an important role in the amount of 
geranylgeraniol that patients ingest. This may also contribute to some of the differences in 
retrospective clinical trials which have either claimed statins have an anti-cancer effect or have 
no effect. Differences in food consumption between different patients may lead to differences 
in the therapeutic effect of statins as anti-cancer agents. An added complication is that 
geranylgeraniol may be liberated from other compounds in intestine like wax esters or 
Geranylgeranyl diphosphate (GGPP) for example  by intestinal phosphatase [389] or esterases, 
or even acid hydrolysis. However, the bioavailability of the liberated geranylgeraniol, and the 
parent compounds, is still unknown and further studies are needed to estimate the plasma level 
of geranylgeraniol which would result from their consumption. 
 
Some of the extracts, for example those from corn, coconut, walnut and boiled eggs inhibited 
the growth of the ovarian cancer cell cultures when they were tested on their own (in the absence 
of pitavastatin). This was particularly evident when these extracts were tested at higher 
concentrations (figures (4-5,4-10, 4-11and 4-22)). This made it impossible to evaluate whether 
these extracts contained a substance able to suppress the activity of pitavastatin, at least when 
tested at the higher concentrations. We have not yet identified the compounds present in the 
different foods, which are responsible for the inhibitory activity present in these extracts. It may 
simply reflect the effect of large amounts of oil acting in a non-pharmacological manner, for 




mechanism of inhibition by creating droplets that effectively sequester the pitavastatin due to 
its lipophilic structure. 
 
Blockage of the mevalonate pathway by statins results in reduction of the level of cholesterol 
and simultaneously other products of the pathway for instance geranylgeranyl pyrophosphate 
(GGPP), farnesyl pyrophosphate (FPP), dolichols, Co-enzyme Q10 and Cholesterol (Mullen et 
al., 2016). It was, therefore, important to evaluate if compounds other than geranylgeraniol 
could suppress the activity of pitavastatin. Only mevalonate and geranylgeraniol, had a 
significant effect (see figures (4-44 and 4-45). Mevalonate significantly, but not fully, reversed 
the effect of pitavastatin. The inability to completely supress the effect of pitavastatin may 
reflect technical problems in the assay. Mevalonate pathway metabolites can down-regulate 
HMGCR protein levels through feedback regulation of the SREBP transcription factor that 
regulates expression of HMGCR gene. It may be technically challenging to provide exactly the 
right concentration of, for example, mevalonate, to restore full pathway activity without 
activating the negative feedback pathways which would diminish the production of other 
pathway intermediates. Another potential explanation for the failure to completely suppress the 
effects of pitavastatin is that high concentrations of, for example, mevalonate is toxic through 
another mechanism and so it is impossible to compensate for mevalonate pathway inhibition 
by pitavastatin without causing toxicity by another mechanism. In addition, the prenylation of 
proteins by geranylgeranyl transferases requires geranylgeraniol pyrosphosphate. These 
experiments tested geranylgeraniol rather than its pyrophosphate. Using the alcohol rather than 
the pyrophosphate increased the likelihood of the isoprenoid being membrane permeable and 
becoming available inside the cells. The solvent extracts may have also contained 
geranylgeraniol rather than its pyrophosphate due to the alkaline hydrolysis step which would 
be expected to convert any geranylgeraniol present as a pyrophosphate to the corresponding 




compounds in food.  Geranylgeraniol is known to be present as wax esters in various vegetable 
oils. The wax esters often contain geranylgeraniol as esters of palmitic acids, and unsaturated 
C18 acids in particular [390] or even fatty acids containing up to 24 carbon atoms. The literature 
contains conflicting data whether wax esters can be hydrolysed to release free geranylgeraniol, 
but hydrolysis would release geranylgeraniol as its unmodified alcohol[391]. Regardless of the 
source of the geranylgeraniol (from wax esters or added directly into the assay as a control), it 
is not clear how cells can generate geranylgeraniol pyrophosphate from the corresponding 
alcohol. Normally, the pyrophosphate form of the isoprenoids is derived from phosphorylation 
of mevalonate by mevalonate kinase. The phosphorylation of geranylgeraniol by this enzyme 
may be relatively inefficient and so all the geranylgeraniol may not be converted to the 
pyrophosphate.  This could again contribute to the failure of the isoprenoids to completely 
suppress the effect of pitavastatin. 
 
The other metabolites that were tested included co-enzyme Q10, dolichol and cholesterol and 
had no significant effect on the cytotoxic activity of pitavastatin. This is particularly important 
because of the issue of myopathy caused by statins, particularly at high doses. Although all 
statins are relatively safe drugs, they are associated with a significantly increased risk of 
myopathy, ranging in severity from asymptomatic increases in creatine kinase (CK) and muscle 
weakness, aches, and fatigue to fatal rhabdomyolysis. Even though the prevalence of 
rhabdomyolysis is thankfully very small (0.1 percent of all statin users), it is notable the number 
of patients who do not tolerate statins due to myopathic symptoms (1–10 percent)[392]. 
Importantly, co-enzyme-Q10 is sometimes recommended to patients to minimize the likelihood 
of statins causing myopathy. However, the evidence that co-enzymeQ10 is effective in 
suppressing statin-induced myopathy is not particularly convincing. Several studies were 
conducted to determine the association of co-enzyme Q10 concentration in serum and muscle 




have shown that the statins have reduced circulating levels of co-enzyme Q10, while other 
studies have not confirmed a decrease in muscle co-enzyme Q10 levels during statin 
therapy[393]. In some studies, co-enzyme Q10 supplementation can help to increase the plasma 
levels of co-enzyme Q10 in those taking statins[394]. In contrast, other studies show that the 
supplementation of coenzyme Q10 may boost myopathy symptoms[381], [395]. Consequently, 
a causal correlation between reduced co-enzyme Q10 and myopathy has not been definitively 
demonstrated[396]–[398]. In addition, randomised, double-blind clinical trials have failed to 
demonstrate that co-enzyme Q10 supplementation decreases myopathy associated with 
statins[399]. Despite these discrepancies, co-enzyme Q10 continues to be recommended to 
some patients to relieve statin-induced myopathy. Thus, it was particularly important to 
evaluate the effects of co-enzyme Q10 on the activity of pitavastatin.  The observation that co-
enzyme Q10 failed to alter the activity of pitavastatin in the bioassay suggests that if patients 
taking pitavastatin to treat cancer are also recommended to take co-enzyme Q10 to reduce the 
risk of myopathy, it will not interfere with the anti-cancer activity of pitavastatin. 
 
In summary, the goal of these studies was to explore the potential for metabolites of mevalonate 
pathway within food to interfere with the anticancer activity of pitavastatin in clinical trials. 
The data presented here suggested that patients using statins to treat cancer should avoid most 
vegetable oils as well as some “green” food. A number of foods were identified that patients 
could consume in addition to Ensure and this may increase the chance of clinical trial of 
pitavastatin being successful.  In clinical trials, it will be important to assess whether an 
appropriate dose of pitavastatin can be found that is effective against cancer cells without 


































5.  Introduction  
Cancer is a heterogeneous multifactorial disease that continues to be one of the leading causes 
of death worldwide, accounting for 21% of total death and is the second-largest disease 
affecting the people in developed countries[400], [401]. Despite substantial advancement in 
cancer research and the production of medications, the long-term survival of most cancer 
patients remains limited even though, in recent years, an significant body of evidence has 
accumulated supporting the notion that a wide range of both congenital and somatically 
acquired ribosomal abnormalities, as well as regulation of ribosomal function by oncogenic 
factors, lead to a phenotype for cancer [401]. However, phenotypic cancer symptoms tend to 
represent specifically changes in protein synthesis and function, which are also the targets of 
most drugs [402], genomics and transcriptomics have been the focus of study for years.  
 
The inadequacy of current screening services to tackle the deadliest cancers highlights the need 
for innovative methods to strengthen cancer screening, diagnosis, and care. Biomarkers are one 
such tool. For example, biomarkers with susceptibility may indicate screening modalities, if 
any, should be used to evaluate the risk level. Predictive biomarkers can be used for highly 
selective therapies to prospectively identify appropriate patients for treatment, and biomarkers 
for the prognosis can be used to track treatment response. The use of biomarkers in both clinical 
development and marketplace will be essential to success[403]. Biomarkers are classified as 
indicators of normal biological processes, pathogenic processes or pharmacological responses 
to a therapeutic intervention which can be calculated objectively[404]. They may take several 
forms — genes, proteins, carbohydrates, ions, cells or physiological measurements that are 
radioactively identified[405]. However, the detection and development of biomarkers for 
cancer may pose a greater research challenge due to the biological nature of cancer, the varied 
settings where biomarkers can be useful in cancer screening, diagnosis and care include the 




the classification of disease subtypes and prognoses ; choice of the most suitable treatment for 
the particular patient, including dose titration and minimization of adverse events; and control 
of therapy, the needs of biomarkers used in early cancer diagnosis vary from those used in 
disease staging and treatment decisions[403]. No present screening approach for the early 
detection of ovarian cancer has influenced ovarian cancer patients' survival. Developing a 
successful ovarian cancer screening approach is challenging because it is not a single disease 
and can be divided into at least five distinct histological subtypes with distinct recognizable 
risk variables, each with distinct bio-related and clinical characteristics [406].  
 
Statins are potent cholesterol decreasing drugs that have been shown to suppress in vitro 
proliferation of tumour cells and growth of tumours in animal models. In addition, longitudinal 
analyses of human cohorts showed decreased cancer-specific mortality in patients taking 
statins[407]. However, previously included E-cadherin membrane expression as both a marker 
and a mechanism for the resistance to atorvastatin-mediated growth suppression of cancer cells; 
however, a statin sensitivity transcriptome-based biomarker signature has not yet been 
identified[407]. Therefore, we investigated the sensitivity of biomarkers for statin therapy using 
the bioinformatics-experimental approach. 
 
Several studies have recently identified numerous mevalonate pathway (MP) enzymes as 
crucial to the survival of various transformed cells by supplying sterol and isoprenoids and 
other products [408], [409], therefore, the role of MP in many aspects of carcinogenesis has 
contributed to its being considered a therapeutic target. MP deregulation may lead to malignant 
transformation in OC. Recent findings from our laboratory have indicated that pitavastatin is 
superior to other oncological statins as it is the only statin that is both lipophilic, making it more 
active than hydrophilic statins, and has a long half-life (t1/2 ~11 hours) [308], [309], [410], 




inhibition of HMGCR is sufficient to induce cell death, and the gaps in plasma drug 
concentration between prolonged dose intervals with short half-life statins are likely to 
compromise statin activity [412]. HMGCR activity can be deregulated in tumours and become 
resistant to negative sterol feedback regulation, which can help to provide an abundance of 
isoprenoids to promote transformed cell growth. However, despite a good understanding of the 
mevalonate pathway itself, there is no clear mechanistic understanding of how inhibiting it 
causes cancer cell death. This lack of mechanistic understanding also makes it difficult to 
predict which individual cancer patients are mostly likely to benefit from treatment with a statin. 
The research described in this chapter set out to address these deficiencies. The Broad Institute 
has conducted an analysis of the sensitivity of a panel of 500 cancer cell lines to a range of 
therapeutic drugs. The expression profile of these cell lines is has also been reported. This 
allows identification of genes whose expression correlations with drug sensitivity and which 
may correspondingly be involved in setting the cellular sensitivity to the drug. The expression 
of these genes may then both provide biomarkers to identify which patients are most likely to 
respond to the drug as well as provide insight into the mechanism by which the drugs are 
cytotoxic. 
 
Isoprenoids are used to alter many small GTPases of superfamily proteins post-translationally 
and to help their membrane localisation[413], and provide an obvious potential pathway 
affected by pitavastain Superfamily members are important regulators for most cell processes, 
including differentiation, proliferation, dynamics and transport of vesicles and organelles, 
nuclear dynamics, and cytoskeleton regulation[414]. The Rho family's small GTPaes are master 
regulators for actin cytoskeleton rearrangements and cell morphology[415]. GTPases also 





5.1. Microtubules and MAPs 
Microtubules are vital elements of the cytoskeleton and play a critical role in many cellular 
procedures, including cell division, cell motility, intracellular trafficking, and cell cytoskeleton 
maintenance[417]. Microtubules are intrinsically dynamic polymers composed of -tubulin 
heterodimers and their dynamic properties are crucial for the assembly of the mitotic spindle 
and for the attachment and separation of chromosomes during mitosis [418].  
 
Tubulin protein family members share a strongly homologous structure consisting of a globular 
body created from the N-terminal and intermediate domains and an extremely flexible and 
disordered carboxy-terminal (C-terminal) tail area[419]. The C-terminal tail of the tubulin 
proteins stretches outside the microtubule wall, where it is the location for a broad spectrum of 
post-translation modifications and protein interactions that control the dynamics of 
microtubules and other signalling effectors[419], [420]. The C-terminal tails are the most 
divergent areas among different  isoforms of β-tubulin, making this area a prominent candidate 
in identifying the particular function of the tubulin proteins[421]. The structure of tubulin 
isoforms is a key element of the tubulin code, together with post-translation modifications. 
 
Several microtubules associated proteins (MAPs) have been identified. Maps can alter the 
dynamic parameters of microtubules and organize microtubules into complicated structures 
[422]. The MAP family also involves microtubule motors that slide along the MTs. The motors 
use ATP hydrolysis to move cargo along microtubules, carrying vesicles, chromosomes, DNA, 
RNA and even other microtubules[423], [424].  Therefore, MT networks and related MAPs 
play important roles in different biological processes, including cell division, intracellular 
trafficking and cell morphogenesis[424], [425].  MAPs are a family of proteins that bind to and 
stabilize microtubules, MAP protein structures include members of the proteins MAP1, MAP2, 




that bind along the microtubular surface [426], [427]. There are several comprehensive reports 
on the interactions of MAPs with microtubules, which concentrate on the actin binding and 
function of the MAPs — MAP1/2/4 and Tau structures as microtubule – actin cross linking 
activities[426]. 
 
One member of family of MAPs is Ensconsin / MAP7 and it is connected with the cytoskeleton 
interphase microtubules, but its over-expression in cultivated cells does not appear to influence 
the dynamics of microtubules during interphase; instead mitotic defects often happen during 
cell division[428]. 
 
Figure (5-1): MAPs and cancer cell resistance / sensitivity to the action of microtubule-targeting medicines, 
Intracellular proteins control the action of agents that stabilise or destabilise microtubules which affect the 
dynamics of the microtubules and how the microtubule-targeting drugs induce apoptosis[429]. 
 
Microtubule-associated proteins (MAPs) were first identified as proteins that bound to 
microtubules and stabilise them. Currently, a still growing number of MAPs shows a more 
complex image of such proteins as microtubule cytoskeleton organisers with a broad range of 
functions, MAPs require microtubules to participate in a variety of cellular processes such as 




of ciliary axonemas[430]. MAP4 is widely expressed, whereas MAP1 and MAP2 are 
predominantly expressed in neurons and MAP7 is limited to epithelial cells [431]. All members 
of the MAPs family have a similar organisation, with two preserved domains predicted to be 
helical, linked by an unstructured linker. The neuronal MAPs tau and MAP2 hinder motility of 
kinesin-1[432]–[434]. Monroy and their colleagues found the reconstitutions in vitro with 
purified proteins showed that MAP7 recruited kinesin-1 to MTs and reduced motor speed but 
only had a mild effect on kinesin-1 running length[432]. MAP7 was extremely immobile in 
these trials and was not co-transported with the engine, indicating that MAP7 affects the initial 
recruitment of kinesin to MTs but has little effect on kinesin-1 movement [432]. Some 
researchers measured function of three MAPs which are required for kinesin-1, initially using 
the distribution of mitochondria as a readout, because it strongly depends on kinesin1 KIF5B; 
in the absence of KIF5B, mitochondria were no longer distributed in the cytoplasm but clustered 
around the nucleus [435]. The MAPs family members are firmly established as positive kinesin-
1 regulators[423], [436], [437]. MAP7 proteins are represented in flies by one homologue 
(ensconsin), and in mammals by four isoforms encoded by different genes (MAP7, MAP7D1, 
MAP7D2, and MAP7D3)[438]–[440]. All members of the MAP7 family have a similar 
organisation, with two retained domains expected to be helical, connected by an unstructured 
linker. Study in flies, however, have shown that ensconsin's C-terminal fragment lacks the MT-
binding domain [423], [436], [437]. Kinesin-1 is well known to be auto-inhibited by its C-
terminal cargo-binding domains[441], and it has been proposed that ensconsin may play a role 
in alleviating kinesin auto-inhibition [423]. Hooikaas and his colleagues tried to produce a 
functional triple knockout of MAP7, MAP7D1, and MAP7D3, but these cells were not viable 
[442]. Unlikely, the lack of kinesin-1-mediated transport, as KIF5B knockout cells display no 
clear growth or proliferation deficiencies, and the other two kinesin-1 isoforms, KIF5A and 
KIF5C, do not appear to be expressed in HeLa cells [443], while they found that the protein of 




of its downstream phosphorylation of Cdk1/cycline B. This contributes to a decrease in 
interphase stability of the microtubules, which can contribute to the growth of centrosomally 
nucleated microtubules [444].  MAP7 proteins may contribute to cell division, as ensconsin is 
known to be involved in  spindle formation in flies [445]. At the meantime, eliminating three 
MAP7 counterparts using MAP7D1 and MAP7D3 siRNA-mediated knockdowns in a stable 
MAP7 knockout line, resulting in an effective loss of all three MAP7 family members,  
phenocopiedthe impact of KIF5B knockout, leading to a tight perinuclear clustering of 
mitochondria. They concluded that members of the MAP7 family function redundantly in the 
localization of mitochondria and that this effect is unlikely to be due to changes in the structure 
of the MT network [442]. Additionally, the MT-affinity regions are located in the MAP7 and 
MAP7D3 C-terminal connector [439], [446]. MAP7 is necessary for proper kinesin1-dependent 
nuclear distribution in mammalian myotubes [438]. Conversely, a protective mechanism to 
inhibit runway proliferation of oncogene-transformed cells similar to senescence and apoptosis 
could be an improper expression of MAPs and disruption of microtubule dynamics, as in early 
cutaneous melanoma [447].  
 
MAP7 also allows the motor protein kinesin-1 (KIF5) to interact with microtubules. Both 
MAP7 and kinesin-1  are needed in to support nucleus placement and spacing in multinuclear 
muscles cells, processes necessary for muscle function [448]. There is a direct interaction 
between Kinesin-1 and the Ensconsin C-terminal domain (the kinesin-binding domain, or 
KBD) [449]. The binding of the ensconsin N-terminal MT-binding domain (MBD) and the 
kinesin-1 engine domain is therefore necessary to rescue nucleus-positioning flaws after 
kinesin-1 or ensconsin is knocked down [438].  
 
The majority of cellular tubulin is cytoplasmic but a significant fraction is associated with the 




membrane isolation procedures, because association with plasma membrane changes some of 
the properties of tubulin. The association of tubulin with membranes is relatively strong because 
neutral detergent is required to release the dimer from the membranes[450]. It was a mystery 
how tubulin, which is a very polar protein, can become so strongly associated with the 
membrane considering hydrophobic interactions are more likely to be required[450]. 
Morphological cells structures suggest that microtubules can be bound to plasma or organelle 
membranes by connectors proteins that have not yet been identified. A bifunctional membrane 
anchor may result in a hydrophobic interaction with the membrane on the one side and a second, 
potentially but not necessarily more polar interaction with tubulin on the other[451]. A possible 
protein connecting microtubules to the plasma membrane is 2,3 -cyclic nucleotide-3 -
phosphodiesterase (CNP)[452]. CNP is both prenylated and palmitoylated[453], which 
provides a  hydrophobic moeity for membrane intercalation. CNP protein binds to microtubules 
and this affect their in vitro polymerization activity [453][451]. CNP can also directly associate 
with F-actin [454]. 
Table (5-1): The function of highly expression genes which used in these experiments  
Genes Mechanism of gene action   
Rab11-FIP4  Rab11-FIP4's over-expression considerably increased the mobility and 
invasiveness of in vitro HCC cells[455], A significantly favorable 
correlation between the expression of Rab11-FIP4 and HIF-1α was noted 
in HCC tissues and a more precious predictor of bad prognosis for HCC 
patients were shown the combination of Rab11-FIP4 and HIF-1α. To 
conclude, Rab11-FIP4 is a HIF-1α target gene and has a pro-metastatic 
function in HCC, indicating that Rab11-FIP4 may be a promising 
candidate for HCC therapy [455]. Some studies have shown that Rab11-
family interacting proteins (Rab11-FIPs) are tumour-related and can act 




GRhL-2 Grainyhead-like 2 (Grhl2), a transcription factor belonging to the 
grainyhead-like(Grhl) family, plays a major role in establishing 
epithelial polarity and in acquiring and maintaining epithelial-specific 
functions[457]. Grainyhead-like 2 (GRHL2) knockout eliminates the 
development of oral cancer by reciprocal control of the signalling 
pathways for MAP kinase and TGF-β[458].  In addition, Grainyhead 
transcription factor 2 over-expression is associated with poor prognosis 
in human pancreatic carcinoma[458]. 
BSPRY BSPRY (B-box and SPRY-domain containing protein) Originally 
recognized as a binding partner in the epithelial Ca2+ channel family of 
transient receptor potential vanilloid 5 (TRPV5). BSPRY's overexpression 
in kidney epithelial cells is an adverse regulator of Ca+ transport [459].  
PRR15 This is a family of proteins found in eukaryotes that consists of proline-rich 
15 (PRR15) and proline-rich 15-like proteins. PRR15 is expressed almost 
exclusively in post-mitotic cells both during foetal development and in 
adult tissues, such as the intestinal epithelium and the testis. Its expression 
in mouse and human gastrointestinal tumours is linked, directly or 
indirectly, to the disruption of the Wnt signalling pathway[460]. The 
patient developed eventually peritoneal metastases and died following 
surgery for 15 months. Molecular analyses have identified a KRAS 
mutation and a novel PRR15L-RSPO2 fusion in both SuSA and 




This enzyme condenses acetyl-CoA with acetoacetyl-CoA to create HMG-




same response in the biosynthetic sterol pathway, and HMGCS2 diverges 
from HMGCS1 [462]. 
RBM35A ESRP1(epithelial splicing regulatory protein 1) and ESRP2 manage 
alternative splicing occurrences linked to cell epithelial phenotypes[463], 
and ESRP1 is over-expressed in ovarian cancer and promotes the flipping 
of ovarian cancer cells from mesenchymal to epithelial[464]. 
CCDC64B BICD2 is a multifunctional adapter for motor proteins with minus end-
directed dynein-dynactin and plus end-directed kinesin-1 kinesin family 
5A for microtubules. Adapter proteins mediate the particular binding 
between the motor protein and its cargo. In this way, adapters control the 
motor protein's function and location. Motor proteins have significant tasks 
not only in microtubular transport, but also in controlling the dynamics of 
microtubular polymerization and microtubular length [465].  
FXYD3 FXYD domain ion transport regulator 3 (FXYD3), FXYD3 is a Na / K-
ATPase regulator recently associated with the development and 
progression of different cancers; thus, FXYD3 has been proposed as a 
possible therapeutic target for these cancers[466]. 
MAP7 MAPs are a family of proteins that bind microtubules and stabilize them 
[467]. While MAP4 is omnipresent, MAP1 and MAP2 isoforms are mainly 
expressed in neurons and MAP7 is limited to epithelial cells[422], [423]. 
Aberrant expression and significance of MAPs to the resistant phenotype 
of a broad spectrum of microtubular targeting agents. MAP7 connects 
branch sites to microtubules to support branch maturation in neuronal cells 
[446]. 
 




Genes Mechanism of gene action   
Frizzled-
2(FZD-2) 
FZDs play key roles in cell polarity regulation, embryonic development, 
cell proliferation, neural synapse formation, and many other developmental 
and adult organism growth procedures. The proteins of the WNT secreted 
glycoproteins and FZD ligands consist of nineteen members that can attach 
to the cell surface complex, a FZD family member and a co-receptor Low 
density lipoprotein-related protein 5/6 (LRP5/6), each FZD member can 
combine individually with the several distinct WNT proteins to trigger 
either canonical WNT/β-catenin or non-canonical WNT / PCP signalling 
pathways (planar cell polarity) and WNT / Ca2 + [468], [469] 
FGF Growth factors for fibroblasts (FGFs) are a large family of growth and 
differentiation variables (24 members). FGFs mediate their impacts by life 
on the cell surface with FGF receptors (FGFRs). FGFs and the receptors ' 
signalling axis play significant roles in controlling cell proliferation, 
migration, angiogenesis, wound healing, and differentiation. It has been 
shown that the FGF – FGFR axis modulates tumour stroma and cancer 
development. On the other side, in certain situations, FGF signals may have 
tumour-suppressive features. FGF signalling mechanisms have been 
shown to be involved in cancer development by causing mitogenesis, cell 
migration and tumour angiogenesis. Consequently, aberrant signals of FGF 
can encourage the growth of cancer[470], [471] 
AXL AXL plays a major role in controlling cell invasion and migration in 
tumour cells. In tumour cells with low metastatic potential, over-expression 
of AXL encourages migration and invasion. Furthermore, blocking AXL 




tumour cells. In vivo, breast and glioma tumour models have lately defined 
a function for AXL in invasion and metastasis[472]–[474]. 
VIM This gene encodes an intermediate protein of the type III filament. The 
cytoskeleton consists of intermediate filaments, microtubules and actin 
microfilaments. The encoded protein is accountable for keeping the 
cytoplasm's cell form and integrity and for stabilizing cytoskeletal 
interactions. This protein is engaged in the transportation of neuritogenesis 
and cholesterol and acts as an organizer of several other critical proteins 
engaged in cell attachment, migration and signalling. [475]–[477] 
CYR61 CYR61 involves various biological processes, including cell proliferation, 
inflammation, cell adherence, migration, embryogenesis, and wound 
repair[478]. Intriguingly, CYR61-Mediated Multidrug Resistance in 
Gastric Adenocarcinoma AGS Cells[479]. Furthermore, Cyr61/CCN1 
regulates the dCK and CTGF of pancreatic ductal adenocarcinoma and 
induces gemcitabine resistant phenotype[480]. 
PTRF PTRF protein translocates from caveolae to the cytosol after stimulation of 
insulin[43]. Caveolae comprise truncated forms of PTRP protein and may 
be the site of proteolysis dependent on phosphorylation. Caveolin is an 
integral membrane protein, both exposed to the cytosolic surface of the 
plasma membrane with N-and C-termini[481]. Caveolin's N-terminal 
domain can interact with and concentrate a variety of signal transduction 
proteins on the surface of the caveolae, such as G-proteins, Src-like 
kinases, C and H-Ras proteins[482].  
MAP7D1 MAP7D1 (MAP7 Domain Containing 1) is a Protein Coding gene, The 
microtubules connected with the Map7 and Map7D1 (Map7/7D1) proteins 




signal transducer Disheveled, which connects directly to the cortical 
location of Disheveled and facilitates the cortical targeting of MT plus-
ends in reaction to Wnt5a in Hela cells [483]. 
MARVELD3 MarvelD3 is a tight junction transmembrane element. Tight junctions also 
control processes of signalling that guide the proliferation of cells[484]. 
Occludin, tricellulin and MarvelD3 share a common MARVEL among the 
transmembrane proteins (MAL and associated vesicle trafc and membrane 
connection proteins) Domain that differentiates them from the other 
proteins of the claudin family junctional tetraspan transmembrane [484]. 
The junctional MARVEL domain proteins can modulate junctional 
permeability characteristics, they are believed to work mostly as regulators 
of tight junctions or elements of signalling processes that signal tight 






5.2. Results: - 
5.2.1. Identification of genes potentially associated with cellular sensitivity to statins. 
The Broad Institute’s cancer therapeutics response portal of  online data on the website: - 
(http://portals.broadinstitute.org/ctrp/?compoundId=27894&compoundName=simvastatin) 
was interrogated to identify the high or low p-value gene expression in ovarian cancer cell lines 
was associated with sensitivity to simvastatin, fluvastatin and lovastatin in 500 cell lines from 
a range of cancer types. Genes were selected for further investigation that were associated to 
more than one statin. The genes selected are described in tables (5-1, 5-2). No specific level of 
significance (P value) was used to select the genes for investigation; rather the 15 genes which 
showed the most significant association with statin sensitivity were selected. Further studies 
were then performed to evaluate whether these expressions of these genes predicted sensitivity 
to pitavastatin in ovarian cancer cell lines. 
5.2.2. Pitavastatin growth inhibition activity in six cells line of ovarian cancer 
To compare gene expression profiles of ovarian cancer cells to their sensitivity to pitavastatin, 
the potency of pitavastatin was first evaluated in cell growth assays (figure (5-2)). The results 
showed that four of the six cell lines had broadly similar sensitivities to pitavastatin, but that 
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Figure (5-2): Dose response curve of cell proliferation assays. The cells were exposed to the indicated 
concentration of pitavastatin (starting with 100µM) for 72 hours and the relative number of surviving cells 
determined by staining with SRB. The results are expressed as a fraction of the relative cell number measured in 
samples treated with solvent (mean ± SD; n = 3). “C” on the x-axis indicates a samples treated with drug solvent 
alone.  
 
Table (5-3): IC50s of pitavastatin growth inhibition activity in six cells line of ovarian 
cancer (mean ± S.D, n= 3) 
No Cell line  growth inhibition activity (IC50, µM) 
1 Cov318 7.7 ± 1.4 
2 Cov362 8.6 ± 0.7 
3 Fuov-1 6.2 ± 0.9 
4 Ovcar-4 5.6 ± 1.2 
5 Ovcar-8 0.82 ± 2  
6 Ovsaho 0.78± 1.9  
 
5.2.3.   Results of gene expression  
The expression of the genes identified as correlating with sensitivity to statins was then 
measured in the panel of 6 ovarian cancer cell lines by both RT-qPCR and western blotting. 
Notably, some genes were highly expressed in single cell line when measured by western 
blotting, for example Rab-11fip4, BSPRY and FXYD3 in OVCAR-4 while some genes show 
highly expression in all cell lines used in this experiment, e.g.  FGF5, AXL, VIM, GRHL-2 and 
PPR15Lin both western blotting and qPCR experiments. In addition, the results showed high 
expression of CDCC64B gene in COV362 cell lines in both experiments (western blotting and 
qPCR).  In general, the result from the qPCR analysis were consistent with the results from 
western blotting. There were a few exceptions to this however. Notably, AXL showed high 
levels of protein in blotting experiments using OVSAHO while very lows of expression when 
measured by qPCR in the same cells. In contrast, the same gene showed low protein levels in 






Most of these observations did not reveal a correlation between expression of the protein and 
the cells’ sensitivity to pitavastatin. However, Map7 was highly expressed in the two cell lines 
more sensitive to pitavastatin in both western blotting (Fig 5-3) and RT-qPCR analysis 
suggesting it may be a candidate marker for cellular sensitivity to pitavastatin or may be a key 









Figure (5-3): Evaluation of the expression of 18 genes in ovarian cancer cells by western blotting. Protein lysates 
were obtained from six cell lines of ovarian cancer (COV362, Ovsaho, COV318, Ovcar-4, Ovcar-8 and Fuov-1) 







Figure (5-4): A. Quantification of the level of AXL protein measured in 6 ovarian cancer cell line measured by 
western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of mRNA 
expression of AXL in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± S.D., n =3) 
were normalized to actin. 
 
 
Figure (5-5): A. Quantification of the level of Frizzled-2 protein measured in 6 ovarian cancer cell line measured 
by western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of 
mRNA expression of Frizzled-2 in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± 
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Figure (5-6): A. Quantification of the level of FGF-5 protein measured in 6 ovarian cancer cell line measured by 
western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of mRNA 
expression of FGF-5 in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± S.D., n =3) 

























































































































Figure (5-7): A. Quantification of the level of VIM protein measured in 6 ovarian cancer cell line measured by 
western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of mRNA 
expression of VIM in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± S.D., n =3) 
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Figure (5-8): A. Quantification of the level of Rab11-fip-4 protein measured in 6 ovarian cancer cell line measured 
by western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of 
mRNA expression of Rab11-fip-4 in 6 ovarian cancer cell line was measured by using qPCR. The results (mean 






















































































































(B ) G R L H 2
 
 
Figure (5-9): A. Quantification of the level of GRHL2 protein measured in 6 ovarian cancer cell line measured by 
western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of mRNA 
expression of GRHL2 in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± S.D., n =3) 

























































































































(B )  C y r6 1
 
 
Figure (5-10): A. Quantification of the level of Cyr61 protein measured in 6 ovarian cancer cell line measured by 
western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of mRNA 
expression of Cyr61 in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± S.D., n =3) 























































































































(B )  P T R F
 
 
Figure (5-11): A. Quantification of the level of PTRF protein measured in 6 ovarian cancer cell line measured by 
western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of mRNA 
expression of PTRF in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± S.D., n =3) 


























































































































(B ) B S P R Y
 
 
Figure (5-12): A. Quantification of the level of BSPRY protein measured in 6 ovarian cancer cell line measured 
by western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of 
mRNA expression of BSPRY in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± 






















































































































(B )  M A P 7 D 1
 
 
Figure (5-13): A. Quantification of the level of MAP7-D1 protein measured in 6 ovarian cancer cell line measured 
by western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of 
mRNA expression of MAP7-D1 in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± 
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Figure (5-14): A. Quantification of the level of PRR-15L protein measured in 6 ovarian cancer cell line measured 
by western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of 
mRNA expression of PRR-15L in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± 






















































































































(B ) H m g c s 1
 
 
Figure (5-15): A. Quantification of the level of Hmgcs1 protein measured in 6 ovarian cancer cell line measured 
by western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of 
mRNA expression of Hmgcs1 in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± 





























































































































(B ) R b m 3 5 A
 
 
Figure (5-16): A. Quantification of the level of Rbm35A protein measured in 6 ovarian cancer cell line measured 
by western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of 
mRNA expression of Rbm35A in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± 



























































































































(B ) M A R V E L D 3
 
 
Figure (5-17): A. Quantification of the level of MARVELD3 protein measured in 6 ovarian cancer cell line 
measured by western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) 
Relative of mRNA expression of MARVELD3 in 6 ovarian cancer cell line was measured by using qPCR. The 






















































































































(B )  C C D C 6 4 B
 
 
Figure (5-18): A. Quantification of the level of CCDC64B protein measured in 6 ovarian cancer cell line measured 
by western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of 
mRNA expression of CCDC64B in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± 


























































































































(B )F X Y D 3
 
 
Figure (5-19): A. Quantification of the level of FXYD3 protein measured in 6 ovarian cancer cell line measured 
by western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of 
mRNA expression of FXYD3 in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± 






























































































































(B )M A P 7
 
 
Figure (5-20): A. Quantification of the level of MAP7 protein measured in 6 ovarian cancer cell line measured by 
western blotting. The results (mean ± S.D., n=3) which normalized to GAPDH as a control. (B) Relative of mRNA 
expression of MAP7 in 6 ovarian cancer cell line was measured by using qPCR. The results (mean ± S.D., n =3) 
were normalized to actin. 
 
5.2.3.  Knock-downs of the pitavastatin-sensitive genes in Ovcar-8 and Ovsaho cell line 
The previous data suggested that the expression of MAP7 correlated with the sensitivity of 
ovarian cancer cells to pitavastatin. To explore this further, the expression of MAP7 was 
repressed by RNAi and the effect on pitavastatin sensitivity determined. Considering that one 
of the major binding partners of MAP7 is tumour Kinesin-1 (KIF5B), its expression was also 
repressed by RNAi. 
 
In order to ensure efficient transfection without noticeable toxicity, the expression of the 
candidate genes after RNAi and the transfection conditions for each siRNA were optimized 
before evaluating the effect of knock-down. OVCAR-8 and OVSAHO cells were transfected 
with 4 separate siRNA corresponding to each gene and the number of surviving cells compared 











































O V C A R -8
 
Figure (5-21): OVCAR-8 cells were transfected with each of the indicated siRNA to MAP7 (100nM) and after a 
further 72 hours the cells stained with SRB. The results (n=3, mean ± S.D.) the expressed measured in cells 
transfected with a non-targeting siRNA (NT-1). The results were not significantly different from the cell growth 











































Figure (5-22): OVCAR-8 cells were transfected with each of the indicated siRNA to KIF5B (100nM) and after a 
further 72 hours the cells stained with SRB. The results (n=3, mean±S.D.) the expressed measured in cells 
transfected with a non-targeting siRNA (NT-1). The results were not significantly different from the cell growth 
measured in cells transfected with a NT-1 where indicated (paired t-test; *, P< 0.05; **, P< 0.01; *** P< 0.001). 
 
Having established non-toxic transfection conditions, the impact of knockdown on protein 
levels was determined using 3 separate siRNAs. The results revealed a variable extent of knock-
down of the various targeted genes, but at least 2 siRNAs were found for each gene that caused 





Figure (5-23): Knock-down of OVCAR-8 with MAP-7 and KIF5B was measured by western blotting. The 
expression of MAP7 and KIF5B protein was determined by western blotting of protein lysates obtained from 




















































O V C A R -8 , M A P 7
 
Figure (5-24): Quantification of knock-down of MAP-7 in OVCAR-8 cells was measured by western blotting. The 
results of the knockdown of MAP-7 were quantified by image analysis and are expressed (n=3, mean±S.D.) as a 
fraction of that measured in cells transfected with a non-targeting siRNA (NT-1) then normalized with GAPDH. 
The results were significantly different from the expression measured in cells transfected with a NT-1 where 

















































O V C A R -8 , K IF 5 B
 
Figure (5-25): Quantification of knock-down of KIF5-B in OVCAR-8 cells was measured by western blotting. 
The results of the knockdown of KIF5B were quantified by image analysis and are expressed (n=3, mean±S.D.) 
as a fraction of that measured in cells transfected with a non-targeting siRNA (NT-1) then normalized with 
GAPDH. The results were significantly different from the expression measured in cells transfected with a NT-1 
where indicated (paired t-test; *, P< 0.05; **, P< 0.01; *** P< 0.001). 
 
Figure (5-26): Knock-down of OVSAHO cells with MAP-7 and KIF5B was determined by western blotting of 






















































O V S A H O , M A P -7
 
Figure (5-27): Quantification of knock-down of MAP-7 in OVSAHO cells was measured by western blotting. The 
results were quantified by image analysis and are expressed (n=3, mean±S.D.) as a fraction of that measured in 
cells transfected with a non-targeting siRNA (NT-1) then normalized with GAPDH. The results were significantly 
different from the expression measured in cells transfected with a NT-1 where indicated (paired t-test; *, P< 0.05; 













































O V S A H O , K IF 5 B
 
Figure (5-28): Quantification of knock-down of KIF5-B in OVSAHO cells was measured by western blotting. The 
results were quantified by image analysis and are expressed (n=3, mean±S.D.) as a fraction of that measured in 
cells transfected with a non-targeting siRNA (NT-1) then normalized with GAPDH. The results were significantly 
different from the expression measured in cells transfected with a NT-1 where indicated (paired t-test; *, P< 0.05; 
**, P< 0.01; *** P< 0.001). 
 
5.2.4.  Effect of genes knock-down on the sensitivity to pitavastatin in cell growth 
assays  
To determine the effect of knockdown of the candidate drug-sensitivity genes, siRNA which 




effect on the potency of pitavastatin measured in cell growth assay and compared to cells 
transfected with non-targeting siRNA or an siRNA to the mRNA encoding CD45, which is not 
expressed in epithelial cells.  
 
In OVCAR-8 cells, knockdown of MAP7 or KIF5B using three separate siRNA had no 
significant effect on the sensitivity to pitavastatin (Figs 5-29, 5-30). In contrast, in OVSAHO 
cells, two siRNA directed to MAP7 decreased the sensitivity to pitavastatin modestly as did 










































Figure (5-29): OVCAR-8 cells were transfected with either 100 nM NT-1 or 100 nM of the siRNA targeting the 
indicated genes. After 24 hours a range of concentrations of pitavastatin were added and after a further 72 hours 
the cells stained with SRB The IC50 of pitavastatin (n=3, mean± S.D.) The results were non-significant different 
from the expression measured in transfected with a NT-1, NT-3 (Non targeting) and PTPRC (targets an irrelevant 
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Figure (5-30): OVCAR-8 cells were transfected with either 100 nM NT-1 or 100 nM of the siRNA targeting the 
indicated genes. After 24 hours a range of concentrations of pitavastatin were added and after a further 72 hours 
the cells stained with SRB The IC50 of pitavastatin (n=3, mean± S.D.) The results were non-significant different 
from the expression measured in transfected with a NT-1, NT-3 (Non targeting) and PTPRC (On targeting) where 




































O V S A H O , M A P -7
  
Figure (5-31): OVSAHO cells were transfected with either 100 nM NT-1 or 100 nM of the siRNA targeting the 
indicated genes. After 24 hours a range of concentrations of pitavastatin were added and after a further 72 hours 
the cells stained with SRB The IC50 of pitavastatin (n=3, mean± S.D.) The results were non-significant different 
from the expression measured in transfected with a NT-1, NT-3 (Non targeting) and PTPRC (On targeting) where 
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Figure (5-32): OVSAHO cells were transfected with either 100 nM NT-1 or 100 nM of the siRNA targeting the 
indicated genes. After 24 hours a range of concentrations of pitavastatin were added and after a further 72 hours 
the cells stained with SRB The IC50 of pitavastatin (n=3, mean± S.D.) The results were non-significant different 
from the expression measured in transfected with a NT-1, NT-3 (Non targeting) and PTPRC (an irrelevant protein) 
where indicated (One Way Anova; *, P< 0.05; **, P< 0.01; *** P< 0.001). 
 
5.2.5.  Expression of -tubulin in ovarian cancer cell treated with pitavastatin 
Considering that MAP7 and KIF5B are both involved in regulating microtubule function, the 
effect of pitavastatin on microtubules was explored. Expression of tubulin was assessed by 
western blotting in OVCAR-8 and OVSAHO cells after exposure to pitavastatin for different 
time of (24h, 48 and 72h). The concentration of pitavastatin used in each cell line was one or 
two times the IC50 measured in cell growth assays. Pitavastatin reduced the level of tubulin 
compared to untreated cells at both concentrations. Interestingly, the tubulin levels showed a 
massive decrease after 24 and 48 hours while there was a slight recovery of tubulin expression 





Figure (5-33): The expression of tubulin protein was determined by western blotting of protein lysates obtained 
from OVCAR-8 and OVSAHO cell lines after 24, 48 and 72 hours of treatment with IC50   (0.78µM) and + IC50 


















































































Figures (5-34): Tubulin expression in OVSAHO cells were measured by western blotting after exposure to the 
indicated concentration of pitavastatin for 24, 48 or 72 hours. The results and were quantified by image analysis 
(n=3, mean±S.D.) and are expressed as a fraction of the tubulin measured in cells treated with drug solvent and 
then normalized to GAPDH. The results were significantly different from the expression measured in untreated 





















































































O V C A R -8 , T u b u lin
 
Figures (5-35): Tubulin expression in OVCAR-8 cells were measured by western blotting after exposure to the 
indicated concentration of pitavastatin for 24, 48 or 72 hours. The results and were quantified by image analysis 
(n=3, mean±S.D.) and are expressed as a fraction of the tubulin measured in cells treated with drug solvent and 
then normalized to GAPDH. The results were significantly different from the expression measured in untreated 
cells where indicated (One Way Anova; *, P< 0.05; **, P< 0.01; *** P< 0.001). 
 
5.2.6. Immunostaining of -tubulin expression in OVCAR-8 and OVSAHO ovarian 
cancer cell treated with pitavastatin 
Considering that the significant changes the in levels of tubulin expression measured by western 
blotting in both cell lines (OVSAHO and OVCAR-8) these experiments were repeated using 
immunofluorescence in OVCAR-8 and OVSAHO to visualize microtubules. There was again 
a rapid effect of pitavastatin on the microtubules after 24, 48 hours of treatment and again this 





          
 
           
 
Figure (5-36): Measurement of tubulin by immunocytochemistry in Ovcar -8 cells. The cells  were treated with 
drug solvent (A) or with the IC50 (0.82 µM) pitavastatin for 24 hours (B), 48 hours (C) or 72 hours (D) and stained 
for  -tubulin (Green) and with DAPI (nuclei, blue).  The results are representative of three experiments. the 




























































O V C A R -8 , T u b u lin
 
Figure (5-37): Quantification the effect of pitavastatin on microtubules tubulin expression in OVCAR-8 counted 
by Fiji (computer program). Cells were grown on a slide chamber for 24 hours then treated with pitavatatin at a 
concentration equal to its IC50 in cell growth assays for 24 ,48 or 72 hours. The results were significantly different 
from the expression measured in untreated cell as a control where indicated (One Way Anova; *, P< 0.05; **, P< 
0.01; *** P< 0.001).  
 
     
     
 
Figures (5-38): Measurement of tubulin by immunocytochemistry in OVSAHO. The cells  were treated with drug 
solvent (A) or with the IC50 (0.78 µM) pitavastatin for 24 hours (B), 48 hours (C) or 72 hours (D) and stained for  
-tubulin (Green) and with DAPI (nuclei, blue).  The results are representative of three experiments. the images 
have taken by confocal microscope with 50 μm scale. 
A  B  



















































Figure (5-39): Quantification the effect of pitavastatin on microtubules tubulin expression in OVSAHO counted 
by Fiji (computer program). Cells were grown on a slide chamber for 24 hours then treated with pitavatatin at a 
concentration equal to its IC50 in cell growth assays for 24 ,48 or 72 hours. The results were significantly different 
from the expression measured in untreated cell as a control where indicated (One Way Anova; *, P< 0.05; **, P< 
0.01; *** P< 0.001).  
 
 
5.2.7. Expression of Actin in ovarian cancer cell after treatment with pitavastatin 
Considering the effects of pitavastatin on the microtubule cytoskeleton, the effect on the actin 
cytoskeleton were also investigated.  Expression of Actin was assessed by Western blotting of 
OVCAR-8 and OVSAHO cells. The western blotting revealed a decreased in actin levels after 
24 hours’ exposure to pitavastatin, but by 48 hours this had essentially recovered to the amount 
in the control cells (fig (5-40)). 
 
Figure (5-40): The expression of actin protein was determined by western blotting of protein lysates obtained from 
OVCAR-8 and OVSAHO cell lines after 24, 48 and 72 hours of exposure to pitavastatin. The drug concentrations 
were equal to the IC50   (0.78µM) and 2x IC50 (1.56µM) measured in cell growth assay using with OVSAHO cells 

































































O V C A R -8 , A c tin
 
Figure (5-41): Actin expression in Ovcar-8 were measured by western blotting. after exposure to the indicated 
concentration of pitavastatin for 24, 48 or 72 hours. The results and were quantified by image analysis (n=3, 
mean±S.D.) and are expressed as a fraction of the actin measured in cells treated with drug solvent and then 
normalized to GAPDH. The results were significantly different from the expression measured in untreated cells 
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Figure (5-42): Actin expression in Ovsaho were measured by western blotting. after exposure to the indicated 
concentration of pitavastatin for 24, 48 or 72 hours. The results and were quantified by image analysis (n=3, 
mean±S.D.) and are expressed as a fraction of the actin measured in cells treated with drug solvent and then 
normalized to GAPDH. The results were significantly different from the expression measured in untreated cells 
where indicated (One Way Anova; *, P< 0.05; **, P< 0.01; *** P< 0.001). 
 
 
5.2.8.   CNP expression and immunohistochemistry   
CNP is post-translationally modified by an isoprenylation process at its C terminus. 
CNP is a potential protein connecting the microtubules to the plasma membrane. This made it 
a potential candidate for the effects of pitavastatin on the microtubules. Ovcar-8 and Ovsaho 
were treated with pitavastatin with or without geranylgeraniol or and farnesol for 24 hours. The 




fraction determined by western blotting.  Pitavastatin caused the loss of CNP from both the 
cytosolic and cell membrane fractions and this could be restored by supplementation with either 
















































Figure (5-43): (A) The expression of CNP protein was determined by western blotting of protein lysates obtained 
from cytosol of OVSAHO cell lines 24 hours after pitavastatin treatment (IC50 0.78µM) with/without isoprenoids 
(GGOH (5 µM) and Farnesol (5 µM)). (B)cytosolic CNP expression in Ovsaho were measured by western blot. 
The results (n=3, mean±S.D.) are expressed as a fraction of that measured in treated cells IC50 of pitavastatin alone 
and with/without GGOH and farnesol for 24 hours then normalized with GAPDH. The results were significantly 
different from the expression measured in Untreated cell as a control where indicated (paired t-test; *, P< 0.05; 


































































(B )  O V S A H O , M e m b r a n e  C N P
 
Figure (5-44): (A) The expression of CNP protein was determined by western blotting of protein lysates obtained 
from membrane of OVSAHO cell lines 24 hours after pitavastatin treatment (IC50 0.78µM) with/without 
isoprenoids (GGOH (5 µM) and Farnesol(5 µM)). (B)Membrane CNP expression in Ovsaho were measured by 
western blot. The results (n=3, mean±S.D.) are expressed as a fraction of that measured in treated cells IC50 of 
pitavastatin alone and with/without GGOH and farnesol for 24 hours then normalized with GAPDH. The results 
were significantly different from the expression measured in Untreated cell as a control where indicated (paired t-

































































(B )  O V C A R -8 ,  C y to s o l ic  C N P
 
 
Figure (5-45): (A) The expression of CNP protein was determined by western blotting of protein lysates obtained 
from cytosol of OVCAR-8 cell lines 24 hours after pitavastatin treatment (IC50 0.82µM) with/without isoprenoids 
(GGOH (5 µM) and Farnesol(5 µM)). (B)cytosolic CNP expression in Ovcar-8 were measured by western blot. 
The results (n=3, mean±S.D.) are expressed as a fraction of that measured in treated cells IC50 of pitavastatin alone 
and with/without GGOH and farnesol for 24 hours then normalized with GAPDH. The results were significantly 
different from the expression measured in Untreated cell as a control where indicated (paired t-test; *, P< 0.05; 


































































(B )O V C A R -8 , M e m b r a n e  C N P
 
Figure (5-46): (A) The expression of CNP protein was determined by western blotting of protein lysates obtained 
from membrane of OVCAR-8 cell lines 24 hours after pitavastatin treatment (IC50 0.82µM) with/without 
isoprenoids (GGOH (5 µM) and Farnesol(5 µM)). (B)Membrane CNP expression in Ovcar-8 were measured by 
western blot. The results (n=3, mean±S.D.) are expressed as a fraction of that measured in treated cells IC50 of 
pitavastatin alone and with/without GGOH and farnesol for 24 hours then normalized with GAPDH. The results 
were significantly different from the expression measured in Untreated cell as a control where indicated (paired t-




5.2.3.  Immunostaining of CNP expression in OVCAR-8 ovarian cancer cell treated 
with pitavastatin  





Pitavastatin induced the loss of CNP from the cytosolic and cell membrane fractions and this 
could be reversed by either farnesol or geranylgeraniol supplementation which confirmed by 
immunostaining images below (fig. (5-47)). 
     
     
     
 
Figures (5-47): CNP Immunostaining of Ovcar-8 (Green staining), and nuclei (DAPI, blue) after 24 hours of 
pitavastatin treatment with IC50 (0.82µM) (A) drug solvent, (B) pitavastatin (C) pitavastatin and geranylgeranyl, 
(D) pitavastatin and farnesol € geranylgeranio alone (F) farnesol alone. The results are representative of three 









































































O V C A R -8
  
Figure (5-48): Quantitate the CNP expression in Ovcar-8 counted by Fiji (computer program). Cells were grown 
on a slide chamber for 24 hours then treated with IC50 of pitavastatin with/ without GGOH(5µm) and farnesol 
(5µm) for 24 hours and an anti-CNP monoclonal antibody and secondary antibody applied for two hours for each 
after fixation the cells with formaldehyde 10%, mounting the cells after removing the chambers and imaging by 
confocal microscope. The results were significantly different from the expression measured in untreated cell as a 





A critical problem in designing personalised cancer medicine is the understanding of how to 
make the most of a patient's genomic knowledge while determining treatment options. Over the 
past decade, comprehensive efforts have been made to sequence genomes of cancer in large 
patient populations[486], sparking hopes of identify new targets for more successful and 
targeted treatment opportunities. Such sequencing efforts have uncovered a remarkable degree 
of genetic heterogeneity between and within different cancers types, which explains in part why 
the typical "one-size-fits-all" therapeutic strategies for cancer frequently provided 
disappointing results in clinical trials[487]. 
 
Different cell lines show different sensitivities to pitavastatin and the same may be true of 
patient’s tumours. It is, therefore, important to identify biomarkers which predict a patient’s 
response to pitavastatin. Although E-cadherin membrane expression has been reported to be 
both a marker and resistance mechanism for atorvastatin-mediated growth suppression of 
cancer cells [407], a transcriptome-based biomarker signature for statin sensitivity would also 
facilitate  clinical treatment. Some progress has already been made to achieve that with other 
cancers [407], [488]. The goal of this study was to identify markers that predicted the statin 
sensitivity of ovarian cancer cells. We have attempted to confirm published gene expression 
data from the Broad Institutes “Cancer Therapeutics Response portal. This provided a resource 
to identify a correlation with the sensitivity of cancer cells to statins. Although the original data 
was published on a broad panel of cell lines from different cancer types, we attempted to 
replicate those findings using ovarian cancer cell lines.   
 
The expression of these genes that were selected for investigation was assessed by both qPCR 
and western blotting in the panel of 6 ovarian cancer cell lines and compared to the sensitivity 




by using just one technique. Some of the genes investigated were only highly single expressed 
in a single cell line when assessed by western blotting. A thorough analysis of more than 2 
million manually annotated, high-resolution, images based on immunohistochemistry found a 
large fraction, of proteins are expressed proteins in most cells and tissues, with very few 
proteins, about 2 percent, were unique to a single cell type.[489]. It is therefore surprising that 
some genes appear to be only expressed one cell line of six, all of which were derived from the 
same tissue. This cell- line specific” expression, therefore, likely to reflect genetic abnormalities 
in cancer cells and these abnormalities affect drug sensitivity.  It is possible that there are several 
mechanisms of drug resistance/sensitivity and that some cell lines make use of only one of 
these.  Alternatively, is possible that some of the genes that were selected for investigation in 
fact do not contribute to drug sensitivity.  It is also possible that the mechanisms that confer 
drug sensitivity to ovarian cancer cells are different from the mechanisms in other cancer types. 
Further investigation would be necessary to investigate this, for example, the expression of 
these genes could be altered in ovarian cancer cells and the effect on sensitivity determined. It 
would also be desirable confirm the results reported by the Cancer Therapeutics response portal, 
testing the sensitivity of the statins investigated there (which did not include pitavsastatin) in 
exactly the cell lines used by those investigators; it would also be worthwhile to alter the 
expression of these genes in those cell lines and test the impact on the sensitivity to the statins 
those investigators examined.   
 
Some genes displayed high expression in all of the ovarian cancer cell lines used in both 
experiments (western blotting and qPCR). This was surprising considering that the ovarian 
cancer cells showed differences in sensitivity to pitavastatin. Again, it would be worthwhile to 
reproduce the results of from the Broad Institute using their experimental conditions and also 





There was also some inconsistency between the qPCR and western blotting data.  However, 
some genes showed strong protein expression in a single cell when measured by western 
blotting, while less expression was evident by the qPCR technique This may reflect that mRNA 
and protein levels are regulated by different mechanisms and suggests that most of mRNA is 
efficiently translated into its corresponding protein or that the mRNA has a short half-life. By 
comparison, few genes showed poor expression when measured by blotting but at the same 
time showed high expression by qPCR. In these cases, the mRNA may not be efficiently 
transcribed into the corresponding protein. 
 
Arguably the most encouraging results from this analysis was that, among all genes used in this 
experiment, MAP7 was highly expressed in ovarian cancer sensitive cells to pitavastatin 
(OVCAR-8 and OVSAHO). This raised the possibility that this gene was involved in setting 
the sensitivity to pitavastatin. Although the data gave some encouragement that MAP7 may 
play a role ovarian cells’ sensitivity to pitavastatin treatment. this was only a correlation. Only 
two sensitive cell lines were used so it is possible that the correlation of this gene with drug 
sensitivity arose by l pure chance. It would have been preferable to have a larger panel of statin 
sensitive and statin resistant cells to increase the power of the observations. However, as an 
alternative, RNAi experiments were performed to assess whether altering the expression of 
MAP7 changed the sensitivity to pitavastatin.  
 
MAP7 expression was repressed by RNAi in the two cell lines where it was highly expressed. 
Preliminary experiments were performed to identify at least two different siRNA that decreased 
the protein levels of MAP7 without being overtly toxic. Multiple siRNA was used to give 
confidence that any affect of the siRNA did indeed result from an affect on MAP7 and not an 
off-target effect of the siRNA.  Once appropriate conditions were identified, the effect of 




In OVCAR8 cells knockdown of MAP7 with two separate siRNA had little effect on the 
sensitivity to pitavastatin. In contrast, in OVSAHO cells, knockdown of MAP7 by siRNA led 
to a decrease in the sensitivity to pitavastatin. Furthermore, this was only observed in one cell 
line and with one of the two siRNA tested. This raised further concerns whether MAP7 really 
played a role in the effect of pitavastatin on cancer cells. It is possible that MAP7 plays role in 
the sensitivity to pitavastatin in one of the cell lines tested (OVSAHO). Alternatively, the rapid 
growth rate of OVCAR-8 cells after knocking down may somehow compensate for the effect 
of the final results of knockdown.   
 
To explore further whether MAP7 may play a role in the sensitivity of cells to pitavastatin, the 
expression of one of its binding partners, KIF5B was investigated.   KIF5B is the major MT 
plus-end motor involved in a wide range of transport processes[490], This motor is well known 
for being controlled by various MAPs. The MAP7 protein N-terminal domain interacts strongly 
with MTs, while the C-terminal domain binds to the kinesin-1 stalk region[432], [436], [437], 
and KIF5B may have a role in determining the sensitivity of drugs targeting microtubules. 
Mixed results were also obtained following knockdown of KIF5B. Again in OVCAR8, 
knockdown had little effect on the sensitivity of the cells to pitavastatin. However, in OVSAHO 
cells, one of the two siRNA tested reduced sensitivity to pitavastatin. This again made it 
difficult to draw definitive conclusions about the role of these proteins. It is striking however, 
that positive results were again observed with OVSAHO cells and not OVCAR-8 cells, possibly 
pointing to a cell-specific mechanism of drug sensitivity. 
 
Considering the inconclusive nature of the data obtained to the is point and that MAP7 binds to 
microtubules, the effect of pitavastatin on the microtubule cytoskeleton was investigated. Here, 
at least, the results were more convincing. Pitavastatin caused a clear and transient decrease in 




immunostaining) showed very significant changes after different periods of exposure to 
pitavastatin especially after 24, 48 hours with a slight recovery after 72 hours. The transient 
nature of this effect may be due to loss of feedback inhibition of the mevalonate pathway. 
Pitavastatin also had an effect on the actin cytoskeleton and if anything the results were even 
more transient and returned to normal after 24 hours of treatment with pitavastatin. However, 
it is not clear whether the effects of pitavastatin on microtubules depend on MAP7 or KIF5B. 
 
To explore how pitavastatin may affect microtubules, further studies were performed.  Some 
MAPs are known to bind microtubules to actin and/or intermediate filaments, and are called 
cytoskeletal cross-linkers. For a variety of cellular functions such as lateral cell migration and 
neuronal pathfinding, the interaction of these various cytoskeletal components is 
necessary[430]. Other MAPS help anchor microtubules to the cell membrane. Tubulin strongly 
binds CNP. Significantly, CNP is associated with membranes by virtue of its isoprenylation 
[380], making a potential link to pitavastatin. CNP can bind tubulin to membranes and control 
the distribution of cytoplasmic microtubules [491]. This suggests that the binding of 
microtubules to cell membranes may require a prenylated protein. Tubulin itself does not have 
a C-terminal CAAX box for prenylation [453]. Thus, CNP may make a linker between 
cytoskeleton protein (tubulin) and isoprenoids membranous proteins. Bifulco and colleagues 
have obtained compelling data at that such an interaction takes place and suggest that CNP has 
MAP-like properties. They find a strong interaction in brain tissue and FRTL-5 cells in two 
separate locations: cytoplasm and membranes. CNP promotes the polymerisation of pure rat 
brain tubulin at low molar ratios as determined by both protein pelleting and light dispersion 
[451], They concluded that normal microtubular distribution depends on  CNP.  In addition, 
CNP was reportedly bound to cytoskeletal elements based on actin [381] providing a potential 




that CNP is a linker between microtubules and the cell membrane and that loss of its prenylation 
results in the effects of pitavastatin one microtubule cytoskeleton.  
 
The effect of pitavastatin on CNP was therefore evaluated. Cell fractionation experiments and 
immunofluorescence studies both revealed that pitavastatin causes a loss of CNP from cell 
membranes and cytosol. This could be blocked by supplementation with geranylgeraniol and 
surprisingly also by farnesol. In previous experiments evaluating the ability of these isoprenoids 
to block the effects of pitavastatin on cell growth or apoptosis only geranylgeraniol, and not 
farnesol, were able to suppress the effects of pitavastatin. This suggests that although CNP may 
be affected by pitavastatin and this may contribute to the cytotoxic activity of pitavastatin, it is 
unlikely to be the sole mechanism by which pitavastatin is cytotoxic. Interestingly, another 
study reported that both prenyl groups, farnesyl and geranylgeranyl, modify CNP [432], which 
support our findings.  
 
There are a number of issues with the approach taken in this study.   The use of a relatively 
small number of cell lines may have meant that this study lacked sufficient power to identify 
genes which do indeed determine drug sensitivity.  As discussed above, MAP7 may have been 
identified by pure chance. In addition, using single-targeting siRNAs to knockdown gene 
expression is problematic. Apart from the potential for off-target affects, any on-target effects 
may vary according to the duration of the experiment and the rate of growth of the cells.  
Moreover, the cell types in the NCI-60 cell line panel of the National Cancer Institute show that 
(i) there is not the same broad range of refractoriness (resisting ordinary medical methods) as 
clinically found in tumours in patients, and (ii) the susceptibility spectrum in culture for these 
cells is in no way similar to the solid tumours. Studies with cultured cells may therefore only 
investigate a portion of a tumour's response to potential drugs[492]. Cancers are heterogeneous, 




fraction of the cells present in a tumour. Another issue is how well ovarian cancer cell lines 
reflect clinical tumours[493]. 
 
Lastly, the role of the prenylated CNP as a microtubule membrane anchor can provide more 
insight into how novel anti-cancer agents may be discovered. Drugs targeting the microtubule 
cytoskeleton are already widely used in the treatment of cancer. In vitro studies and multiple in 
vivo correlative findings on the expression and vulnerability of various cancers to microtubule-
targeting drugs argue that MAPs may provide alternative drug targets or predictors of sensitivity 
to existing drugs which target microtubules. While currently restricted, further information on 
the tumour MAP expression profile and the mechanisms regulating it could encourage 
combination therapies with agents resulting in a change in the expression of appropriate MAP 
in the desired direction (either up-or down-regulation). In addition, techniques to enhance 
MAP-tubulin interaction could be explored. High-throughput screening of small molecule 
libraries is an appealing technique for detecting compounds that interfere with MAP-tubulin 
interactions, altered expression of MAPs and their effect on sensitivity to microtubule-targeting 
drugs [447]. This provides an opportunity to control MAP-tubulin interactions influencing 










































6.  Introduction  
Cancer chemotherapy's primary objective is to eliminate malignant tissues. After the failure of 
single agents, combining drugs is a plausible approach for cancer treatment [494]. The 
fundamental rationale for cytotoxic chemotherapy drug combinations is that this 
simultaneously targets several cellular pathways[494], [495]. This provides several benefits 
including increased tumour cell death and therapeutic efficacy, reduced resistance and possibly 
reduced toxicity connected with high-dose chemotherapy[495].  Combinations involving 
pitavastatin are also plausible. Pitavastatin and prednisolone, or pitavastatin and 
bisphosphonates, show significant synergies in ovarian cancer cells [242], pitavastatin and 
dacarbazine combination therapy induces apoptosis and autophagy leading to synergistic 
cytotoxicity in melanoma cells [496].  Thus, the work in this chapter describes the exploration 
of a novel pitavastatin drug combination. 
 
There are several reasons to believe that drug combinations can be particularly useful in treating 
cancer. First, tumours are a heterogeneous group of diseases whose development involves 
different pathological mechanisms [497]. As a result, drug combinations that inhibit different 
fundamental pathways could be potentially more effective than single agents because drugs 
could simultaneously influence different cell populations [498]. Second, drug combinations can 
simultaneously affect different signalling pathways in individual cancer cells. Such medications 
may act synergistically to increase the effectiveness of the treatment above that of the single 
agents. Third, mutation and epigenetic changes may trigger numerous compensatory pathways 
in cancer cells during cancer pharmacotherapy, leading to the development of drug-resistant 
subpopulations. Therefore, drug combinations or the use of multi-targeted drugs can provide 
an opportunity to achieve an improved clinical response [499], [500]. Finally, the use of 
combinations of drugs has a historical precedent, and many conventional chemotherapy 





The elevated price of new molecularly targeted agents in most nations is likely to place a 
significant burden on healthcare budgets [501]. It takes a long time and a significant cost to 
develop a new drug and translate it to the clinic. It is presently estimated that the discovery, 
development and marketing of a fresh medication requires roughly $2 billion expenditure. This 
results in an exceptionally elevated price for the new targeted therapy, with annual treatment 
expenses often ranging from $50,000 to $100,000 per treatment course [502]. Since 1950, every 
decade the amount of newly licensed drugs has dropped by half. A recent study defined the 
drug development process as a crisis of efficiency. The crisis is especially difficult for the 
discovery of oncology drugs. Between 2003 and 2011, the number of non-oncological drugs 
authorized by the FDA was twice the number of oncological drugs that were approved [502]. 
At the same time, the price of developing cancer drugs has risen dramatically from 1990 to 
2011[501]. Furthermore, there is significant attrition during drug development, with 
approximately only 10% of new cancer drugs that enter clinic trials eventually receiving 
marketing authorization. The cost of these failures must be covered by the profit derived from 
successful drugs, further elevating the cost of the latter[501]. Therefore, drug repurposing is an 
attractive alternative approach to developing new treatment options. 
 
Drug repurposing, also referred to as redeployment, could be described as the process to 
validate and market new indications for a drug beyond the scope of the original medical use 
[503], [504]. It provides a strong clinical impact with low development costs relative to  de 
novo drugs [504]. The goal of oncology pharmaceutical companies is to gain market acceptance 
by demonstrating the efficacy and superiority of their drugs. Pharmaceutical companies may 
lack incentives to invest in drug combinations, as this may entail negotiating with competing 
pharmaceutical companies. In the case of drug repositioning, there may be only a limited period 




Indeed, the cost of clinical trials may not be covered by the brief period of financial returns for 
the repurposed drugs. Nonetheless, drug repositioning could benefit from safer, cheaper and 
faster validation protocols [501]. Repurposing accepted medication with a history of clinical 
application often provides a wealth of easily accessible data that includes guidelines of 
pharmacokinetics, pharmacodynamics, toxicology and dosage. The availability of such 
information may reduce the duration of clinical development of prescription products which is 
otherwise usually 5 to 7 years [506]. Another major benefit to healthcare systems of repurposing 
drugs is the use of low-cost generic drugs. Once the period of patent protection ends, drugs are 
often sold in a “generic” format at greatly reduced cost. This decreases the potential high costs 
of care that can put a significant burden on the government health finances of advanced 
countries and can be cheap for poor and middle-income countries[502]. However, it does raise 
the question of who would pay for clinical trials of generic drugs. 
 
Figure (6-1): Shows the principle of drug repurposing [507]. 
There are many examples of successful drug repositioning which circumvent the obstacles 
associated with new drug development and speed up therapeutic discovery [508]. One  well 
known example of drug repositioning  is "The fall and rise of thalidomide," a drug that was 




England [509]. At least 15,000 infants were born to mothers who had used thalidomide during 
the first trimester of pregnancy. Unfortunately, the medication resulted in serious deafness, 
blindness and deficiencies in the growth of limbs. However, it was later accidentally found that 
thalidomide was effective in the treatment of leprosy inflammatory disease` erythema nodosum 
laprosum (ENL). The medication was administered to relieve the pain of critically ill patients 
with ENL at the University Hospital in Marseille. Not only did the drug ease the pain, but it 
also healed the patient's sores [506]. As a result, a follow-up study funded by the WHO of over 
4000 ENL patients reported full remission of disease within less than two weeks [510]. 
Thalidomide was found to inhibit the development of fresh blood vessels in the corneal model 
of the rabbit, which explains the teratogenic effects of this drug [511]. In 1994, the 
antiangiogenic properties of thalidomide allowed it to be redeployed as a candidate for 
oncology at the Children's Hospital in Boston and this opened the way for its use in cancer 
therapies, including for the treatment of multiple myeloma and breast cancer [506]. Several 
other effective drug repositioning attempts have also been successful, such as aspirin, an 
antagonist of cyclooxygenase, for the treatment of coronary artery disease, sildenafil, a 
phosphodiesterase blocker first formulated to treat hypertension and angina and then 
repurposed to treat erectile dysfunction, and antibiotic erythromycin now used in increasing of 
stomach motility [512], [513]. Several studies have shown that statins hinder cell growth and 
induce apoptosis in vitro in cell lines from a number of cancers [364], [514], [515]. Statins have 
also been found to inhibit the growth of xenograft tumours in mice [516]. Recently, our 
laboratory data has shown that pitavastatin induces tumour regression in mice with a controlled 
diet [308]. The work described in earlier chapters was designed to support the repurposing of 
pitavastatin to treat cancer. Nonetheless, for an adequate plasma concentration of the drug in 
patients, comparatively high doses of statins are likely to be needed [517], [518]. This raises 
concerns about the potential danger of myopathy, which is often associated with statin use 




reduce the statin dose required for patients. This could potentially reduce the chance of patients 
developing myopathy. It is particularly appealing to repurpose other drugs to combine with 
pitavastatin to achieve this. 
 
6.1.   Ivermectin  
Ivermectin is a major anti-parasitic drug first recognized in the 1970s. Ivermectin's composition 
is that of a macrocyclic lactone, and Streptomyces avermitilis naturally produces the chemical 
in soil[520]. This compound was first isolated from a soil sample from a Japanese golf 
course[521]. Although originally considered solely for veterinary uses, the research team 
rapidly evaluated its potential for human use and in 1987 this led to authorization of the drug 
by the French regulatory authorities. Since then, ivermectin has been recognized as an 
extremely safe and dramatically effective drug in onchocerciasis therapy[522]. Case studies 
and some formal studies have also demonstrated the usefulness of the drug in the treatment of 
numerous systemic and cutaneous parasite diseases, including filariasis, skin larvae, scabies 
and pediculosis[520]. Ivermectin was approved by the United States Federal Administration of 
Food and Drugs (FDA) for onchocerciasis and strongyloidiasis in 1996 [523]. Ivermectin has 
also been used to treat livestock and a trial in 1981 by Dr. Mohamed Aziz in Dakar, 
Senegal[524] demonstrated its effectiveness in treating river blindness in animals[525]. 
 
6.1.1. Ivermectin Uses in Veterinary and Human Medicine   
Ivermectin is one of the most effective medicines for the prevention of parasitic infection in 
veterinary and human medicine and was its discoverer was the recipient of the Nobel Prize in 
Physiology or Medicine 2015, some 35 years after its remarkable discovery[526]. Ivermectin’s 
effectiveness against both endoparasites and ectoparasites led to the creation of the word 
'endectocide' and in 1981 Merck & Co. launched this first drug of its kind to the animal health 




problems of neglected tropical diseases. The UN-based Special Program for Research & 
Training in Tropical Diseases (TDR) was established in 1975 after the establishment of the 
OCP in 1974 [520]. Onchocerciasis, one of two filarial infections among the eight target 
diseases of the TDR, was a major public health issue that affected 20-40 million people in 
endemic areas. Ironically, ivermectin has proved to be even more of a' wonder drug' in human 
health, nutritional improvement, overall health and well-being of billions of people around the 
world since it was first used to human use in 1988 to treat onchocerciasis[527]. Furthermore, it 
has proven to be ideal in many respects, highly effective and with a broad range of activity, 
well tolerated and easy to administer (a single annual oral dose). It is used to treat a number of 
internal nematode infections, including Onchocerciasis, Strongyloidiasis, Ascariasis, 
Cutaneous Migrants, Filariasis, Gnathostomiasis and Trichuriasis, as well as oral treatment of 
ectoparasitic infections such as Pediculosis (lice infestation) and Scabies (mite 
infestation)[520], [524], [527]. 
 
6.1.2. Mechanism of action of Ivermectin 
The antiparasitic effect of ivermectin is thought to depend on it acting as an agonist of peripheral 
chloride ion-channels. The literature contains conflicting information whether its effects are 
mediated by glutamate or glycine-gated chloride channels of parasites [528] [529]. In either 
case, ivermectin simulates the ligand by ' opening the door ' and allowing an efflux of chloride 
ions to release the associated neurotransmitter, -aminobutyric acid (GABA) (hyper 
polarization mimicks GABA) of parasite [529]. Continuous neuronal discharge at high doses is 
supposed to fully paralyze the parasite; nevertheless, this is not certain to be the mode of action 
in parasites susceptible to ivermectin.  Other authors believe that ivermectin primarily interferes 
with the gastrointestinal tract in the parasite [530],  causing the parasite to starve to death. 
Ivermectin is a powerful antiviral drugs, ivermectin is a potent inhibitor of flaviviral replication 




SARS-CoV-2 replication in vitro [532]. It has also been proposed as an anticancer drugs [533]–
[535]. Ivermectin interacts with many cancer pathways and these are summarizedin figure (6-
2) [534]. 
1. Ivermectin inhibits the cancer cell's P-glycoprotein pump, which causes a multidrug 
resistance phenotype. 2. Ivermectinopens chloride channels to induce apoptosis which death of 
osmotic cells. 3. By decreasing the mitochondrial complex I function, ivermectin restricts the 
electronic movement of the oxidative phosphorylation pathway, which stimulates the rate of 
oxygen consumption to produce ATP for the cell. Concomitantly, Akt's phosphorylation levels 
are reduced, impacting in the biogenesis process of the mitochondrial. In addition, changes in 
the mitochondrial machinery are associated with increased levels of reactive oxygen species, 
which damage DNA. 4. Ivermectin stimulates immunogenic cell death (ICD) by enhancing a 
microenvironment enriched with ATP-and HMGB1 which promotes inflammation. This drug 
also increases the sensitivity of ATP and calcium signals in membrane receptors P2X, 
especially P2X4 and P2X7, to induce immune responses based on ATP. 5. Ivermectin 
encourages the kinase PAK1 poly-ubiquitination, which leads it to proteasome degradation. In 
effect, defective PAK1 inhibits the Akt / mTOR pathway, at the same time, ivermectin activates 
Beclin1 and Atg5 expression, both linked to autophagy induction, and decreases the activity of 
the negative apoptosis regulator Bcl-2. It causes autophagy and apoptosis, combined. 6. 
Ivermectin suppresses AXIN2, LGR5 and ASCL2, all of which are positive WNT-TCF 
regulators thus supporting the WNT signal repressor FILIP1L. As a result, ivermectin promotes 
the expression of many genes linked to IFN, such as IFIT1, IFIT2, IF144, ISG20, IRF9 and 
OASL. 7. Ivermectin alters the epigenetic characteristic and self-renewal process in the 
malignant cell because of the need to to mimic the SIN3 interaction binding to the PAH2 pattern 
of cancer-associated deregulators SIN3A and SIN3B. SIN3A naturally activates NANOG and 
SOX2 which are pluripotence stimulants for stem cells. 8. Ivermectin restricts the activity of 




transcriptional modifications, as well as to mRNA degradation. DDX23 functions as a miR-21 
promoter and is a well-recognized tumour progression stimulator. 9. Ivermectin inhibits the 
CSC population ideally, and up-regulates the NANOG, SOX2 and OCT4 genes for 
pluripotency and self-renewal. IVM: ivermectin; ATP: triphosphate adenosine; OCR: intake 
rate of oxygen; ROS: reactive oxygen species. 
 
 
Figure (6-2): Mechanisms of repositioning antitumour for ivermectin [534] 
 
Considering the potential for ivermectin to act as an anti-cancer agent prompted consideration 
whether it would synergize with pitavastatin and the research described in this chapter set out 






6.2. Results   
6.2.1.  Testing the activity of Ivermectin on the ovarian cancer cell lines 
Six ovarian cancer cell lines (COV318, FUOV-1, COV362, OVCAR-4, OVCAR-8 and 
OVSAHO) were used to evaluate the anticancer activity of ivermectin. When tested as a single 
agent ivermectin inhibited the growth of all six cell lines (table 1) with comparable potencies, 
IC50s varying from 13 to 16 μM, table (6-1) and fig. (6-1). 
Table (6-1): Potency of ivermectin in cell growth assays with ovarian cancer cells. The 
IC50s of ivermectin as a single agent for inhibition of the growth of six ovarian cancer cell lines 
are reported (mean ± S.D., n=3). 
Cell line  Ivermectin IC50s (μM) 
Cov318 14. 6 ± 2 
Fuov-1 12.9 ± 2.2 
Cov362 14.6 ± 1.3 
Ovcar-4 11.9 ± 0.9 
Ovcar-8 15.8 ± 1.2 
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Figure (6-3): Effect of ivermectin on ovarian cancer cell lines. Cells were exposed to a range of concentrations of 
pitavastatin for 72 hours, except for the slow growing cell lines Cov-318 and Cov-362 which were exposed for 
120 hours. The numbers of surviving cells were estimated using SRB assay. Dose response curve generated by 
curve fitting curve fitting and the results are expressed (mean ± SD, n ≥ 3) as a fraction of the top of the curve in 





6.2.2.  Confirmation of antiproliferative combination effect of pitavastatin with fixed 
doses of Ivermectin   
To measure the activity of pitavastatin in combination with ivermectin the ovarian cancer 
cells were exposed to the indicated concentration of pitavastatin alone and in combination with 
fixed concentration of ivermectin for 72 hours or 120 hours (for COV318 and COV362) and 
the cells were stained using SRB. The concentrations of ivermectin used were those which on 
their own had 5%, 10% and 20% effect in the cell growth assays (referred to as f.a. (fraction 
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Figures (6-4): Effect of ivermectin combined with pitavastatin in ovarian cancer cell lines.  (A) COV318, 5-3 (B) 
FUOV-1, 5-4 (C) COV362, 5-5 (D) OVCAR-4, 5-6 (E) OVCAR-8, 5-7 (F) OVSAHO).  Cells were exposed to a 
range of concentrations of pitavastatin for 72 hours, except for the slow growing cell lines Cov-318 and Cov-362 
which were exposed for 120 hours. The numbers of surviving cells were estimated using SRB assay. Dose response 
curves were generated by curve fitting curve and the results are expressed (mean ± SD, n ≥ 3) as a fraction of the 
top of the curve in each experiment. “C” on the x-axis indicates control samples measured in the absence of the 
drug. The concentration of ivermectin is denoted by 5%, 10%, 20%, referring to the fraction of cells affected and 
is summarized in table (6-2). 
 
Pitavastatin combined with ivermection showed synergistic activity in 3 out of 6 cell lines tested 
(COV318, COV362 and FOUV1) at all concentration fraction of ivermection tested, Additive 
activity was observed in the three other cell lines (OVCAR-4, OVSAHO and OVCAR-8) at the 
same effective ivermectin concentrations (figures (6-5), (6-6) and (6-7)). These data indicate 
that ivermectin could be an effective choice for combining with pitavastatin, and led to further 
studies focusing on this combination. 
Table (6-2): Ivermectin concentrations which had 5%, 10% and 20% effect on their (i.e. 
the fraction affected was 5%, 10%, 20%)  
Cell lines  f.a. = 5%  f.a. = 10% f.a. =20%  
Cov318 4.94 µM 6.61 µM 8.97 µM 
Fuov-1 4.35 µM 6.15 µM 8.81 µM 
Cov362 4.5 µM 5.97 µM 8.01 µM 
Ovcar-4 4.16 µM 5.88 µM 8.43 µM 
Ovcar-8 4.56 µM 6.1 µM 8.3 µM 









































Figure (6-5): Evaluation of the combination of pitavastatin and ivermectin in cell growth assays. The indicated 
cells were simultaneously exposed to a range of pitavastatin concentrations with a fixed concentration with of 
ivermectin which, on its own, inhibited cell growth by 5% (denoted as fa 5%).Combination indices (CI) (mean ± 
S.D., n=3-4) are quoted at a fraction affected of 0.5 and differed significantly from unity where indicated (*, P 








































Figure (6-6): Evaluation of the combination of pitavastatin and ivermectin in cell growth assays. The indicated 
cells were simultaneously exposed to a range of pitavastatin concentrations with a fixed concentration with of 
ivermectin which, on its own, inhibited cell growth by 10% (denoted as fa 10%).Combination indices (CI) (mean 
± S.D., n=3-4) are quoted at a fraction affected of 0.5 and differed significantly from unity where indicated (*, P 







































Figure (6-7): Evaluation of the combination of pitavastatin and ivermectin in cell growth assays. The indicated 
cells were simultaneously exposed to a range of pitavastatin concentrations with a fixed concentration with of 
ivermectin which, on its own, inhibited cell growth by 20% (denoted as fa 20%).Combination indices (CI) (mean 
± S.D., n=3-4) are quoted at a fraction affected of 0.5 and differed significantly from unity where indicated (*, P 





6.2.3. Cell viability assay after combination treatment  
The effect of the drug combinations on cell viability was further assessed by trypan blue 
staining (figures (6-8, 6-9, 6-10)) to validate the previous results and to confirm that the drug 
combination induced cell death. These experiments were performed in the cells in which 
synergy was observed in the cell growth assays. The findings were generally consistent with 
those obtained in cell growth assays. Synergy was observed in COV318, COV362, and FUOV-
1 cells with all the concentrations of ivermectin that were tested. The results showed 
significantly more cells death than the expected effect if the drugs were additive; the effect if 
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Figure (6-8): The effect of ivermectin in combination with pitavastatin on cell toxicity in COV318 cell lines were 
exposed to pitavastatin at a concentration equal to its IC50 (6.2 μM) with/without ivermectin at a concentration 
which affected 5% (4.94 μM), 10% (6.61 μM) or 20% of the cells The number of dead cells (mean ± S.D., n=3) 
was determined by staining with trypan blue and the percentage of viable cells calculated. There were significantly 
more dead cells in samples exposed to the combination than would be expected if the drugs acted additively 








































































































































Figure (6-9): The effect of ivermectin in combination with pitavastatin on cell toxicity in COV362 cell lines 
COV362 cell line were exposed to the IC50 of pitavastatin (6.2 μM) with/without 5% (4.94 μM), 10% (6.61 μM) 
from IC50 of ivermectin after 72 hours the dead cells (mean ± S.D., n=3) was determined by staining with trypan 
blue and the percentage of viable cells. There were significantly less viable cells in cells treated with pitavastatin 
alone compared to the cells treated with 5% (4.94 μM), 10% (6.61 μM) from IC50 of ivermectin (paired t- test, *, 








































































































































Figure (6-10): The effect of ivermectin in combination with pitavastatin on cell toxicity in FOUV-1 cell lines, 
FOUV-1 cell line were exposed to the IC50 of pitavastatin (6.2 μM) with/without 5% (4.94 μM), 10% (6.61 μM) 
from IC50 of ivermectin after 72 hours the dead cells (mean ± S.D., n=3) was determined by staining with trypan 
blue and the percentage of viable cells. There were significantly less viable cells in cells treated with pitavastatin 
alone compared to the cells treated with 5% (4.94 μM), 10% (6.61 μM) from Ic50 of ivermectin (paired t- test, *, 





6.2.4. Caspase 3/7 activity assay  
Previous work has shown that pitavastatin causes apoptosis. To determine if the combination 
of pitavastatin and ivermectin causes apoptosis, the effect of the combination on caspase-3/7 
activity was determined. Activation of caspase 3/7 by the combination was reminiscent of the 
effect measured in the trypan blue assay, and was greater than that of the effect of pitavastatin 
alone. In these experiments, the additive effect could not be estimated by the Bliss 
independence criterion because the maximum caspase activity is difficult to determine (it is 
transient and the time at which peak activity is observed is not predictable). Consequently, the 
effect of the combination was compared to the effect of pitavastatin alone. This seems 
reasonable considering that ivermectin on its own had no effect on caspase-3/7 activity (fig 6-
11).   In COV318 cells, the combinations of ivermectin with pitavastatin showed significantly 
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Figure (6-11): Relative caspase 3/7 activity in COV318 cells. Cov318 cells were exposed to pitavastatin (1&2 μM) 
with/without 5% (4.94 μM), 10% (6.61 μM) from IC50 of ivermectin and after 72 hours’ caspase 3/7 activity was 
measured. To control for potential effects of the drugs on cell number after 72 hours, Caspase 3/7 activity was 
normalised to the number of surviving cells estimated at the same time by staining a separate plate with SRB. The 
results are expressed as a fraction of that measured in untreated cells (mean ± SD, n=3) alone. The results were 






6.2.5.  Confirmation of the synergy between Ivermectin and Pitavastatin by flow 
cytometry 
To confirm the effect of the drug combination on apoptosis, the effect of the combination was 
also measured by flow cytometry to measure apoptosis by Annexin V/propidium iodide 
staining.  In these experiments the results were again compared to the effect of pitavastatin 
alone because of the difficulty of knowing how to apply the Bliss criterion when there are four 
potential outcomes (live, early apoptotic, late apoptotic or necrotic cells). The drug combination 
resulted in significantly more early and late apoptotic cells, and significantly less cells alive, 






                                                                      
  
 
Figures (6-12): The effect of ivermectin combinations on annexin V/propidium iodide staining Cov318 cells were 
treated with the indicated concentration of ivermectin with/ or without pitavastatin (8.2 μM) for 48 hours. The 
cells were labelled with annexin V and propidium iodide and analysed by flow cytometry, (Q1-UL= necrotic cells, 
Q1-LL = live cells, Q1-LR= pre – apoptotic cells, Q1-UR= apoptotic cells). The results shown in the figures are 


















































































































L iv e  C e ll s
p r e -  a p o p to t i c
A p o p to t ic  c e l l s
N e c r o t ic  C e l l s
a n n e x in  V  / C O V 3 1 8
* *
* * * * * * *
 
Figure (6-13): The effect of ivermectin combinations on annexin V/propidium iodide staining Cov318 cells were 
treated with the indicated concentration of ivermectin, with/without pitavastatin (8.2 μM) for 48 hours, the cells 
were labelled with annexin V and propidium iodide and analysed by flow cytometry, the results are expressed as 
a fraction of that measured in untreated cells (mean ± SD, n=3) alone. The results were significantly different from 
those in cells treated with pitavastatin alone where indicated (*, P< 0.05, **, P<0.01paired t-test). Note: the 
necrotic cells not be reduced but it’s very little numbers. 
 
6.3. Discussion 
Failure to treat cancer poses a major challenge for modern medicine[191]. Sadly, the efficacy 
of chemotherapy is limited by side effects, damage to normal tissue and drug resistance. Multi-
drug regimens for cancer are therefore used to boost effectiveness and the need for large doses 
of drugs [536]. Simultaneously, it is well recognized that cancer is a heterogeneous group of 
diseases with different pathogenesis molecular mechanisms, it is therefore advantageous to 
target multiple pathways to inhibit tumour growth and enhance survival [537], [538]. This study 
indicated that one way to potentiate the cytotoxic activity of statins in OC is to use a 
combination of pitavastatin and ivermectin. While repurposing statins is attractive, legitimate 
concerns have been raised about the potential for causing myopathy [519], [539]. This makes 
it important to identify drugs that may reduce the dose of pitavastatin used in patients to reduce 





Although ivermectin was investigated as a potential addition to pitavastatin, like pitavastatin, 
ivermectin as a single agent inhibited the growth of ovarian cancer cell lines but it was slightly 
less potent than pitavastatin.  Ivermectin showed comparable potency as a single agent in all 
the cell lines tested. According our evidence, the concentration of ivermectin that we used in 
table (6-1) to get synergy is achievable in patient’s plasma or within a normal dose to use it as 
a single agent even though the wide margin of safety of ivermectin[540] therefore, it could 
achieve the IC50s concentration in patients and higher doses is possible. 
 
In this study, ivermectin was observed to act synergistically with pitavastatin using several 
different assays using three different cell lines, namely COV318, COV362, FUOV1. In 
contrast, there was an apparently additive interaction observed in cell growth assays using 
OVCAR-4, OVCAR-8 and OVSAHO cells. Synergy between pitavastatin and ivermectin was 
also observed using two other assays in COV362, FUOV1 and COV318 cells. Ivermectin 
potentiated the activity of pitavastatin in inducing apoptosis, assed by measuring caspase-3/7 
activity and annexin V/propidium iodide labelling.  These later studies were only performed 
with COV318 cells because significant synergy was observed with these cells in previous 
experiments. Tremendous morphological changes of all treated cells were also evident under 
the light microscope. The fact that synergy was observed between pitavastatin and ivermectin 
using several different assays give confidence that this observation is robust. It would have 
been helpful to test the combination in OVCAR-4, OVCAR-8 and OVSAHO cells as well, but 
time did not permit this. It would also be worthwhile to investigate different periods of drug 
exposure in case different cells exhibit different kinetics of cell death. 
 
The studies presented here did not address the mechanistic explanation for synergy between 
pitavastatin and ivermectin. Pitavastatin inhibits HMGCR, thus reducing the supply of 




the mevalonate pathway. Thus, this is unlikely to be the mechanism underlying the synergy 
between these two drugs. However, this is significant because it gives a good indication that 
ivermectin is unlikely to increase the risk of myopathy. 
 
Ivermectin inhibits multiple pathways which contribute to cancer cells growth figure (6-2). One 
of these includes YAP-1, and this is particularly important because it is inhibited by both 
lipophilic statins [541] and ivermectin [542], [543]. A library screen for YAP1 targeting 
compounds demonstrated that  ivermectin has antitumour activity through dysregulated 
signalling of YAP1/TAZ and TGF-β which mediates hepatocarcinogenesis in Mob1a/1b 
deficient mice[542], [543]. Thus, this may be one pathway that is inhibited by two drugs and 
which leads to synergy.    
 
It has also been shown that ivermectin has anti-ovarian cancer KPNB1-dependent gene  
properties, KPNB1 in a nuclear transporter and its inhibitors exert antitumor activity through 
the arrest and activation of multiphase cell cycles and apoptosis [544]. Ivermectin was observed 
to block KPNB1 function.  potentially providing a further mechanism for the anti-cancer 
activity of ivermectin[544]. Interestingly,  ivermectin showed antitumor effects on epithelial 
ovarian cancer via KPNB1-dependent, acting as an alternative treatment for patients with higher 
rates of KPNB1 expression with earlier recurrence and better prognosis than those with lower 
levels of KPNB1 expression [544]. It was found that the combination of ivermectin and 
paclitaxel had a greater anti-tumour effect on OC in vitro and in vivo than any single drug[507], 
[544], Thus, it is possible that inhibition of KPNB1 by ivermectin contributes to the synergy 
observed with paclitaxel. 
 
Ivermectin has already been explored as an anti-cancer agent by others and this may help 
understand the basis for synergy between pitavastatin and ivermectin. For example, ivermectin  




xenographs in mice with no adverse effects [545]. However, the mechanism by which 
ivermectin sensitizes cells to pitavastatin is unclear, research to explore new indications for 
ivermectin  as an antiviral and or an anticancer agent has shed light on this [546]. Multiple 
diseases, including intestinal and lung cancers, require constitutive activation of canonical 
WNT-TCF signalling, but there are no WNT-TCF antagonists in clinical usage. The 
repositioning of WNT-TCF blockers response aim to recapitulate the genetic blockade that 
dominant-negative TCF has afforded. A drug repositioning screen for WNT-TCF blockers 
showed that ivermectin inhibits WNT-TCF target expression and blocks proliferation and 
increases apoptosis in different types of human cancer[547].  In colon and lung cancer cells, 
macrocyclic lactones that are structurally related to ivermectin have also been identified as 
effective WNT-TCF response blockers and confirmed in primary tumours obtained from 
patients in colorectal cancer (CRC) preclinical tumour growth models [548].  It is possible that 
the effects of ivermectin on the WNT pathway synergize with the anti-cancer effects of 
pitavastatin. 
 
It is also possible that there are multiple mechanisms underlying the synergy between 
ivermectin and pitavastatin. Ivermectin may have multiple modes of action like most, if not all, 
of the drugs. Its function as an anti-parastic drug is believed to rely on its ability to activate 
glutamate-chloride channels, thereby altering chloride flux and preventing neuronal 
excitement, resulting in parasite paralysis and death [528]. It was proposed that the same mode 
of action could underlie the toxicity of ivermectin to liquid tumour cells and its ability to 
sensitise cancer cells to classical chemotherapy[545]. Research to redeploy ivermectin to treat 
skin, breast, lung, ovary and colon cancers [549], could identify other possible targets for 





In addition, in these studies it was noticed that the cells grown in DMEM growth media 
(COV318, COV362 and FUOV1) showed significant synergy while others grown in RPMI 
growth medium did not show synergy. It would be worthwhile swapping media for all these 
cells and measuring the impact on synergy between pitavastatin and ivermectin. Comparison 
of the different constituents of these media might also provide insight into the mechanism 
underlying the synergy. 
 
These data suggest that it may be worthwhile to explore further the ivermectin and pitavastatin 
combination in further studies. The use of ivermectin as single agent for cancer treatment may 
also be possible even though, numerous targeted drugs have entered clinical trials but have 
shown limited effectiveness so far, often due to variability in treatment responses and 
sometimes rapidly increasing resistance. For more successful treatment options, multi-target 
drugs or drug combinations may be preferred to avoid drug resistance escape mechanisms.  
Interestingly, ivermectin's in vitro and in vivo anticancer activities are reported at 
concentrations that can be reached clinically, based on the human pharmacokinetic trials in 
healthy and patients infested with parasite. Existing knowledge on ivermectin may thus allow 
its rapid transition into clinical trials with cancer patients[534]. Ivermectin's pharmacokinetic 
characteristics and safety profile for exploring novel uses for further expanding its use through 
strategies for mass drug administration to boost coverage levels. Additionally, in healthy 
subjects, ivermectin binds strongly to plasma proteins (93.2%) with a specific serum albumin 
binding, there were two binding sites at the primary site, with a persistent interaction of 2 ×108 
mol−1. This is of considerable significance as the medication is administered in worldwide areas 
where malnutrition and hypoalbuminemia are prevalent, so a decrease in plasma proteins may 
be anticipated in such patients, and thus a higher free fraction of ivermectin [550]. It will be 




In conclusion, these findings show that ivermectin in combination with pitavastatin limits the 
growth of ovarian cancer cells; his may help decrease the dose of pitavastatin for cancer 












































7. Conclusion  
Every year, ovarian cancer accounts for about 240,000 new cases worldwide with 152,000 
deaths. Europe has the highest rates of new cases (11.4 per 100,000) and deaths (6.0 per 
100,000) [551]. There is a very poor prognosis for advanced ovarian cancer patients [552]. 
Advanced ovarian cancer treatment currently includes surgery followed by adjuvant 
chemotherapy consisting of three weekly cycles of carboplatin and paclitaxel, while most 
patients respond to initial chemotherapy, drug resistance frequently occurs with few remaining 
treatment options and only about 40% of patients survive 5 years after initial diagnosis of 
advanced ovarian cancer. Drug resistance is one of the major obstacles to improving the 
prognosis of a patient and substantially leads to the low survival rate of OC patients [553]. 
Therefore, new strategies of ovarian cancer therapies are urgently needed. This thesis has 
attempted to make a contribution to the development of these new therapies. 
 
Targeting metabolic pathways in malignant disease care provides an exciting new potential 
intervention. Inhibiting the mevalonate pathway may provide one new therapeutic approaches 
[227]. A recent study from our laboratory has identified the need for consideration of a patient's 
diet for the effective use of pitavastatin in clinical trials. It was observed that geranylgeraniol 
in mouse food can reverse the  cytotoxic activity of pitavastatin and feeding mice with 
controlled diet resulted in an increase in statin efficacy [308]. It has also been reported that the 
introduction of high-fat diet decreases statin activity and increases the growth of renal tumour 
cells in mice [554], [555].The work reported in Chapter 4 evaluated which foods could suppress 
the cytotoxic effects of pitavastatin (e.g. sunflower oil) and which did not. These observations 
suggest that dietary sources of geranylgeraniol may interfere with cytotoxic/cytostatic activity 
of statins and should be controlled during clinical trials of statins in oncology. Our data identify 
potential foods which patient can eat while being treated with pitavastatin for cancer therapy. 




anticancer activity like mevalonate or other factors not yet discovered that could interfere with 
pitavastatin action. In addition, it is likely that the food constituents differ according to source 
(differ from country to country, perhaps depending on soil compositions) and a particular 
species of fruit, or vegetable that is consumed. It may be advisable to test foods in each country 
to allow pitavastatin to be used as an anticancer therapy. 
 
Currently there is a need for the production of reliable, non-invasive biomarkers that can be 
used in cancer patients to predict response to statin therapy. We have attempted to identify 
biomarkers which predict patients that are sensitive or resistant to pitavastatin. We identified 
18 genes whose expression correlated with sensitivity to pitavastatin from publically available 
databases reporting gene expression and drug sensitivity The expression of these candidate 
biomarkers was assessed in a panel of ovarian cancer cell lines by western blotting and qPCR. 
MAP-7 was found to be highly expressed in cells sensitive to pitavastatin. MAP7 is a member 
of a family of cellular proteins associated with, and altering the dynamics of, microtubules. The 
growing family of microtubule-associated proteins (MAP) includes products from oncogenes 
apoptosis regulators[447]. It is perhaps not surprising then that microtubule function impacts 
the activity of other classes of drugs, in this case a statin, and can have anti-cancer effects. 
However, it is unclear to what extent the effect statins have on microtubules contributes to the 
drug’s anticancer activity compared to effects on other pathways. And in particular, CNP does 
not appear to be a “key target” affected by statins because farnesol blocks the effect of 
pitavastatin on CNP subcellular localization, but it does not suppress the anti-cancer effects of 
statins.  In addition, our hypothesis that KIF5B might play a role in setting sensitivity to 
pitavastatin, based on its association with MAP7, did not appear to be supported by the 
experimental data. Further research into MAP7 and KIF5B is desirable to understand the 
contribution of these proteins to the activity of pitavastatin.  The role of the prenylated CNP as 




and/or pitavastatin can affect microtubulesact as an anti-cancer agent, these insights may give 
us an indication how to select other anticancer which anticipated make synergistic effect with 
pitavastatin and decreasing the incidence of resistance.   
    
Preclinical studies have shown that in vivo and in vitro,  inhibitors of the MP are have anti-
cancer efficacy [462], [556]–[560]. The most significant advantage of the antitumour effects of 
statins is that they maintain their effectiveness against OC cell line that is fairly resistant to 
chemotherapy[412]. Previous studies found that the induction of cell death required continuous 
blockage of HMGCR with long half-life statins [412] and potentially using a high dose of statin. 
This brings with it the risk of myopathy. Myopathy, and rhabdomyolysis in particular, remains 
one of the most devastating consequences of high statin dose [561]. There are a range of 
pharmacologically tractable targets that could be tested to identify possible combinations to 
enhance the sensitivity of OC cells to pitavastatin.   Although it has been documented that statin 
inhibition of prenyltransferases may not be the cause of muscle cytotoxicity [218]. One strategy 
to achieve this is to find other drugs which inhibit the mevalonate pathway. The results in 
Chapter 6 showed that Ivermectin was synergistic with pitavastatin in half of the cell lines 
tested.  Ivermectin may be a worthy option to obtain a synergistic effect in clinical treatment, 
especially because ivermectin showed a good synergetic effect those cells less sensitive cells to 
pitavastatin. Animal studies to confirm this observation using ovarian cancer xenografts are 
desirable to justify subsequent clinical trials.  Ivermectin may also be useful in the treatment of 
ovarian cancer independent of its role in sensitizing cells to pitavaststin. Several potential new 
therapeutic target of pitavastatin have been identified including YAP1 [493], and KPNB1 [455]. 
It may be worth exploring ivermectin’s activity as a single agent against ovarian cancer. 
Another major challenge in the field of exploring the role of MP inhibitors is to identify the 
substrates of prenyl transferase that are responsible for mediating antitumour activity in 




that are prenylated and several hundred other proteins are also holding the CAXX box whose 
prenylation is waiting to be confirmed [563], [564]. Drugs inhibiting these prenylated proteins 
may also be synergistic with pitavastatin and deserve investigation. The role of prenylated 
proteins in malignant transformation has also stimulated interest in developing prenyl 
transferase enzyme inhibitors as an anticancer agent. These may also be synergistic with 
pitavastatin, although work from our group has alsready shown that both geranylgeranyl 
transferase 1 and II must be inhibited and inhibition of one isoform is inadequate [242].  
It is also possible that drugs could be used with statins which have no anti-cancer effect but 
which minimize the risk of myopathy. The work presented here suggests that conenzyme Q10, 
which is already used to reduce statin-induced myopathy, does not interfere with pitavastatin’s 
anti-cancer activity.  It was also recently suggested that curcumin, a natural dietary polyphenol, 
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